paclitaxel has been researched along with Metastase in 1072 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.09) | 18.7374 |
| 1990's | 206 (19.22) | 18.2507 |
| 2000's | 361 (33.68) | 29.6817 |
| 2010's | 437 (40.76) | 24.3611 |
| 2020's | 67 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, G; Ma, Y; Zhao, N | 1 |
| Dong, Y; Li, Z; Liu, G; Ma, Y; Wang, C; Wang, S | 1 |
| Fan, P; Li, D; Lou, H; Ye, Y; Yuan, H; Zhang, T | 1 |
| Chang, TT; Chen, CL; Chen, WS; Fu, CW; Hsiao, PW; Li, WS; Tsai, HE | 1 |
| De, A; Deo, AN; Dhadve, AC; Ray, P; Rekhi, B; Thorat, R | 1 |
| Hwang, JH; Kim, J; Kim, JH; Lee, JC; Lee, YS | 1 |
| Guo, J; Li, W; Li, Y; Ma, Z; Sun, Q; Wang, X; Zhang, C; Zhang, H | 1 |
| Chen, J; Liu, A; Shi, B; Shi, Y | 1 |
| Adhav, R; An, T; Chan, UI; Deng, CX; Lei, JH; Li, J; Liu, J; Miao, K; Mo, L; Shu, X; Su, SM; Wang, Y; Xu, J; Xu, X; Zhang, X | 1 |
| Choi, J; Chung, JS; Ha, JS; Jang, WB; Kim, JH; Kim, YJ; Kwon, SM; Lee, DH; Ly, TTG; Min, SH; Rethineswaran, VK; Van Le, TH; Yang, JS; Yun, J | 1 |
| Bernard, B; Chang, S; Chun, B; Conlin, AK; Conrad, V; Fields, PA; Kim, I; Koguchi, Y; McArthur, HL; Nikitin, B; Page, DB; Polaske, N; Pucilowska, J; Rajamanickam, V; Redmond, WL; Schmidt, M; Urba, WJ | 1 |
| Akazawa, M; Narimatsu, H; Sasahara, Y; Takumoto, Y | 1 |
| Chen, T; Chen, X; Cheng, W; Jiang, Y; Nie, X; Zhong, Y | 1 |
| Banala, RR; Bodlapati, R; Devraj, VM; Halder, S; Jana, K; Mallarpu, CS; Mukherjee, S; Neerudu, UK; Rachamalla, HK; Thakkumalai, M; Vemuri, SK; Venkata, GRA; Venkata, SGP | 1 |
| Cai, L; Guo, X; Hu, X; Jiang, Z; Luo, J; Pan, Y; Shao, Z; Sun, T; Teng, YE; Wang, B; Wang, S; Wang, X; Wang, Z; Wu, J; Yan, M; Zhang, J; Zhao, Y | 1 |
| Aktas, B; Büdi, L; Gluz, O; Klare, P; Magdolna, D; Mangel, L; Morita, S; Müller, V; Ohno, S; Pikó, B; Schneeweiss, A; Toi, M; Yamamoto, Y; Yamashiro, H | 1 |
| Jin, Z; Ma, X; Ni, R; Pan, Y; Wu, Q; Yang, G | 1 |
| Adorno-Cruz, V; Almubarak, HF; Azadi, P; Cobb, BA; Colley, KJ; Cristofanilli, M; D'Amico, P; Dandar, T; Dashzeveg, NK; El-Shennawy, L; Gerratana, L; Gradishar, WJ; Hoffmann, AD; Jia, Y; Liu, H; Manai, M; Muller, WA; Patel, P; Platanias, LC; Ramos, EK; Reduzzi, C; Scholten, D; Schuster, EJ; Shah, AN; Shajahan, A; Sokolowski, MT; Taftaf, R; Zhang, Q; Zhang, Y | 1 |
| Aceto, N; Gvozdenovic, A | 1 |
| Fan, C; Lee, BH; Mo, C; Shetti, D; Wei, K; Zhang, B | 1 |
| Er-Bu, A; Tsering, T; Xie, HJ; Zhan-Dui, N; Zhao, J; Zhuo-Ma, D | 1 |
| Menon, R; Mensing, S; Nuthalapati, S; Ratajczak, CK; Shepherd, SP; Stodtmann, S; Xiong, H | 1 |
| Ishigami, H; Kanda, M; Kitayama, J; Kobayashi, D; Kodera, Y; Tanaka, C; Yamaguchi, H | 1 |
| Cao, K; Chen, H; Gao, X; Jia, Z; Li, J; Lian, B; Liu, Z; Shao, C; Sun, Y; Wang, L; Wang, T; Wang, W; Xu, J; Yang, Q; Zhang, W | 1 |
| Chen, X; He, Q; Li, M; Liu, Y; Sheng, Q; Shi, K; Wang, Y; Yu, Q; Zhang, Z | 1 |
| Ikeda, Y; Kajiyama, H; Kikkawa, F; Niimi, K; Nishino, K; Sakata, J; Shimbo, A; Suzuki, S; Tamauchi, S; Yoshikawa, N | 1 |
| Chen, F; Chen, Y; Luo, X; Zhang, K; Zhou, L | 1 |
| Baradaran, B; Darabi, M; Javadian, M; Kazemi, T; Mansoori, B; Maralbashi, S; Mohammadi, A; Shanehbandi, D; Shekari, N; Soltani-Zangbar, MS | 1 |
| Dhillon, S; Syed, YY | 1 |
| Chen, E; Jiao, Y; Li, J; Li, X; Liu, P; Lu, B; Lu, Y; Mi, C; Qian, X; Qiu, Q; Yang, J; Yi, J; Yu, M; Zhang, J | 1 |
| Adams, S; Barrios, CH; Chui, SY; Diéras, V; Emens, LA; Henschel, V; Husain, A; Iwata, H; Loi, S; Maiya, V; Molinero, L; Rugo, HS; Schmid, P; Schneeweiss, A; Winer, EP | 1 |
| Amiri-Kordestani, L; Beaver, JA; Bloomquist, E; Blumenthal, GM; Fu, W; Gao, JJ; Ghosh, S; Goldberg, KB; Gong, Y; Hou, S; Ibrahim, A; Kalavar, S; King-Kallimanis, BL; Kluetz, PG; Liu, J; Narayan, P; Pazdur, R; Philip, R; Song, P; Sridhara, R; Tang, S; Theoret, MR; Wahby, S; Xu, Y | 1 |
| Barra, F; Bifulco, G; Della Corte, L; Evangelisti, G; Ferrero, S; Foreste, V; Giampaolino, P | 1 |
| Li, Q; Liao, W; Wang, F; Wang, X; Wu, Q; Zhang, M | 1 |
| Akbulut, H; Aykan, F; Coskun, HS; Dane, F; Demirag, GG; Evrensel, T; Hayran, M; Isikdogan, A; Karabulut, B; Kilickap, S; Oksuzoglu, B; Ozdemir, F; Ozdemir, NY; Ozkan, M; Sevinc, A; Turna, H; Ustaoglu, MA; Yalcin, S; Yavuzsen, T; Yuce, D | 1 |
| Ainslie, KM; Bachelder, EM; Graham-Gurysh, EG; Hingtgen, SD; Lee, T; Moore, KM; Schorzman, AN; Zamboni, WC | 1 |
| Chen, H; Li, J; Li, P; Liu, J; Liu, P; Miao, Y; Wang, R | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Chen, L; Jiang, J; Li, J; Lu, P; Zhang, T; Zhao, J | 1 |
| Abraham, P; Gricar, J; Shankaran, V; Zhang, Y | 1 |
| Camidge, DR; Danysh, HE; Hackshaw, MD; Iwata, H; Ladner, A; Powell, CA; Ritchey, ME; Singh, J; Taitt, C | 1 |
| Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B | 1 |
| Li, H; Meng, R; Rui, M; Shang, Y; Shi, F | 1 |
| Andrikou, K; Bernardini, L; Casadei-Gardini, A; Catanese, S; Falcone, A; Formica, V; Fornaro, L; Lencioni, M; Massa, V; Pecora, I; Rapposelli, GI; Riggi, L; Rovesti, G; Salani, F; Vasile, E; Vivaldi, C | 1 |
| Cui, W; Li, H; Li, X; Li, Y; Wang, D; Yang, X; Zhao, D | 1 |
| Hui, Y; Li, N; Liu, Z; Lu, P; Ma, Z; Pi, J; Zhang, B; Zhang, Y | 1 |
| Dobleman, T; Hu, S; Liu, J; Xiao, GG; Xiao, KC; Yang, Q | 1 |
| Catalano, M; Conca, R; D'Angelo, A; Ianza, A; Mini, E; Nobili, S; Palmieri, VE; Panella, B; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Griffin, JI; Ho, RJ; McConnachie, LA; Mu, Q; Perazzolo, S; Shen, DD; Yu, J; Zhu, L | 1 |
| Cui, J; Qu, S; Wang, L; Zhang, X | 1 |
| Alavi, S; Chekerov, R; Chinczewski, L; DrÖge, LA; Feldhaus, FW; Muallem, MZ; Pietzner, K; Sehouli, J; Taube, ET | 1 |
| Ahlström, H; Botling, J; Dahlstrand, H; Koliadi, A; Öberg, K; Tholander, B; Ullenhag, GJ; Von Heideman, A | 1 |
| Avraham, S; Geiger, T; Harel, M; Loven, D; Mukherjee, A; Orian-Rousseau, V; Prinz, E; Sagredo, LM; Shaked, Y; Shechter, D; Wolfenson, H | 1 |
| Aieta, M; Catalano, M; Conca, R; D'Angelo, A; Dreoni, L; Gasperoni, S; Ianza, A; Mini, E; Nobili, S; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Slater, H | 1 |
| Cabezas-Camarero, S; Cabrera-Martin, MN; Perez-Segura, P; Saiz-Pardo Sanz, M | 1 |
| Gote, V; Pal, D; Sharma, AD | 1 |
| Bunnell, CA; Chen, WY; Freedman, RA; Lynce, F; Mayer, EL; Overmoyer, B; Partridge, AH; Regan, MM; Tolaney, SM; Williams, JT; Winer, EP | 1 |
| Funaoka, A; Ishii, T; Kaneko, T; Komiyama, S; Maeda, S; Miwa, H; Nishimura, M; Numata, K; Sato, T; Sugimori, K; Sugimori, M; Suzuki, Y; Tozuka, Y; Tsuchiya, H | 1 |
| Bois, MC; Chakrabarti, S; Chandrasekharan, C; Dong, H; Foster, NR; Graham, RP; Kankeu Fonkoua, LA; Kasi, PM; Liu, AJ; Markovic, SN; Maus, RL; Nevala, WK; Pitot, HC; Ross, HJ; Sonbol, MB; Starr, JS; Villasboas, JC; Weiss, M; Wu, TT; Yoon, HH | 1 |
| Astaras, C; Borner, M; De Dosso, S; Fritsch, R; Meisel, A; Siebenhüner, AR; Szturz, P; Winder, T | 1 |
| Burdio-Pinilla, F; Casasola-Sánchez, LE; Pereira-Rodríguez, JA; Radosevic, A; Sánchez-Velázquez, P; Visa, L | 1 |
| Cao, R; Guo, YJ; Han, CB; Huang, LT; Jing, W; Ma, J; Song, J; Sun, L; Wang, YR; Zhang, SL; Zhang, XY; Zhao, JZ | 1 |
| Fukuda, K; Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Barinova, M; Bratova, M; Cernovska, M; Coupkova, H; Dolezal, D; Fischer, O; Hrnciarik, M; Hurdalkova, K; Koubkova, L; Krejci, D; Krejci, J; Kultan, J; Opalka, P; Pesek, M; Safanda, M; Skrickova, J; Svaton, M; Zemanova, M; Zemanova, P | 1 |
| Annan, DA; Cong, L; Hida, K; Hida, Y; Maishi, N; Morimoto, H; Morimoto, M; Nam, JM; Young, MF | 1 |
| Cho, IR; Chun, JW; Huh, G; Kim, JS; Kim, YT; Lee, SH; Paik, WH; Park, N; Ryu, JK | 1 |
| Chen, J; Chen, Y; Gao, X; Hu, K; Huang, Y; Li, F; Liu, S; Liu, Y; Lu, H; Mei, N; Wang, D; Xu, M; Zhang, Q; Zhou, S | 1 |
| Bartolini, G; Bernardini, L; Casadei-Gardini, A; Cucchetti, A; Frassineti, GL; Massa, V; Passardi, A; Rapposelli, IG; Vivaldi, C | 1 |
| Chakravarti, A; Cole, MW; Das, M; Knoblaugh, SE; Lian, AW; Ostrowski, MC; Ray, A; Richardson, DS; Schafer, RE; Shakya, R; Sizemore, GM; Sizemore, ST; Spehar, JM; Steck, SA; Thies, KA; Timmers, CD | 1 |
| Childs, DS; Costello, BA; Pagliaro, LC; Quevedo, JF | 1 |
| Koukourakis, IM; Koukourakis, MI; Kouloulias, V; Zygogianni, A | 1 |
| Abe, T; Aoshika, T; Hirai, R; Igari, M; Iino, M; Kagamu, H; Kaira, K; Kato, S; Kumazaki, Y; Miura, Y; Noda, SE; Ohta, T; Ryuno, Y; Saito, S | 1 |
| Chanu, P; Kotani, N; Sane, R; Wade, JR; Wang, N; Wilkins, J; Winkler, J; Yoshida, K | 1 |
| Jiang, D; Lu, H; Qiu, M; Shan, C; Wang, Q; Xu, X; Zha, S; Zhang, W; Zheng, X | 1 |
| Baron, MK; Garrido-Laguna, I; Haaland, B; Moser, JC; Nevala-Plagemann, C; Wang, X | 1 |
| Fujisaki, K; Miyoshi, T; Ootsubo, Y; Sai, G; Shiina, N; Wakabayashi, Y; Yokomizo, J | 1 |
| Abdelfattah, ON; Bakri, HM; Eid, S; Mohamed, RF | 1 |
| Asselain, B; Berger, F; Beuzeboc, P; Bidard, FC; Cottu, PH; Dieras, V; Dujaric, ME; Escalup, L; Laurence, V; LE Tourneau, C; Pierga, JY; Piperno-Neumann, S; Pop, S; Robain, M | 1 |
| Ali, S; Asaduzzaman, M; Constantinou, S; Coombes, RC; Gallon, J; Hu, Y; Lam, EW; Lin, ML; Min, H; Raguz, S; Shousha, S; Singh, P; Yagüe, E | 1 |
| Imamura, F; Inoue, T; Kimura, M; Kumagai, T; Nishino, K; Tamiya, M | 1 |
| Choi, JI; Kim, DJ; Kim, SJ; Lee, JH; Park, BS; Park, HR; Song, JM; Woo, BH | 1 |
| Binitie, O; Brohl, AS; Bui, MM; Caracciolo, J; Gonzalez, RJ; Henderson-Jackson, E; Hoggard, TM; Reed, DR; Teer, JK; Yoder, S | 1 |
| Feng, J; Hurvitz, S; Jiang, Z; Lee, KS; Liu, D; Ng, TY; Noel-Baron, F; Ridolfi, A; Ringeisen, F; Shao, Z; Shen, K; Toi, M; Tseng, LM; Wang, X; Xu, B; Zhang, Q | 1 |
| Barbolosi, D; Benzekry, S; Ciccolini, J; El Cheikh, R; Imbs, DC; Mollard, S | 1 |
| Guerra, I; McCormack, M; Munk, VC; Nogueira-Rodrigues, A; Rosen, VM; Sasse, A; Shang, A | 1 |
| Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Schrag, D; Wolpin, BM | 1 |
| Baum, V; Christopoulos, P; Eberhardt, W; Engel-Riedel, W; Grohé, C; Gütz, S; Kollmeier, J; Kropf-Sanchen, C; Nimmrich, I; Schnabel, PA; Serke, M; Sieder, C; Thomas, M; Ukena, D; von Pawel, J | 1 |
| Dong, X; Gong, M; Han, X; He, R; Li, J; Li, Z; Lu, X; Luo, L; Wang, M; Xu, R | 1 |
| Allende, D; Fadare, O; Forscher, C; Roma, AA; Rutgers, JK | 1 |
| Bianchi, G; Capri, G; de Braud, F; Ferrari, B; Maggi, C; Mariani, G; Mennitto, A; Mennitto, R; Milano, M; Re, B; Rinaldi, L; Stefanetti, C; Vernieri, C | 1 |
| Barry, WT; Gobburu, JV; Gray, E; Hudis, C; Lad, TE; Lyss, AP; Mehrotra, S; Moreno-Aspitia, A; Overmoyer, B; Ratain, MJ; Rugo, H; Sharma, MR; Toppmeyer, DL; Valasco, M; Winer, EP; Wu, K | 1 |
| Chen, X; Ju, C; Su, Z; Sun, Q; Tang, C; Tian, C; Xue, L; Yin, Y; Zhang, C; Zhang, Y | 1 |
| Adán-Ladrón de Guevara, A; Gallardo-Pérez, JC; Marín-Hernández, A; Moreno-Sánchez, R; Rodríguez-Enríquez, S | 1 |
| Gong, W; Liu, A; Liu, J; Mu, Z; Sun, P; Yu, C | 1 |
| Decker, T; Göhler, T; Indorf, M; Nusch, A; Overkamp, F; Rösel, S; Sahlmann, J; Trarbach, T | 1 |
| Burugu, S; Chen, B; Gao, D; Gelmon, KA; Kos, Z; Leung, S; Liu, S; Nielsen, TO; Parulekar, WR; Shepherd, L; Virk, S | 1 |
| Chang, YS; Hai, T; Jalgaonkar, SP; Middleton, JD | 1 |
| Imai, S; Nio, Y; Sakamoto, M; Tamaoki, M; Uesugi, K | 1 |
| Bonafede, M; Cai, Q; McBride, A; Parisi, M; Patel, M; Pelletier, C; Princic, N; Tran, O | 1 |
| Deng, Y; He, C; Jin, Y; Li, X; Liu, Y; Qu, X; Wang, D; Wang, Z; Zhou, Y; Zou, Y | 1 |
| Cruz, JJ; Gomez, A; Lozano, R; Martin, T; Rodriguez, CA | 1 |
| Chen, MB; Laber, DA | 1 |
| Akiyama, F; Fukada, I; Horii, R; Ito, Y; Iwase, T; Kobayashi, K; Ohno, S; Shibayama, T; Takahashi, S | 1 |
| Fukushima, H; Kawabata, K; Marshall, S; Mitani, H; Nakano, K; Sasaki, T; Sato, Y; Shimbashi, W; Taira, S; Takahashi, S; Tomomatsu, J; Yonekawa, H | 1 |
| Baxi, SS; Dunn, LA; Fury, MG; Haque, S; Ho, AL; Katabi, N; Korte, S; Pfister, C; Pfister, DG; Sherman, EJ; Xiao, H | 1 |
| Dadi, N; O'Neil, BH; Sehdev, A; Shahda, S; Stanley, M | 1 |
| Bernstein, V; Chi, K; Clemons, M; Dent, SF; Dhesy-Thind, SK; Ellard, SL; Feilotter, H; Gelmon, KA; Hagerman, LJ; Ksienski, D; Lui, H; Mates, M; Panasci, L; Salim, M; Seymour, L; Simmons, C; Song, X; Tu, D; Verma, S | 1 |
| Bondarenko, I; Campone, M; Chmielowska, E; Citrin, D; Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Gradishar, W; Han, HS; Isakoff, SJ; Jager, A; Jakobsen, EH; Kaklamani, V; Kaufman, B; Marcom, PK; Nickner, C; Palácová, M; Puhalla, S; Qian, J; Qin, Q; Ratajczak, CK; Robson, M; Shepherd, SP; Shparyk, Y; Telli, ML | 1 |
| Bang, SM; Chang, H; Kim, JH; Kim, JW; Kim, MJ; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, KW | 1 |
| Ahn, JH; Chae, YS; Han, HS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Lee, SJ; Park, IH; Park, YH; Sohn, JH | 1 |
| Furuta, R; Ina, K | 1 |
| Aghajanian, C; Alvarez Secord, A; Carney, ME; Coleman, RL; Gray, HJ; Hanjani, P; Hu, W; Kehoe, SM; Landrum, LM; Lankes, HA; Pearl, ML; Richardson, DL; Sill, MW; Sood, AK; Van Le, L; Zhou, XC | 1 |
| Gourd, E | 1 |
| Hara, H; Hasegawa, Y; Homma, A; Kiyota, N; Minato, K; Muro, K; Onoe, T; Saijo, K; Suzuki, M; Taguchi, J; Tahara, M; Takahashi, S; Ueda, S; Yamanaka, T; Yane, K; Yokota, T | 1 |
| Baggio, C; Bhowmick, NA; Billet, S; Chen, JF; Gambini, L; Pellecchia, M; Posadas, EM; Salem, AF; Tseng, HR; Udompholkul, P; Wang, S | 1 |
| Brahmer, JR; Coleman, B; Ettinger, DS; Forde, PM; Gabrielson, E; Hann, CL; Kelly, RJ; Marrone, KA; Purtell, M; Rosner, GL; Zhou, X | 1 |
| Grzanka, A; Grzanka, D; Hałas-Wiśniewska, M; Klimaszewska-Wiśniewska, A | 1 |
| Chen, J; Fan, Y; Hong, R; Ma, F; Ou, K; Sang, D; Wang, J; Xu, B; Yuan, P; Zhai, X; Zhao, C | 1 |
| Horn, T; Krege, S; Retz, M | 1 |
| Botteman, M; Cortes, J; Fandi, A; Ko, A; Margunato-Debay, S; Pérez-García, J; Solem, C; Tai, MH; Wan, Y; Whiting, S | 1 |
| He, W; Li, S; Lv, Y; Xiao, Q; Yin, L; Zhao, X; Zhu, L | 1 |
| Akao, J; Otsuka, N; Shimizu, K; Tahara, J; Takayama, Y; Tokushige, K | 1 |
| Barlesi, F; Cappuzzo, F; Coleman, S; Deng, Y; Finley, G; Jotte, RM; Kelsch, C; Kowanetz, M; Lee, A; Lopez-Chavez, A; Moro-Sibilot, D; Nogami, N; Orlandi, F; Reck, M; Rodríguez-Abreu, D; Sandler, A; Shen, Y; Socinski, MA; Stroyakovskiy, D; Thomas, CA | 1 |
| Ali, U; Kazi, F; Mahmood, H; Tajammul, SS | 1 |
| Bang, SM; Choi, IS; Choi, M; Kang, B; Kim, JH; Kim, JW; Kim, SH; Kim, YJ; Lee, JH; Lee, JO; Lee, JS; Lee, JY; Lee, KW; Suh, KJ | 1 |
| Bianchi, G; Capri, G; Cona, MS; de Braud, F; Ferrari, B; Huber, V; Maggi, C; Manoukian, S; Mariani, G; Mennitto, A; Milano, M; Prisciandaro, M; Rinaldi, L; Rivoltini, L; Vernieri, C | 1 |
| Adessi, C; Dang, JS; Laurent, J; McIntyre, C; Meneses-Lorente, G; Mercier, F; Ravva, P; Xu, C | 1 |
| An, C; Bang, S; Cho, IR; Chung, JB; Chung, MJ; Jo, JH; Jung, SY; Kang, H; Lee, HS; Park, JY; Park, MS; Park, SW; Song, SY | 1 |
| Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M | 1 |
| Chen, H; Dong, W; Hou, Y; Li, B; Lin, M; Lou, G; Xia, B; Zhang, X | 1 |
| Bae, S; Banchereau, J; Banchereau, R; Blankenship, D; Brookes, HM; Cepika, AM; Chung, CH; George, J; Kim, KI; Lavecchio, E; Levin, MK; Marches, F; Martinek, J; O'Shaughnessy, J; Obermoser, G; Oxley, KL; Palucka, AK; Pascual, V; Smith, JL; Snipes, GJ; Turner, J; Wang, X; Wu, TC; Xu, K; Young, RR; Zurawski, S | 1 |
| Cheng, L; Fu, M; Ju, RJ; Li, XT; Liu, JJ; Wang, X; Xiao, Y; Xie, HJ | 1 |
| Alspach, E; Burnette, B; Faget, DV; Flanagan, KC; Fu, Y; Gruosso, T; Johnson, RM; Leahy, K; Luo, X; Mbalaviele, G; Monahan, JB; Murali, B; Park, M; Ren, Q; Ross, MH; Stewart, SA; Su, X; Wang, C; Weilbaecher, KN | 1 |
| Grebhardt, S; Hansen, R; Harde, J; Marschner, N; Nusch, A; Potthoff, K; Salat, C; Söling, U | 1 |
| Bos, MEMM; Bouma, JM; Claessens, AKM; de Graaf, H; Erdkamp, FLG; Honkoop, AH; Lopez-Yurda, M; Rademaker-Lakhai, JM; Tjan-Heijnen, VCG; van der Sangen, MJC; van Druten, E; van Warmerdam, LJC | 1 |
| Arihara, F; Horita, Y; Kida, A; Matsuda, K; Matsuda, M; Mizukami, A; Nishino, M; Sakai, A; Sugimoto, S; Yano, M | 1 |
| Chen, Q; Lin, X; Shi, C; Wang, X; Yang, B | 1 |
| Benson, AB; Catalano, PJ; Lubner, SJ; Menge, MR; Munshi, HG; Nimeiri, HS; O'Dwyer, PJ; Sahai, V; Zalupski, MM | 1 |
| Fiorino, L; Kumar, A; O'Dwyer, H; Tinker, AV | 1 |
| El-Sokkary, GH; Ismail, IA; Saber, SH | 1 |
| Banerjee, S; Bhattacharya, S; Dauer, P; Dudeja, V; Giri, B; Gupta, VK; Kesh, K; Nomura, A; Saluja, A; Sharma, NS | 1 |
| Ishikawa, M; Kitagawa, R; Kobayashi, H; Nakamura, K; Shibata, T; Tanaka, K; Yaegashi, N | 1 |
| Adams, S; Chang, CW; Diamond, JR; Foster, PG; Funke, R; Hamilton, E; Iizuka, K; Molinero, L; Pohlmann, PR; Powderly, J; Tolaney, SM; Zhang, W | 1 |
| El-Tabba', RM; Khajah, MA; Masocha, W; Mathew, P | 1 |
| Aksoy, S; Aktas, BY; Alacacioglu, A; Aliyev, A; Artac, M; Basaran, G; Beypinar, I; Bilen, E; Bilici, A; Cabuk, D; Cetin, B; Cicin, I; Cil, T; Degirmencioglu, S; Demir, A; Demir, H; Demirci, U; Er, O; Erdur, E; Eren, T; Erturk, I; Esin, E; Evrensel, T; Gumusay, O; Haksoyler, V; Harputluoglu, H; Imamoglu, I; Kaplan, MA; Karaagac, M; Karadurmus, N; Kocer, M; Korkmaz, T; Kostek, O; Oksuzoglu, B; Olgun, P; Oyan, B; Ozdemir, O; Paydas, S; Pilanci, KN; Sakalar, T; Sakin, A; Seker, M; Sumbul, AT; Tanrikulu, E; Urun, Y; Yetisir, E; Yildirim, N; Yilmaz, H; Yumuk, PF | 1 |
| Choi, JH; Choi, YH; Huh, G; Kim, YT; Lee, SH; Paik, WH; Ryu, JK; You, MS | 1 |
| Adeva, J; Alés-Díaz, I; Buxò, E; Cañabate, M; Carmona-Bayonas, A; De la Cámara, J; Fernández, A; Gallardo, E; Gallego, J; García, A; González, P; Guillén, C; Jiménez-Fonseca, P; Llorca, C; López, C; López, LJ; Muñoz, A; Navarro-Pérez, V; Pazo-Cid, RA; Quintero, G; Ramírez, P; Reboredo, M; Ruiz-Miravet, N; Salgado, M; Sanchez-Cánovas, M; Vera, R | 1 |
| Arsenyan, A; Blanchard, S; Burhenn, P; Choi, J; Chung, S; Hurria, A; Katheria, V; Lee, T; Levi, A; Li, D; Luu, TH; Morrison, R; Mortimer, JE; Noonan, AM; Rotter, A; Rubalcava, A; Somlo, G; Soto-Perez-de-Celis, E; Sudan, N; Waisman, JR; Yeon, CH; Yuan, Y | 1 |
| Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E | 1 |
| Aggarwal, R; Bondarenko, I; Ewesuedo, R; Freyman, A; Hingmire, S; Iwase, H; Krivorotko, PV; Lee, KS; Li, R; Li, RK; Pegram, MD; Pikiel, J; Tan-Chiu, E; Vana, A; Yin, D; Zacharchuk, C; Zorzetto, MMC | 1 |
| Chandarlapaty, S; Dang, CT; Hudis, CA; Iyengar, N; Jochelson, M; Modi, S; Norton, L; Patil, S; Smyth, LM; Wang, R | 1 |
| Antolín, S; Atienza, M; Benito, S; Caballero, R; Carrasco, E; Escudero, MJ; Falcón, A; Gil-Martin, M; Montaño, Á; Montero, JC; Ocana, A; Orlando, J; Pandiella, A; Pernas, S; Ribelles, N; Rojo, F; Ruiz-Borrego, M; Urruticoechea, A | 1 |
| Hata, H; Hiura, A; Kato, M; Maeda, T; Nagai, K; Oaku, S; Yoshino, K | 1 |
| Chow, A; Hilberg, F; Kerbel, RS; Man, S; Reguera-Nuñez, E; Xu, P | 1 |
| Chauhan, N; Chauhan, SC; Chowdhury, P; Hafeez, BB; Jaggi, M; Kashyap, VK; Kumari, S; Li, W; Miller, DD; Nagesh, PKB; Setua, S; Wang, Q; Yallapu, MM | 1 |
| Arndorfer, S; Arunachalam, A; Burke, TA; Frederickson, AM; Insinga, R; Lorenzi, M; Simon, GR; Zhang, I | 1 |
| Petitjean, A; Roze, S; Smith-Palmer, J; Tehard, B; Valentine, W | 1 |
| Bekaii-Saab, T | 1 |
| Le Tourneau, C; Ricci, F | 1 |
| Alarcón, E; Armstrong, AC; Cheung, SYA; Corcoran, C; Cullberg, M; Davies, BR; de Bruin, EC; Foxley, A; Gómez Villanueva, A; Lindemann, JPO; López Chuken, YA; Maudsley, R; Moschetta, M; Oliveira, M; Outhwaite, E; Pass, M; Pérez-Fidalgo, JA; Philco, M; Rugman, P; Sablin, MP; Schiavon, G; Tamura, K; Turner, NC | 1 |
| Carr, TH; Citi, V; Cutts, R; de Bruin, EC; Fenwick, K; Garcia-Murillas, I; Hrebien, S; Kozarewa, I; Maudsley, R; McEwen, R; Oliveira, M; Ratnayake, J; Schiavon, G; Turner, N | 1 |
| Hsieh, YL; Liou, JP; Pan, SL; Tu, HJ; Yang, CR | 1 |
| Chan, J; Corrie, P; di Pietro, M; Fitzgerald, RC; Januszewicz, W; Liu, H | 1 |
| Chang, Q; Chu, T; Han, B; Qian, J; Qiang, H; Xu, J; Zhang, B; Zhang, Y; Zhong, R | 1 |
| Beith, J; De Boer, RH; Redfern, A; Truman, M; White, M; Woodward, N; Young, J | 1 |
| Iyikesici, MS | 1 |
| Doucey, P; Jacquin, JP; Magné, N; Mery, B; Rowinski, E; Simoens, X; Vallard, A | 1 |
| Akın Telli, T; Kılıçkap, S; Kıvrak Salim, D; Tatlı, AM; Yumuk, PF | 1 |
| Hu, K; Liu, X; Meng, Q; Wang, W; Zhang, F | 1 |
| Chigurupati, S; Hasan, MN; Islam, MJ; Kabir, S; Pervin, S; Roshid, B | 1 |
| Bynon, JS; Cen, P; Dinh, BC; Gonzalez, A; Mohlere, V; Thosani, NC; Wray, CJ; Zhang, S | 1 |
| Komune, N; Matsuo, M; Nakagawa, T; Taura, M; Uchi, R; Wakasaki, T; Yasumatsu, R | 1 |
| Chauhan, N; Chauhan, SC; Hafeez, BB; Jaggi, M; Kashyap, VK; Khan, S; Kumari, S; Mandil, H; Massey, AE; Setua, S; Shetty, AB; Sikander, M; Yallapu, MM | 1 |
| Harper, NW; Hodges, KB; Huang, B; O'Connor, KL; Romond, EH; Stewart, RL; Wu, J | 1 |
| Luo, X; Peng, L; Tan, C; Wan, X; Zeng, X; Zhang, Y | 1 |
| Bang, K; Chang, HM; Hwang, I; Jeong, JH; Kim, KP; Kim, MH; Lee, K; Lee, SK; Lee, SS; Oh, D; Park, DH; Park, JH; Ryoo, BY; Song, TJ; Yoo, C | 1 |
| Bertino, EM; Liu, T; Mo, X; Otterson, GA; Owen, DH; Roychowdhury, S; Schweitzer, C; Timmers, CD; Webb, A; Williams, TM | 1 |
| Fu, Y; Gong, T; Hu, D; Huang, Y; Li, H; Luo, J; Zhang, P; Zhang, ZR | 1 |
| Buckner, CA; Conlon, MS; Lafrenie, RM; Pawelec, G; Shipp, C; Speigl, L | 1 |
| Chang, W; Choi, MK; Hong, JY; Jung, HA; Kim, S; Kim, YS; Lee, J; Lee, SJ; Maeng, CH; Park, S | 1 |
| Cortot, AB; Delourme, J; Dhalluin, X; Habib, S; Lafitte, JJ; Petyt, G; Scherpereel, A; Tacelli, N | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R | 1 |
| Adjei, AA; Belani, CP; Chow, LQ; Dy, GK; Fortin, C; Gupta, A; Jonker, DI; Laurie, SA; Nicholas, G; Park, JS; Patricia, D; Sbar, EI; Zhang, S | 1 |
| Fan, W; Huang, Y; Jiang, D; Sui, M; Zhong, W | 1 |
| Alba, E; Ciruelos, E; Liria, MR; Lluch, A; López, R; López-Vega, JM; Martín, M; Muñoz, M; Pérez-Alcántara, F; Sánchez-Rovira, P; Seguí, MÁ | 1 |
| Boy, D; Bruzzi, P; Ceccarelli, M; Cognetti, F; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Kazeem, G; La Torre, I; Mansutti, M; Marchi, P; Merlo, DF; Venturini, M | 1 |
| Allen, P; Buchholz, TA; Buzdar, AU; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Kim, MM; Kuerer, HM; Litton, JK; Meric-Bernstam, F; Mittendorf, EA; Woodward, WA | 1 |
| Abbas, R; Bondarenko, I; Chow, LW; Freyman, A; Gupta, S; Vo Van, ML; Xu, B; Zhao, Y | 1 |
| Aldrighetti, D; Amadori, D; Campone, M; Conte, P; Lee, F; Liu, D; McHenry, MB; Melisko, M; Pivot, X; Rugo, HS; Villanueva, C; Wardley, A | 1 |
| Brewster, AM; Esteva, FJ; Florance, AM; Franco, SX; Hagan, MK; Perez, A; Somer, RA; Stein, S; Turner, S; Williams, W | 1 |
| Bach, A; Clawson, A; Conlin, AK; Forero, A; Hackney, MH; Hudis, CA; Lake, D; Moynahan, ME; Norton, L; Seidman, AD; Wright, GS | 1 |
| Fagotti, A; Fanfani, F; Ferrandina, G; Margariti, PA; Nero, C; Pedone, AL; Petrillo, M; Scambia, G; Vizzielli, G | 1 |
| Dakhil, SR; Hirsh, V; Hon, JK; Okamoto, I; Orsini, J; Page, RD; Renschler, MF; Socinski, MA; Yamamoto, N; Zhang, H | 1 |
| Jarboe, J; Saif, MW | 1 |
| Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Biankin, AV; Caldon, CE; Clark, SJ; Cowley, MJ; Gallego-Ortega, D; Gee, JM; McCloy, RA; Musgrove, EA; Nicholson, RI; Ormandy, CJ; Print, CG; Sergio, CM; Stone, A; Valdes-Mora, F | 1 |
| Kawamura, M; Kyoda, S; Nakano, S; Tabei, I; Takeyama, H; Yoshida, K | 1 |
| Agarwal, S; Beckman, J; Cotreau, MM; Dickler, MN; Duarte, A; Mayer, EL; Richly, H; Scheulen, ME; Steelman, L; Strahs, AL; Winer, EP | 1 |
| Aigner, J; Jaeger, D; Marmé, F; Schneeweiss, A; Schuetz, F; Smetanay, K | 1 |
| Hidalgo, M; Ma, WW | 1 |
| Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Rovida, A; Scanziani, E; Scarlato, V | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Bush, TL; Chung, G; Friberg, G; Hanestad, K; Heller, S; Kendall, RL; Loberg, R; Payton, M; Radinsky, R; Rottman, JB; Saffran, D | 1 |
| Chen, WW; Cheng, AL; Hsu, CH; Huang, TC; Lin, CC; Yeh, KH | 1 |
| Costa, VM; Diniz, C; Fresco, P; Soares, AS | 2 |
| Erickson, D; Mak, M | 1 |
| Carmichael, J; Chan, A; Clemons, M; Dent, RA; Lindeman, GJ; Lowe, ES; McCarthy, NJ; Singer, CF; Watkins, CL; Wildiers, H | 1 |
| Alvarez, I; García-Estévez, L; Lluch, A; Muñoz, M; Seguí, MÁ; Tusquets, I | 1 |
| Crivellaro, C; Cuzzocrea, M; Dell'Anna, T; Dolci, C; Fruscio, R; Guerra, L; Messa, C; Milani, R; Signorelli, M; Sina, F | 1 |
| Abraham, J; Adamson, LM; Buyse, M; Jacobs, SA; Jankowitz, RC; Limentani, SA; Tan, AR; Tierno, MB; Wolmark, N | 1 |
| El-Khattouti, A; Gomez, CR; Haïkel, Y; Hassan, M; Megahed, M; Selimovic, D | 1 |
| Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS | 1 |
| Ozdemir, O; Ozdemir, P; Ozhan, MH; Uluer, H; Veral, A | 1 |
| Blackwell, K; Broadwater, G; Hamilton, E; Hopkins, J; Kimmick, G; Marcom, PK; Rocha, G; Welch, R | 1 |
| Amadio, G; Masciullo, V; Scambia, G; Stefano, L | 1 |
| Beckman, RA; Chmielowska, E; Fox, T; Greenberg, J; Hadler, D; Krzakowski, M; Reck, M; Sebastian, M; von Pawel, J; Wang, Q | 1 |
| Chaigneau, L; Chelly, J; Fiteni, F; Limat, S; Meneveau, N; Monnot, T; Montcuquet, P; Nerich, V; Perrin, S; Pivot, X; Villanueva, C; Voidey, A | 1 |
| Gu, MF; Huang, SM; Su, Y; Wu, Z; Zeng, RF | 1 |
| Chi, HD; Liu, Z; Orlando, M; Quinlivan, M; Xu, B; Zhang, XQ | 1 |
| Bastide, C; Bruyère, F; Deville, JL; Flechon, A; Guy, L; Karsenty, G | 1 |
| Saif, MW | 1 |
| Kautio, AL; Kellokumpu-Lehtinen, PL; Lehtinen, I; Tanner, M; Tuunanen, T | 1 |
| Fujisawa, M; Inoue, T; Miyake, H; Miyazaki, A; Tanaka, H; Terakawa, T; Yokoyama, N | 1 |
| Beijnen, JH; Gelderblom, H; Guchelaar, HJ; Rosing, H; Scheulen, ME; Slingerland, M; van Warmerdam, LJ | 1 |
| Ashida, A; Okuyama, R; Sato, Y; Uhara, H | 1 |
| Ahn, JS; Chang, W; Choi, MK; Im, SA; Im, YH; Kim, S; Lee, SY; Park, YH; Woo, SY | 1 |
| Amagasa, H; Ami, K; Ando, M; Arai, K; Fujiya, K; Fukuda, A; Ganno, H; Kamikozuru, H; Nagahama, T; Seki, R; Takasaki, J; Tei, S | 1 |
| Aomatsu, N; Asano, Y; Hirakawa, K; Ishihara, S; Ishikawa, T; Kashiwagi, S; Kawajiri, H; Morisaki, T; Noda, S; Onoda, N; Takashima, T; Watanabe, M | 1 |
| Azarnia, N; Baselga, J; Byakhov, M; Cortés, J; Forenza, S; Goldfarb, RH; Hudis, CA; Llombart, A; Lokanatha, D; Manikhas, A; Matera, J; Roman, L; Rozencweig, M; Semiglazov, VF | 1 |
| Barsky, SH; Boley, KM; Chu, K; Cristofanilli, M; Green, TL; Heise, C; Liu, H; Moraes, R; Robertson, FM; Wright, MC; Ye, Z; Zhang, X | 1 |
| Kashihara, H; Murata, T; Shimizu, Y; Taga, R; Tsuji, K; Yamada, C; Yonezawa, M; Yoshino, H | 1 |
| Barni, S; Coinu, A; Lorusso, D; Petrelli, F; Raspagliesi, F | 1 |
| Markman, M | 3 |
| Barranger, E; Bertheau, P; Bousquet, G; de Bazelaire, C; Ferreira, I; Feugeas, JP; Janin, A; Jourdan, N; Vercellino, L | 1 |
| Huang, H; Landrum, LM; Leitao, MM; Long, HJ; Michael, HE; Monk, BJ; Oaknin, A; Penson, RT; Ramondetta, LM; Reid, TJ; Sill, MW; Tewari, KS | 1 |
| Hurvitz, SA; Megerdichian, C; Olimpiadi, Y | 1 |
| Akslen, LA; Birkeland, E; Bredholt, T; Halle, MK; Krakstad, C; Salvesen, HB; Tangen, IL; Trovik, J; Werner, HM; Wik, E | 1 |
| Budi, L; Cseh, J; Dank, M; Erfan, J; Landherr, L; Mangel, L; Piko, B; Ruzsa, A | 1 |
| Jia, Y; Marks, E; Saif, MW | 1 |
| Deng, W; Guan, Z; Huang, M; Huang, W; Jiang, W; Kang, T; Li, L; Li, S; Liu, Q; Liu, R; Pan, C; Tan, W; Thomas, GR; Wu, J; Ye, W; Ying, X; Zeng, M; Zhang, L | 1 |
| Markham, MJ; Murphy, MC | 1 |
| Berlin, JD; Pauff, JM; Thota, R | 1 |
| Charalambous, E; Dimopoulos, MA; Dionysopoulos, D; Fountzilas, G; Kotoula, V; Koutras, A; Kouvatseas, G; Papandreou, CN; Papazisis, K; Pectasides, D; Pentheroudakis, G; Samantas, E; Zagouri, F | 1 |
| Bongaerts, AH; Brouwers, AH; de Jong, JR; de Vries, EG; Gaykema, SB; Lub-de Hooge, MN; Oude Munnink, TH; Perik, PJ; Schröder, CP | 1 |
| Bondareva, A; Jirik, FR; Singla, AK | 1 |
| DeSilvio, M; Ellis, C; Guan, Z; Jiang, Z; Leigh, M; Russo, M; Shen, Z; Tong, Z; Xu, B; Yang, J | 1 |
| Ichioka, D; Joraku, A; Kandori, S; Kawai, K; Kojima, T; Kurobe, M; Miyazaki, J; Nishiyama, H; Oikawa, T; Suetomi, T; Takaoka, E | 1 |
| Arpino, G; De Angelis, C; De Placido, S | 1 |
| Du, J; Hu, B; Hu, C; Wang, F; Zhang, Y | 1 |
| Bellile, E; Bradford, CR; Carey, T; Chanowski, EJ; Chepeha, DB; Chinn, SB; Eisbruch, A; Gallagher, KK; Ibrahim, M; McHugh, JB; Moyer, JS; Prince, ME; Spector, ME; Vainshtein, J; Walline, HM; Wolf, GT; Worden, FP | 1 |
| Iguchi, F; Kusano, J; Murai, N; Takahashi, Y; Taniguchi, Z | 1 |
| Hoy, SM | 1 |
| Kontrogianni-Konstantopoulos, A; Martin, SS; Perry, NA; Vitolo, MI | 1 |
| DeNardo, D; Griggs, C; Hall, K; Kohio, P; Rajput, S; Ran, S; Volk-Draper, L | 1 |
| Amano, S; Enomoto, K; Hara, Y; Makishima, M; Nagashima, S; Sakurai, K; Suzuki, S | 1 |
| Bachinger, A; Jaeger, D; Marmé, F; Schneeweiss, A; Schuetz, F; Seitz, J; Sinn, HP; Smetanay, K; Zorn, M | 1 |
| Chang, GJ; Crane, CH; Das, P; Eng, C; Ohinata, A; Pathak, P; Phillips, JK; Rodriguez-Bigas, M; Rogers, JE; Sethi, S; Vauthey, JN; Wolff, RA; Xing, Y; You, YN | 1 |
| Iida, S; Iwamoto, M; Kurita, T; Saegusa, H; Takei, H; Uchida, E; Yamashita, K; Yanagihara, K | 1 |
| Chevreau, C; Culine, S; Delva, R; Eymard, JC; Fizazi, K; Fléchon, A; Geoffrois, L; Gravis, G; Habibian, M; Journeau, F; Kerbrat, P; Laplanche, A; Linassier, C; Logothetis, C; Malhaire, JP; Mardiak, J; Martin, AL; Pagliaro, L; Reckova, M; Rolland, F; Roubaud, G; Theodore, C | 1 |
| Eustermann, H; Harich, HD; Hinke, A; Jackisch, C; Reichert, D; Schoenegg, W; Selbach, J; Tesch, H; Welslau, M; Wohlfarth, T | 1 |
| Augustin, HG; Besemfelder, E; Hu, J; Jugold, M; Kapel, SS; Korn, C; Pasparakis, M; Savant, S; Srivastava, K; Teichert, M; Thomas, M | 1 |
| Blanchard, MS; Brown, J; Choi, A; Chung, CT; Doan, CM; Feng, T; Hurria, A; Katheria, V; Luu, T; Mortimer, J; Ramani, R; Rotter, AJ; Somlo, G; Synold, TW; Wong, C | 1 |
| Akiyama, K; Alam, MT; Hida, K; Hida, Y; Kawamoto, T; Maishi, N; Ohba, Y; Ohga, N; Ohmura, H; Shindoh, M; Torii, C; Yamada, K | 1 |
| Chen, Q; Liang, C; Liu, Z; Wang, C | 1 |
| Amith, SR; Baksh, S; Fliegel, L; Wilkinson, JM | 1 |
| Aldairy, W; Borin, MT; Chen, M; Chittenden, J; Mocci, S; Rubets, I; Stroh, M | 1 |
| Beitler, J; Blumenschein, G; Bogart, J; Bradley, JD; Choy, H; Curran, W; Forster, K; Garces, YI; Gaur, R; Hu, C; Iyengar, P; Kavadi, V; Komaki, R; Koprowski, C; Magliocco, A; Masters, G; Meng, J; Narayan, S; Paulus, R; Robinson, C; Schild, S; Wynn, RB | 1 |
| Azzariti, A; Cocco, T; Ferretta, A; Guida, G; Guida, M; Guida, S; Iacobazzi, RM; Maida, I; Porcelli, L; Quatrale, AE; Sidella, L; Stolfa, DA; Strippoli, S; Tommasi, S | 1 |
| Krill, LS; Tewari, KS | 1 |
| Barbolina, MV; Choi, J; Gurler, H; Kajdacsy-Balla, AA; Yu, Y | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Chen, L; Chen, Y; Gu, W; Huang, Y; Li, Y; Meng, Q; Su, J; Sun, H; Tang, S; Xu, M; Yin, Q; Yu, H; Zhang, Z | 1 |
| Asano, Y; Hirakawa, K; Ishihara, S; Kashiwagi, S; Kawajiri, H; Kurata, K; Morisaki, T; Noda, S; Onoda, N; Sakimura, C; Takashima, T; Tauchi, Y; Tokumoto, M | 1 |
| Bae, SB; Kim, HJ; Kim, K; Lee, KT; Lee, N; Lee, SC; Park, HS; Park, WY; Won, JH | 1 |
| Abramson, VG; Aung, K; Brown, ME; Forero-Torres, A; Hayes, DF; Irvin, WJ; Kidwell, KM; Li, Y; Lin, NU; Liu, MC; Muñiz, MC; Nanda, R; Nangia, JR; Paoletti, C; Storniolo, AM; Thomas, DG; Traina, TA; Vaklavas, C; Van Poznak, CH; Wolff, AC | 1 |
| Abraham, I; Bootman, JL; Gharaibeh, M; McBride, A | 1 |
| Fujita, Y; Nakatsukasa, K; Okamoto, A; Sakaguchi, K; Sugimoto, R; Taguchi, T | 1 |
| Amiji, MM; Duan, Z; Feng, Y; Foster, R; Gao, Y; Hornicek, FJ; Mankin, HJ; Shen, JK; Yang, X | 1 |
| Chalasani, P; Clarke, K; Iannone, M; Livingston, RB; Marron, M; Roe, D; Shan, JS; Stopeck, AT | 1 |
| Han, L; Kang, CS; Liu, X; Mei, M; Ren, Y; Song, X; Tian, WP; Wang, QX; Yang, JJ; Zhang, L; Zhao, XH; Zhou, X; Zhu, ZY | 1 |
| Chen, Q; Liu, Q; Shen, S; Shi, C; Wu, R; Xu, Q; Yang, B | 1 |
| Albarracin, C; Atkins, J; Booser, D; Gilcrease, M; Helgason, T; Janku, F; Koenig, K; Kurzrock, R; Moroney, J; Morrow, PK; Moulder, S; Wheler, J | 1 |
| Abeni, C; Aroldi, F; Bertocchi, P; Di Biasi, B; Meriggi, F; Ogliosi, C; Rizzi, A; Rosso, E; Rota, L; Savelli, G; Zaniboni, A | 1 |
| Alishekevitz, D; Apte, RN; Benhar, M; Fremder, E; Isakov, E; Kaneti, L; Kaplanov, I; Machluf, M; Miller, V; Shaked, Y; Voloshin, T; Voronov, E | 1 |
| Aogi, K; Armour, A; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Nakayama, T; Nishimura, Y; Rai, Y; Sasaki, Y; Shimizu, S | 1 |
| Benedit, P; Carrato, A; García, P; Gostkorzewicz, J; López, R; Macarulla, T; Pérez-Alcántara, F; Rivera, F; Sastre, J | 1 |
| He, J; Hoffman, RM; Li, H; Zhong, N | 1 |
| Cerezuela Fuentes, P; Ferris Villanueva, E; García Márquez, A; Guerrero Bautista, R; Martínez Penella, M; Mira Sirvent, Mdel C | 1 |
| Chen, L; Fang, W; Jiang, H; Mao, C; Mou, H; Qian, J; Teng, L; Wang, Y; Xu, N; Zhang, X; Zhao, P; Zheng, Y | 1 |
| Ahn, JH; Ahn, JS; Han, SW; Im, SA; Im, YH; Jung, KH; Jung, SH; Kang, SY; Kim, JH; Kim, SB; Lee, KS; Lee, MH; Lee, S; Nam, BH; Oh, DY; Park, HS; Park, IH; Park, YH; Ro, J; Sohn, JH; Woo, SY | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yoon, SJ; Yun, T | 1 |
| Barry, WT; Carey, LA; Cirrincione, C; Hudis, C; Leung, E; Lyss, AP; Mayer, EL; Moreno-Aspitia, A; Naughton, M; Perez, EA; Rugo, HS; Toppmeyer, D; Winer, EP | 1 |
| Martín, M | 2 |
| Bang, YJ; Cho, JY; Im, SA; Jung, JA; Kim, JW; Koh, SA; Lee, KH; Lee, KW; Park, YI; Shin, DB; Yu, KS; Zang, DY | 1 |
| Gamoh, M; Ichikawa, S; Kawai, S; Sakamoto, Y; Takahashi, Y | 1 |
| Brachmann, CB; Heise, C; Hidalgo, M; Illei, P; Lopez-Casas, PP; Lopez-Rios, F; Menendez, C; Musteanu, M; Pierce, D; Plaza, C; Romano, A; Tabernero, J; Von Hoff, DD; Wei, X | 1 |
| Gligorov, J; Richard, S | 1 |
| De Laurentiis, M; Mustacchi, G | 1 |
| Arbaud, C; Bachet, JB; Bidault, AT; Bonnetain, F; Coriat, R; Dahan, L; de la Fouchardière, C; Dréanic, J; Dubreuil, O; Hammel, P; Lecomte, T; Lepère, C; Locher, C; Marthey, L; Pernot, S; Portal, A; Taieb, J; Tchoundjeu, B; Tougeron, D | 1 |
| André, T; Bachet, JB; Bonnetain, F; Chibaudel, B; Hammel, P; Louvet, C; Validire, P | 1 |
| Chung, YS; Kang, HC; Lee, T | 1 |
| Bass, JD; Bosserman, LD; Burris, HA; Hainsworth, JD; Harwin, WN; Morgan, SK; O'Shaughnessy, JA; Peacock, NW; Priego, VM; Yardley, DA | 1 |
| Im, YH; Kim, M; Kim, S; Lee, J; Lee, SJ; Park, SH; Park, YH | 1 |
| Adachi, K; Amano, S; Enomoto, K; Hara, Y; Makishima, M; Nagashima, S; Sakurai, K; Suzuki, S | 1 |
| Inoue, T; Kamba, T; Kobayashi, T; Matsui, Y; Negoro, H; Ogawa, O; Okada, Y; Shibasaki, N; Sunada, T; Terada, N; Yamasaki, T | 1 |
| Guo, J; Tang, N; Wang, Y; Wang, Z; Zhang, Q | 1 |
| Bao, Y; Cai, Y; Ditzel, HJ; Feng, M; Goh, JY; Hoon, DS; Kohlbauer, VK; Lee, PL; Lim, E; Tam, WL; Tan, EY; Wang, PP; Wee, ZN; Yatim, SM; Yi, B; Yu, Q; Zhang, S | 1 |
| Leon-Ferre, RA; Markovic, SN | 1 |
| Győrffy, B; Lisanti, MP; Peiris-Pagès, M; Smith, DL; Sotgia, F | 1 |
| Álvarez, I; Ballesteros, AI; Blanco, E; Bueno, C; Cassinello, J; Chacón López-Muñiz, I; Cortés-Funes, H; Fernández-Aramburo, A; Galán, A; Gallegos Sancho, I; Gálve, E; Garau, I; García, MJ; González, S; González, X; González-Santiago, S; Grávalos, C; Llorca, C; Llorente, R; Manso, L; Olier, C; Palomo, AG; Perelló, A; Pérez Carrión, R; Torregrosa, D | 1 |
| Caterino, M; Cognetti, F; De Vita, R; Fabi, A; Ferretti, G; Giannarelli, D; Iacorossi, L; Malaguti, P; Mottolese, M; Nisticò, C; Papaldo, P; Vari, S | 1 |
| Accortanzo, V; Adami, F; Bighin, C; Bruzzi, P; Castiglione, F; Cavazzini, G; Conte, P; Danese, S; Del Mastro, L; Durando, A; Garrone, O; Landucci, E; Levaggi, A; Michelotti, A; Miglietta, L; Pastorino, S; Piras, M; Pronzato, P; Scotto, T | 1 |
| Barton, D; Beck, RM; Brufsky, A; Coleman, RE; Conte, PF; Cortes, J; Glück, S; Harbeck, N; Ko, A; Nabholtz, JM; O'Shaughnessy, J; Renschler, MF; Yardley, DA | 1 |
| Arpino, G; Cortés, J; Leonard, R; Llombart-Cussac, A; Marmé, F; Ricevuto, E | 1 |
| Corzo, D; Enger, C; Fraser, CD; Ko, A; Li, L; Liang, C; Patt, D | 1 |
| Cun, X; Gao, H; He, Q; Lu, L; Wang, Y; Xia, T; Yang, Y; Yu, Q; Zhang, L; Zhang, Q; Zhang, Z | 1 |
| Arena, F; Goldstein, D; Korn, RL; Liu, H; Lu, B; McGovern, D; Moore, M; Ramanathan, RK; Siena, S; Tabernero, J; Teixeira, L; Van Laethem, JL; Von Hoff, DD | 1 |
| Furuse, J; Ikeda, M; Ioka, T; Mizuno, N; Nakajima, TE; Omuro, Y; Ueno, H; Ueno, M | 1 |
| Bacon, CL; Bracken-Clarke, D; Browne, PV; Conneally, E; Daly, PA; Flynn, C; Gardiner, N; Hayden, PJ; Kennedy, MJ; Lee, G; McCaffrey, J; Ni Chonghaile, M; O'Donnell, DM; O'Kane, G; Power, D; Vandenberghe, E | 1 |
| Bajpai, J; Bakshi, AV; Bapsy, PP; Bhatt, N; Bhattacharya, GS; Bhowmik, S; Bondarde, SA; Chimote, G; Desai, CJ; Deshmukh, CD; Digumarti, R; Govind Babu, K; Gupte, SU; Haritha, C; Jain, MM; Khopade, A; Kumar, R; Pathak, AB; Patil, P; Patil, SG; Subramanian, S; Vaid, AK | 1 |
| Brown-Glaberman, U; Chalasani, P; Iannone, M; Livingston, R; Marron, M; Specht, J; Stopeck, AT | 1 |
| Dang, CT; Fleisher, M; Hudis, CA; Jones, LW; Liu, JE; Manrique, C; Mara, E; Patil, S; Pun, S; Steingart, RM; Yu, AF | 1 |
| Ahn, D; Aparo, S; Bekaii-Saab, TS; Ciombor, KK; El-Rayes, B; Farren, MR; Geyer, SM; Huang, Y; Lesinski, GB; Mace, TA; Marshall, JL; Mikhail, S; Noonan, AM; Pant, S; Sexton, J; Tahiri, S; Timmers, CD; Villalona-Calero, MA; Wu, CS; Zwiebel, J | 1 |
| Chen, M; Dong, S; Jiang, ZX; Xia, G; Zhao, P | 1 |
| Fan, A; Haas, D; Harshman, L; Lam, A; Li, S; Narayanan, S; Pachynski, R; Poushnejad, S; Srinivas, S; Vaishampayan, U | 1 |
| Goodarzi, H; Nguyen, A; Tavazoie, SF; Yoshida, M | 1 |
| Cui, S; Hu, X; Liao, N; Liu, D; Luo, R; Sun, Q; Wang, X; Xu, B; Yu, S; Zhang, Q; Zheng, H | 1 |
| Doihara, H; Iwamoto, T; Matsuoka, J; Mitsuhashi, T; Mizoo, T; Motoki, T; Nogami, T; Ogasawara, Y; Shien, T; Taira, N; Tsuji, H; Yoshitomi, S | 1 |
| Bassi, N; Brivio, S; Cadamuro, M; Caslini, C; Fabris, L; Indraccolo, S; Massani, M; Nardo, G; Novelli, E; Rosato, A; Sambado, L; Spagnuolo, G; Spirli, C; Stecca, T; Strazzabosco, M | 1 |
| Chiorean, EG; El-Maraghi, R; Goldstein, D; Harris, M; Li, JS; Liu, H; Lu, B; Ma, WW; Manax, V; Reni, M; Romano, A; Tabernero, J; Von Hoff, DD; Whorf, R | 1 |
| Gill, HS; Mody, MD; Saba, NF | 1 |
| Dang, YZ; Hu, J; Li, WW; Li, X; Ping, LJ; Shi, M; Wei, LC; Zhang, Y; Zhao, LN | 1 |
| Alesse, E; Bafile, A; Cannita, K; Cocciolone, V; Ficorella, C; Irelli, A; Lanfiuti Baldi, P; Manetta, R; Paradisi, S; Ricevuto, E; Rinaldi, L; Zugaro, L | 1 |
| Chanvorachote, P; Chaotham, C; Puchsaka, P | 1 |
| Bateman, S; Heise, C; Hidalgo, M; Hou, S; Maitra, A; Pai, SG; Pierce, DW; Rajeshkumar, NV; Tong, Z; Von Hoff, DD; Yabuuchi, S | 1 |
| Bisagni, G; Ciccarese, M; Fontanella, C; Gamucci, T; Leo, L; Marchetti, P; Molino, A; Puglisi, F; Silva, RR | 1 |
| Anghel, R; Beslija, S; Brodowicz, T; Dank, M; Eniu, A; Greil, R; Inbar, M; Kahán, Z; Láng, I; Melichar, B; Messinger, D; Nisenbaum, B; Petruzelka, L; Pienkowski, T; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Andre, V; Enas, N; Gueorguieva, I; Ribba, B; Tate, SC | 1 |
| Abell, F; Apt, D; Chan, S; Fehrenbacher, L; Gendreau, S; Huizing, M; Laing, R; Petrakova, K; Rooney, I; Roylance, R; Singel, S; Vuylsteke, P; Zhou, J | 1 |
| Ciardiello, F; Conzo, G; De Vita, F; Diana, A; Fabozzi, A; Febbraro, A; Galizia, G; Giordano, G; Laterza, MM; Orditura, M; Petrillo, A; Savastano, B; Troiani, T; Ventriglia, J | 1 |
| Fang, Y; Sun, L; Xu, X; Ye, J; Zhang, Z; Zhou, G | 1 |
| Anchisi, S; Bärtschi, D; Bernhard, J; Bigler, M; Borner, M; Cathomas, R; Hasler-Strub, U; Küng, M; Matter-Walstra, K; Müller, A; Na, KJ; Rauch, D; Rochlitz, C; Rordorf, T; Ruhstaller, T; Trojan, A; Vetter, M; von Moos, R; Wicki, A; Winterhalder, R; Zaman, K | 1 |
| Li, JS; McGovern, D; Romano, A; Römmler-Zehrer, J; Stahl, M; Vogel, A | 1 |
| Alishekevitz, D; Ben-Nun, Y; Blum, G; Gingis-Velitski, S; Gutter-Kapon, L; Hershkovitz, D; Ilan, N; Kaidar-Person, O; Loven, D; Merquiol, E; Miller, V; Mumblat, Y; Rachman-Tzemah, C; Raviv, Z; Satchi-Fainaro, R; Scherer, SD; Shaked, Y; Sleeman, JP; Timaner, M; Vlodavsky, I | 1 |
| Barbier, L; Gertler, FB; Han, S; Jonas, O; Kosciuk, T; Lauffenburger, DA; Miller, MA; Oudin, MJ; Schäfer, C | 1 |
| Gao, B; Guo, LJ; Hao, S; Jiang, Y; Luo, DL; Tian, WG; Zhang, S; Zhang, XH | 1 |
| Angelini, F; Astone, A; Barba, M; Bertolini, I; Buglioni, S; Cassano, A; De Angelis, C; Di Lauro, L; Fabi, A; Gamucci, T; Giordano, A; Grassadonia, A; Magnolfi, E; Marchetti, P; Maugeri-Saccà, M; Mentuccia, L; Michelotti, A; Moscetti, L; Natoli, C; Nisticò, C; Palleschi, M; Pellegrini, D; Pellegrino, A; Pizzuti, L; Rossi, E; Sarobba, MG; Sergi, D; Sini, V; Sperduti, I; Vaccaro, A; Vici, P | 1 |
| Adansa Klain, JC; Berrocal, A; Caballero Daroqui, J; Cruz-Hernández, JJ; Del Barco Morillo, E; González-Rivas, C; Martínez-Galán, J; Martínez-Trufero, J; Mesía, R; Pastor Borgoñon, M; Vázquez Fernández, S; Vera, R | 1 |
| Adenis, A; Bennouna, J; Conroy, T; Ducreux, M; Jeanes, J; Li, L; Lièvre, A; Portales, F; Romano, A | 1 |
| Chen, CM; Chen, S; Jin, X; Shao, ZM; Wang, RX | 1 |
| Dai, X; Jiang, J; Wang, C; Wu, C; Zhang, X | 1 |
| Huong, PT; Minh, NV; Thang, ND | 1 |
| Chen, H; Dai, D; Tang, J; Tang, Y | 1 |
| Ando, Y; Goto, H; Kikumori, T; Maeda, O; Matsuoka, A; Mizutani, T; Nakano, Y; Tsunoda, N | 1 |
| Augspurger, ME; Bogart, JA; Bosch, W; Bradley, JD; Choy, H; Chun, SG; Dobelbower, MC; Galvin, JM; Hu, C; Iyengar, P; Kavadi, VS; Komaki, RU; MacRae, RM; Narayan, S; Paulus, R; Raben, A; Robinson, CG; Schild, SE; Timmerman, RD; Wynn, RB | 1 |
| Adkins, D; Daly, K; Ley, J; Oppelt, P; Wildes, TM | 1 |
| Han, X; Lu, N; Pan, Y; Xu, J | 1 |
| Bouvet, M; Fujiwara, T; Hoffman, RM; Kagawa, S; Kishimoto, H; Takehara, K; Tazawa, H; Urata, Y; Yano, S | 1 |
| Akiyama, Y; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kuwahara, R; Morimoto, Y; Murakami, K; Naito, A; Ohmura, Y; Oneda, Y; Sakamoto, T; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Hoshino, H; Hosoda, Y; Kawada, J; Kim, Y; Nagai, K; Nishino, M; Okano, M; Okuyama, M; Tsujinaka, T | 1 |
| Bi, Y; Chen, Q; Chen, X; He, X; Jiang, C; Liu, L; Ruan, C; Sun, T; Wang, H; Zhang, Y; Zhou, M | 1 |
| Chong, QY; Ding, K; Kong, X; Li, R; Li, X; Lobie, PE; Ma, L; Pandey, V; Qian, P; Wu, Z; Xiong, Z; Yang, Y; Yuan, Y; Zhu, T | 1 |
| Bakri, K; Berry, DA; Cirrincione, C; Fleming, GF; Hudis, C; Lake, D; Marcom, K; Muss, H; Norton, L; Polite, BN; Schwartz, JH; Seidman, A; Shapiro, C; Winer, EP | 1 |
| Blackwell, K; Bullock, K | 1 |
| Bivens, CM; Desai, N; Flister, MJ; Ran, S; Stutzman, A; Trieu, V; Volk, LD | 1 |
| Aravantinos, G; Bafaloukos, D; Bamias, A; Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Papadimitriou, CA; Pectasides, D | 1 |
| Bokemeyer, C; Kollmannsberger, C | 1 |
| Bosnjak, SM; Radulovic, S; Susnjar, S | 1 |
| Blot, E; Ouvrier, MJ; Philippin-Lauridant, G; Thureau, S | 1 |
| Georgoulias, V; Mavroudis, D; Saloustros, E | 1 |
| Bay, JO; Blay, JY; Bompas, E; Brain, EG; Bui, BN; Chevreau, C; Cupissol, D; Fournier, C; Isambert, N; Jimenez, M; Kerbrat, P; Penel, N; Peyrade, F; Piperno-Neumann, S; Ray-Coquard, I; Taieb, S | 1 |
| Jang, MJ; Jin, J; Joo, KM; Kang, BG; Kim, MH; Kim, MS; Lee, GS; Nam, DH; Park, K; Song, SY | 1 |
| Ahn, JB; Chang, H; Chung, HC; Im, CK; Jeung, HC; Kwon, WS; Rha, SY; Roh, JK; Yoo, NC | 1 |
| Dafni, U; Fountzilas, G; Fragkoulidi, A; Fragoulakis, V; Galani, E; Grimani, I; Maniadakis, N | 1 |
| Arbushites, MC; Aziz, Z; Bines, J; Dering, J; Di Leo, A; Finn, RS; Gomez, HL; Guerrera, SF; Koehler, M; Oliva, C; Press, MF; Stein, SH; Williams, LS; Zvirbule, Z | 1 |
| Ilson, DH; Kelsen, DP; Kepler, S; O'Reilly, E; Radovich, D; Saltz, LB; Schrag, D; Schwartz, G; Tew, WP | 1 |
| Cottrell, W; Dranitsaris, G; Hopkins, S; Spirovski, B | 1 |
| Bane, CL; Gross, GG; LaPlant, BR; Palmieri, FM; Roy, V | 1 |
| Aranishi, T; Hausheer, FH; Hisamatsu, K; Kuroi, K; Masuda, N; Morita, S; Ohashi, Y; Ohsumi, S; Shimozuma, K; Takeuchi, A | 1 |
| Autorino, R; Bellelli, T; De Placido, S; Di Lorenzo, G; Giannarini, G; Imbimbo, C; Longo, N; Mirone, V; Montesarchio, V; Morelli, E | 1 |
| Baselga, J; Benavides, M; Cirera, L; Climent, MA; Cortes, J; Cortés-Funes, H; Di Cosimo, S; Dorado, JF; Gascón, P; Gil, M; Lluch, A; Mayordomo, JI; Ojeda, B; Regueiro, P; Rodríguez, CA; Trigo, JM; Vazquez, J | 1 |
| Cobb, P; Houts, AC; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Bria, E; Carpino, A; Cognetti, F; Cuppone, F; Fornier, M; Izzo, F; Nisticò, C; Sperduti, I; Terzoli, E; Tropea, F; Vaccaro, V | 1 |
| Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Petrillo, A; Rinaldo, M; Siani, C | 1 |
| Altieri, V; Autorino, R; Cartenì, G; De Placido, S; Di Lorenzo, G; Doria, F; Faiella, A; Ferro, M; Gonnella, A; Imbimbo, C; Longo, N; Mirone, V; Palmieri, G; Perdonà, S; Rescigno, P | 1 |
| Agarwala, SS; Bokar, JA; Cooney, MM; Dowlati, A; Flick, SM; Fu, P; Hartman, PH; Lavertu, PN; Mooney, CJ; Nagaiah, G; Ortiz, JD; Remick, SC; Savvides, PS; Wang, D; Wasman, JK | 1 |
| Horiguchi, J; Iino, Y; Ikeda, F; Ishikawa, Y; Kikuchi, M; Koibuchi, Y; Nagaoka, H; Nagaoka, R; Odawara, H; Oyama, T; Rokutanda, N; Sato, A; Takata, D; Takeyoshi, I; Yokoe, T | 1 |
| Hisamatsu, K; Horiguchi, J; Ito, Y; Rai, Y; Seriu, T; Tajima, T; Taki, T; Tamura, K | 1 |
| Berneburg, M; Clasen, S; Eigentler, T; Forschner, A; Garbe, C; Guenova, E; Knaudt, B; Leiter, U; Meier, F; Zielinski, C | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Kim, JY; Lim, MC; Park, SY; Yoo, CW | 1 |
| Aravantinos, G; Bamias, A; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Mountzios, G; Papadimitriou, CA; Vourli, G | 1 |
| Bhar, P; Cheporov, S; Clawson, A; Gradishar, WJ; Krasnojon, D; Makhson, AN; Manikhas, GM | 1 |
| Bedikian, A; Gerber, DL; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Ring, S | 1 |
| Sivanesaratnam, V | 1 |
| Abbas, O; Haddad, F; Kibbi, AG; Salem, Z | 1 |
| Beuselinck, B; Dirix, L; Kains, JP; Paridaens, R; Wildiers, H; Wynendaele, W | 1 |
| Gilbert, BE; Kline, K; Latimer, P; Menchaca, M; Sanders, BG; Snyder, RM; Yu, W | 1 |
| Gupta, PB; Jiang, G; Kuperwasser, C; Lander, ES; Onder, TT; Tao, K; Weinberg, RA | 1 |
| Aogi, K; Kakishita, T; Kurita, A; Okita, A; Okita, R; Osumi, S; Saeki, T; Taira, N; Takashima, S | 1 |
| Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Makatsoris, T; Papadimitriou, CA; Papakostas, P; Zagouri, F | 1 |
| Akrivos, T; Daladimos, T; Kalinoglou, N; Karabelis, A; Karvounis, N; Kosmas, C; Malamos, N; Mylonakis, N; Tsakonas, G; Tsavaris, N; Vorgias, G | 1 |
| Bekaii-Saab, T; Byrd, JC; Culler, K; Grever, MR; Lesinski, GB; Lucas, DM; Ramaswamy, B; Ruppert, AS; Schaaf, LJ; Shapiro, CL; Wilkins, D; Wright, JJ; Young, DC | 1 |
| Benedict, A; Cameron, DA; Corson, H; Jones, SE | 1 |
| Fukuda, H; Kamura, T; Katsumata, N; Kitagawa, R; Konishi, I; Saito, I; Shibata, T; Yoshikawa, H | 1 |
| Anderson, C; Gonzalez, R; Haddad, J; Hutchins, L; Jacobson, E; Kong, S; Lawson, D; O'Day, S; Weber, R; Williams, A | 1 |
| Clawson, AA; Gonzalez, R; Gordon, MS; Hersh, EM; O'Day, SJ; Ribas, A; Samlowski, WE; Shechter, DE | 1 |
| Blank, SV; Caputo, TA; Christos, PJ; Einstein, MH; Goldberg, GL; Goldman, N; Hershman, D; Ivy, PS; Kim, M; Kuo, DY; Muggia, F; Pothuri, B; Runowicz, CD | 1 |
| Chang, H; Chung, HC; Im, CK; Jeung, HC; Kim, JJ; Noh, SH; Rha, SY | 1 |
| Figueroa, JA; Kerr, RO; Kwon, J; Lee, MY; Podoltsev, NA; Rowen, E; Rubin, MS; Saif, MW; Yu, J | 1 |
| Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH | 1 |
| Alumkal, J; Beer, TM; Eilers, KM; Ryan, C; Ryan, CW; Sun, J | 1 |
| Kolb, MM; Kozloff, MF; Samant, M; Scappaticci, FA; Socinski, MA | 1 |
| Amano, S; Enomoto, K; Matsuo, S; Sakurai, K; Shiono, M | 1 |
| Chen, CP; Chen, CT; Chung, CT; Han, CH; Huang, CL; Huang, HC; Hwang, LL; Lai, YK; Lee, WS; Shen, CC; Tsai, ML; Tuan, TF; Wang, MH; Yeh, KC | 1 |
| Arbuck, SG; Broglio, K; Buzdar, AU; Holmes, FA; Hortobagyi, GN; Moulder, SL; Seidman, A; Thall, P; Tolcher, AW; Valero, V | 1 |
| Hama, Y; Nakagawa, K | 1 |
| Amonkar, MM; Aziz, Z; Bines, J; Di Leo, A; Gomez, HL; Sherrill, B; Wu, Y; Zvirbule, Z | 1 |
| Hirai, T; Ichikawa, Y; Kishikawa, H; Kobayashi, Y; Nishimura, K; Soda, T; Yamanaka, K | 1 |
| Atkins, MB; Bhatt, RS; Heymach, JV; McDermott, D; Merchan, J; Parker, R; Seery, V; Sukhatme, VP; Wu, HK; Zhang, L | 1 |
| Arbushites, M; Di Leo, A; Downey, L; Guzman, R; Koehler, M; Livingston, RB; Press, MF; Santiago, A; Villalobos, I; Williams, L | 1 |
| Carducci, M; Chen, YH; DiPaola, RS; Patrick-Miller, L; Roth, B; Stein, M; Vaughn, D; White, E; Wilding, G | 1 |
| Bergougnoux, L; Bidard, FC; de Cremoux, P; Degeorges, A; Delva, R; Etienne-Grimaldi, MC; Mathiot, C; Milano, G; Pierga, JY; Pivot, X; Veyret, C | 1 |
| Biganzoli, L; Conte, P; Diéras, V; Glaspy, J; Guarneri, V; Miles, D; Robert, N; Smith, I; Taran, T; Thomssen, C | 1 |
| Monk, BJ; Tewari, KS | 1 |
| Barni, S; Borgonovo, K; Petrelli, F | 1 |
| Khasraw, M; Murphy, CG; Seidman, AD | 1 |
| Bae, SH; Baek, JH; Chae, YS; Do, YR; Kim, JG; Kim, JY; Kim, MK; Lee, KH; Park, KU; Ryoo, HM; Song, HS | 1 |
| Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T | 1 |
| Burstein, HJ; Dhakil, S; Fabian, C; Kozloff, M; Mayer, EL; Parmar, H; Patel, T; Qamar, R; Samant, M; Sundaram, S; Volterra, F | 1 |
| Bhar, P; Biakhov, MY; Desai, N; Iglesias, J; Kononova, GV; Loibl, S; Schmid, AN | 1 |
| Eller, J; Kahán, Z; Kelemen, G; Ormándi, K; Thurzó, L; Uhercsák, G | 1 |
| Albertini, M; Croghan, GA; Eckardt, J; Erlichman, C; Flaherty, L; Linette, G; Ma, C; Maples, WJ; Markovic, SN; Suman, VJ | 1 |
| Ho, PC; Wang, Z | 1 |
| Bryan, M; Pavlick, AC; Pliner, L; Pulte, ED; Saunders, T; Toomey, KC; Wieder, R | 1 |
| Georgoulias, V; Karachaliou, N; Mavroudis, D; Saloustros, E; Vamvakas, L | 1 |
| Aogi, K; Fujimoto, T; Funai, J; Kamigaki, S; Okazaki, M; Saeki, T; Sagara, Y; Takashima, S; Toi, M; Yoshida, M | 1 |
| Airoldi, M; Beatrice, F; Gabriele, AM; Gabriele, P; Garzaro, M; Giordano, C; Pecorari, G; Pedani, F; Raimondo, L | 1 |
| Bousetta, N; Brain, E; Brignone, C; Cvitkovic, F; Gligorov, J; Grygar, C; Gutierrez, M; Jarcau, R; Marcu, M; Medioni, J; Mefti, F; Triebel, F | 1 |
| Ardavanis, A; Doufexis, D; Karagiannis, A; Kardara, E; Kountourakis, P; Maliou, S; Margari, C; Sykoutri, D; Tzovaras, A | 1 |
| Bach, A; Brufsky, AM; Clawson, A; Conlin, AK; D'Andrea, G; Danso, M; Dickler, M; Hudis, CA; Lake, D; Saleh, M; Seidman, AD; Traina, T | 1 |
| Aragane, H; Ichikawa, D; Itokawa, Y; Kakihara, N; Koizumi, K; Morii, J; Morita, S; Nishi, H; Okamoto, K; Otsuji, E; Sakamoto, J; Shimotsuma, M; Taniguchi, F; Ueda, Y; Yamagishi, H; Yamashita, T | 1 |
| Devineni, S; Ghebre, R; Ghosh, G; Jing, Y; Joshi, HP; Ramakrishnan, S; Subramanian, IV; Truskinovsky, AM | 1 |
| Agarwala, S; Bedikian, AY; Conry, R; DeConti, RC; Ernstoff, M; Kim, KB; Papadopoulos, N | 1 |
| Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Mahoney, SL; Papadopoulos, NE | 1 |
| Kezic, I; Milović-Kovačević, M; Popov, I; Radošević-Jelić, L; Stamatovic, L | 1 |
| Komatsu, Y; Kondo, C; Matsuo, K; Mizota, A; Muro, K; Nomura, M; Oze, I; Shitara, K; Takahari, D; Ura, T; Yokota, T; Yuki, S | 1 |
| Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Johnson, MM; Kim, KB; McIntyre, S; Papadopoulos, NE; Rohlfs, M; Warneke, CL | 1 |
| Bordin, F; De Marco, F; Di Nicola, S; Lanzetta, G; Rozzi, A; Salerno, M | 1 |
| Fujii, M; Hasegawa, Y; Kurono, Y; Minami, H; Nibu, K; Onozawa, Y; Sagae, D; Seriu, T; Tahara, M; Tomita, K; Tsukuda, M; Watanabe, A | 1 |
| DI, GH; Hu, XC; Li, JJ; Liu, GY; Lu, JS; Shao, ZM; Wang, Y; Wang, ZH; Wu, J; Yang, WT | 1 |
| Chen, C; Chen, P; Jin, ZL; Li, K; Li, N; Zhang, CC | 1 |
| Amano, S; Enomoto, K; Sakurai, K | 1 |
| Brandberg, Y; Einbeigi, Z; Hatschek, T; Johansson, H; Svensson, H | 1 |
| Berneburg, M; Eigentler, TK; Garbe, C; Ikenberg, K; Keim, U; Leiter, U; Pflugfelder, A; Weide, B | 1 |
| Abbruzzi, A; Bromberg, J; Chang, J; D'Andrea, G; Dang, C; Dickler, M; Fornier, MN; Gilewski, T; Hudis, CA; Modi, S; Morris, PG; Norton, L; Seidman, AD; Sklarin, N | 1 |
| Blake, DJ; Chen, P; Guo, H; Hao, X; Kong, X; Li, M; Niu, R; Zhang, N | 1 |
| Buzdar, AU | 1 |
| Adewoye, H; Adrover, E; Alba, E; Almel, S; Baños, A; Cabaribere, D; Crown, J; Eiermann, W; Hei, YJ; Hurvitz, S; Jagiełło-Gruszfeld, A; Kennedy, MJ; Lang, I; Latreille, J; Lemmerick, Y; Lindsay, MA; Mackey, JR; Martin, M; Moroose, R; Munoz, M; Pienkowski, T; Pinter, T; Priou, F; Provencher, L; Ramos, M; Roche, H; Rolski, J; Rupin, M; Snyder, R | 1 |
| Bazan, F; Chaigneau, L; Demarchi, M; Dufresne, A; N'guyen, T; Pivot, X; Stein, U; Thierry Vuillemin, A; Villanueva, C | 1 |
| Arola, J; Haglund, C; Hagström, J; Heikkilä, A; Heiskanen, I; Louhimo, J; Mäenpää, HO; Siironen, P | 1 |
| Chihade, D; Desai, N; Flister, MJ; Ran, S; Trieu, V; Volk, LD | 1 |
| Brodowicz, T; Loibl, S; Lück, HJ; Nekljudova, V; Schwenkglenks, M; Skacel, T; von Minckwitz, G; Zielinski, C | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| De Palma, M; Lewis, CE | 1 |
| Chen, W; Kreike, B; Liu, G; Meng, F; Miller, FR; Sethi, S; Wu, G; Zhang, H | 1 |
| Chidiac, T; Cosgriff, T; Harker, G; Keaton, M; Min, M; Mirtsching, B | 1 |
| Eastwood, A; Epstein, D; Fox, D; Rodgers, M; Soares, M; Yang, H | 1 |
| Anchisi, S; Bieri, S; Elhfidh, M; Khanfir, K; Matzinger, O; Mirimanoff, RO; Ozsahin, M; Zouhair, A | 1 |
| Albain, KS; Besse, B; Blais, N; Chao, RC; Gervais, R; Hainsworth, JD; Hamm, JT; Kim, ST; Laskin, J; Lipton, A; Masters, GA; Natale, RB; Page, RD; Selaru, P | 1 |
| Jeremić, B; Miličić, B; Milisavljevic, S | 2 |
| Cirrincione, CT; Cohen, HJ; Hudis, C; Hurria, A; Lichtman, SM; Muss, HB; Seidman, AD; Winer, E | 1 |
| Hoshino, K; Ide, H; Masuda, T; Satou, A; Tasaka, Y; Uchida, Y; Yasumizu, Y | 1 |
| Beck, T; Bromund, J; Brufsky, A; Frontiera, M; Hainsworth, J; Hoelzer, K; Keaton, M; Krill-Jackson, E; Kroener, J; Marciniak, MD; Middleman, E; Nadella, P; Obasaju, C; Orlando, M; Panella, T; Paul, D; Tai, F; Whorf, R; Zhao, L | 1 |
| Goel, PN; Gude, RP | 1 |
| Burris, HA; Castillo, R; Hainsworth, JD; Lahiry, A; Locicero, R; Raefsky, E; Shastry, M; Thompson, D; Yardley, DA | 1 |
| Bidoli, E; Capobianco, G; Dessole, F; Lombardi, D; Miolo, G; Santeufemia, DA; Scalone, S; Sorio, R; Spazzapan, S; Tabaro, G; Veronesi, A | 1 |
| Gupta, R; Krissansen, GW; Kuhn-Sherlock, B; Macgibbon, AK; Sun, X; Zhang, J | 1 |
| Acar, A; Çapar, M; Çelik, Ç; Gezginç, K; Karatayli, R; Tavli, L; Yazici, F | 1 |
| Aggarwal, BB; Chaturvedi, MM; Park, B; Sung, B; Yadav, VR | 1 |
| Aapro, M; Bhar, P; Gradishar, W; Tjulandin, S | 1 |
| Ando, M; Fujiwara, Y; Hashimoto, K; Hirata, T; Katsumata, N; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Aravantinos, G; Bafaloukos, D; Bobos, M; Christodoulou, C; Dimopoulos, AM; Efstratiou, I; Fountzilas, G; Kotoula, V; Kourea, HP; Koutras, A; Miliaras, D; Papadimitriou, C; Papakostas, P; Papandreou, CN; Papazisis, KT; Pectasides, D; Pentheroudakis, G; Petraki, K; Razis, E; Repana, D; Televantou, D; Timotheadou, E | 1 |
| Cella, D; Miller, K; Wagner, L; Wang, M | 1 |
| Choi, HL; Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yun, T | 1 |
| Alexandre, J; Bachelot, T; Bourgeois, H; de Rauglaudre, G; Hardy-Bessard, AC; Jaubert, D; Largillier, R; Lortholary, A; Paraiso, D | 1 |
| Cetina, L; Coronel, J; Dueñas-Gonzalez, A | 1 |
| Borad, MJ; Desai, N; Hidalgo, M; Iglesias, JL; Korn, RL; Laheru, DA; Maitra, A; Rajeshkumar, NV; Ramanathan, RK; Shi, T; Smith, LS; Soon-Shiong, P; Trieu, V; Von Hoff, DD; Wood, TE; Zhang, H | 1 |
| Brennan, DJ; Coussens, LM; DeNardo, DG; Gallagher, WM; Hwang, ES; Jirström, K; Junaid, SA; Keil, SD; Madden, SF; Rexhepaj, E; Ruffell, B; Rugo, HS; Shiao, SL; Wadhwani, N; West, BL | 1 |
| Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM | 1 |
| Bekku, K; Kanbara, T; Kioshimoto, R; Kobayashi, Y; Kumon, H; Nasu, Y; Saika, T | 1 |
| Adams, B; Diaz-Montero, CM; Glück, S; Montero, AJ | 1 |
| Hamaguchi, T; Iwasa, S; Kato, K; Kobayashi, K; Matsubara, J; Nagai, Y; Nakajima, TE; Nakayama, N; Shimada, Y; Takagi, S; Tsuji, A; Yamada, Y; Yoshioka, A | 1 |
| Heuer, V; Kummer, G; Neumann, H; Roy, R; Schultheis, B; Strumberg, D | 1 |
| Beyer, J; Griffin, S; Kanjanavaikoon, P; Robinson, WR | 1 |
| Faião-Flores, F; Maria, DA; Pardi, PC; Suarez, JA | 1 |
| Abbas, A; Fakih, M; Nehme, E | 1 |
| Alcalde, J; Aristu, J; Cambeiro, M; Gaztañaga, M; Martínez-Monge, R; Montesdeoca, N; Pagola, M; Rodriguez Ruiz, ME | 1 |
| Asuncion, D; Doroshow, JH; Forman, S; Frankel, P; Koczywas, M; Leong, L; Luu, T; Margolin, K; Morgan, R; Paz, IB; Pezner, R; Shibata, S; Somlo, G; Twardowski, P; VanderWalde, A; Wong, J; Ye, W | 1 |
| Barron, R; Edelsberg, J; Kartashov, A; Lyman, G; Weycker, D | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Somwangprasert, A; Srisukho, S; Sukthomya, V; Tharavichitkul, E; Trakultivakorn, H; Watcharachan, K | 1 |
| Inoue, T; Kamba, T; Matsui, Y; Nishiyama, H; Ogawa, O; Saito, R; Sumiyoshi, T; Xing, ND; Yoshimura, K | 1 |
| Anderson, R; Balkrishnan, R; Camacho, F; Kamal, AH; Kimmick, G; Wei, W | 1 |
| Hindenburg, HJ; Hinke, A; John, M; Mohr, B; Papke, J; Schlosser, J; Stauch, M; Wolf, H | 1 |
| He, J; Kim, JS; Kim, SJ; Kim, SW; Lee, HJ; Papadopoulos, JN; Park, YK; Yoon, Y; Yu, HK | 1 |
| Li, D; Wang, H; Wei, J; Yang, C; Yang, Z; Yin, Z; Zhao, H | 1 |
| Beslija, S; Brodowicz, T; Greil, R; Inbar, MJ; Kahán, Z; Kaufman, B; Lang, I; Messinger, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Buiret, G; Ceruse, P; Chabaud, S; Favier, B; Fayette, J; Girodet, D; Lavergne, E; Péron, J; Pham, BN; Ramade, A; Zrounba, P | 1 |
| Fury, MG; Haque, S; Ho, A; Katabi, N; Kelly, KW; Nwankwo, O; Pfister, DG; Sherman, E; Sima, C | 1 |
| Arbushites, MC; Bernini, P; Bertini, I; Biganzoli, L; Cappadona, S; Claudino, WM; Di Leo, A; Luchinat, C; Nepi, S; Oakman, C; Tenori, L | 1 |
| Bhar, P; Cheporov, S; Clawson, A; Gradishar, WJ; Iglesias, J; Krasnojon, D; Makhson, AN; Manikhas, GM; McGuire, JR | 1 |
| Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG | 1 |
| Imai, A; Mizuta, N; Morita, M; Nakatsukasa, K; Sakaguchi, K; Soushi, M; Taguchi, T | 1 |
| Brahmer, JR; Dahlberg, SE; Hoang, T; Johnson, DH; Sandler, AB; Schiller, JH | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Allan, AL; Hedley, BD; Keeney, M; Lowes, LE | 1 |
| Feng, L; Ma, P; Mumper, RJ; Rahima Benhabbour, S | 1 |
| Bang, YJ; Han, HS; Han, SW; Han, W; Im, SA; Jeon, YK; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Noh, DY; Oh, DY; Park, IA | 1 |
| Kim, KB | 1 |
| Bondarde, S; Gradishar, WJ; Jain, M; Kaklamani, V; Lokanatha, D; Lokker, NA; Raina, V; Ro, SK; Sahoo, TP; Schwartzberg, L | 1 |
| Ding, Y; Liao, Y; Peng, RQ; Zhang, X; Zhang, XS; Zheng, LM | 1 |
| Assaf, E; Bouaita, L; Culine, S; Delbaldo, C; Pouessel, D; Sellam, Z; Verlinde-Carvalho, M | 1 |
| Alba, E; Jiménez, B; Llácer, C; Medina, L; Navarro, V; Pajares, BI; Quero, C; Rueda, A; Sáez, MI; Trigo, JM | 1 |
| Eitaki, M; Inanami, O; Meike, S; Yamamori, T; Yasui, H | 1 |
| Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y | 1 |
| Spigel, DR | 1 |
| Avancha, K; Glück, S; Lopes, G; Montero, AJ | 1 |
| Erickson, D; Mak, M; Reinhart-King, CA | 1 |
| Fukuda, K; Funakoshi, S; Kawakubo, H; Kitagawa, Y; Saikawa, Y; Takahashi, T; Takaishi, H; Takeuchi, H | 1 |
| Aparicio, AM; Bhatia, S; Lao, CD; Margolin, KA; Moon, J; Othus, M; Ribas, A; Sondak, VK; Weber, JS | 1 |
| Catalano, PJ; Colson, YL; Gilmore, DM; Grinstaff, MW; Liu, R; Padera, RF; Xu, X; Zubris, KA | 1 |
| Futagami, F; Hosokawa, A; Nakamura, T; Nishijima, K; Nishimura, G; Ojima, E | 1 |
| Bible, KC; Bossou, AR; Copland, JA; Fisher, KE; Isham, CR; Kumar, R; Lingle, WL; Marlow, L; Negron, V; Sherman, EJ; Smallridge, RC; Suman, VJ | 1 |
| Beslija, S; Brodowicz, T; Greil, R; Kahan, Z; Kaufman, B; Lang, I; Melichar, B; Messinger, D; Pienkowski, T; Ryvo, L; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| DU, M; Jiang, ZF; Meng, XY; Song, ST; Wang, T; Wu, SK; Zhang, SH; Zhao, X | 1 |
| Furuya, Y; Ishida, T; Masuda, N; Matsunami, N; Miyashita, M; Nagata, T; Nakayama, T; Noguchi, S; Nomura, M; Oba, K; Sakamoto, J; Taguchi, T; Wakita, K; Yamamoto, D; Yoshidome, K; Yoshino, H | 1 |
| Bickel, LE; Connolly, DC; Do, TV; Ecsedy, JA; Godwin, AK; Golemis, EA; Howe, C; Hua, X; Klein-Szanto, AJ; Litwin, S; Maglaty, M; O'Brien, SW; Pathak, HB; Schilder, RJ; Xiao, F | 1 |
| Badve, SS; Cobleigh, MA; Davidson, NE; Dickler, MN; Gralow, JR; Gray, RJ; Jiang, G; Li, L; Miller, KD; Müller, S; Perez, EA; Radovich, M; Schneider, BP; Shen, F; Shenkier, TN; Sledge, GW; Sparano, JA; Thor, A; Vance, G; Vang Nielsen, K | 1 |
| Al Zaman, AS | 1 |
| Ligibel, JA; Winer, EP | 1 |
| Perez, EA; Qu, G | 1 |
| Chan, AT; Chiu, SK; Ho, WM; Johnson, PJ; Kwan, WH; Lam, KC; Leung, TW; Mo, FK; Mok, TS; Tse, KK; Yeo, W | 1 |
| Friedrichs, K; Hölzel, F; Jänicke, F | 1 |
| Bourhis, J; Faivre, S; Monnerat, C; Raymond, E; Temam, S | 1 |
| Bach, A; Cramer, L; Dougherty, J; Duck, ET; Hudis, C; Modi, S; Norton, L; Panageas, KS; Seidman, A; Weinstock, N | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; Carles, J; Climent, MA; Cortés-Funes, H; de la Cruz, JJ; Díaz-Rubio, E; González-Larriba, JL; Guillem, V; Paz-Ares, L | 1 |
| Cappugi, P; Coronnello, M; Giannotti, B; Mini, E; Pimpinelli, N; Prignano, F | 1 |
| Burian, M; Cartellieri, M; Fiebiger, W; Formanek, M; Gedlicka, C; Kornek, GV; Kornfehl, J; Marks, B; Selzer, E | 1 |
| Bang, YJ; Boudraa, Y; Daglish, B; Heo, DS; Jacques, C; Kang, WK; Kang, YK; Kim, HC; Kim, NK; Kim, WS; Zuber, E | 1 |
| Eguchi, K; Fujiwara, K; Mandai, K; Segawa, Y; Seki, N; Takata, I; Tokuda, Y; Umemura, S | 1 |
| Ansari, R; Einhorn, LH; Fata, F; McClean, JW; Miller, KD; Porcu, P; Sledge, GW; Soule, SE; Zon, R | 1 |
| Campos, B; Carrete, N; Constenla, M; Garcia-Arroyo, R; Lorenzo, I; Palacios, P | 1 |
| Bucana, C; Dinney, CP; Fan, D; Fidler, IJ; Huang, SF; Karashima, T; Kedar, D; Killion, JJ; Kim, SJ; Lee, AT; Mian, B; Shepherd, D; Sweeney, P | 1 |
| Asola, R; Ekholm, E; Hinkka, S; Korpela, J; Mali, P; Pyrhönen, S; Salminen, E; Varjo, P; Varpula, M | 1 |
| Breidenbach, M; König, E; Kurbacher, C; Mallmann, P; Schwonzen, M | 1 |
| Azli, N; Bisset, D; Kaye, SB; Ramazeilles, C; Riva, A; Roché, H; Terret, C; Twelves, CJ; Vasey, PA; Vernillet, L | 1 |
| Wolff, AC | 1 |
| Benezery, K; Lagrange, JL; Magné, N; Namer, M; Otto, J | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kosmidis, P; Mylonakis, N; Samonis, G; Skarlos, DV; Stathopoulos, G | 1 |
| Booser, DJ; Buzdar, AU; Ewer, M; Frye, D; Giordano, SH; Hortobagyi, GN; Ibrahim, NK; Murray, JL; Ordonez, NG; Rahman, ZU; Rivera, E; Rosales, MF; Theriault, RL; Valero, V | 1 |
| Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H | 1 |
| Besse, B; Spano, JP | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Miles, D; Seidman, AD; von Minckwitz, G | 1 |
| Bontenbal, M; Mross, K; Seynaeve, C; Smorenburg, CH; Sparreboom, A; ten Tije, AJ; van Zomeren, DM; Verweij, J | 1 |
| Crawford, JG; Ellis, MJ; Farhad, A; Hayes, DF; Isaacs, C; Novielli, A; Pennanen, M; Singh, B; Slack, R; Stearns, V; Tibery, C; Tsangaris, T | 1 |
| Antman, K; Brafman, L; Fine, R; Nelsen, C; Petrylak, DP; Shriberg, L; Talbot, S; Tiersten, AD; Troxel, A; Vahdat, L | 1 |
| Roth, AD | 1 |
| Tishler, RB | 1 |
| Chikazawa, M; Fukata, S; Inoue, K; Shuin, T; Yoshikawa, C | 1 |
| Chaplen, R; Gadgeel, SM; Heilbrun, LK; Labadidi, S; Philip, PA; Shields, AF; Zalupski, M | 1 |
| Aglietta, M; Alabiso, O; Capaldi, A; Choa, G; Donadio, M; Faggiuolo, R; Minischetti, M; Montemurro, F; Salomone, A; Sperti, E; Vietti-Ramus, G | 1 |
| Alba, E; Antón, A; Florián, J; Godes, MJ; Llanos, M; López-Vega, JM; Menéndez, M; Pelegri, A; Pérez-Carrión, R; Ribelles, N | 1 |
| Borsellino, N; Colombo, A; Ferrera, P; Gebbia, V; Marrazzo, A; Mauceri, G; Musso, M; Porretto, F; Testa, A; Tirrito, ML | 1 |
| Asmar, L; Canfield, VA; Ellis, PG; Ferri, WA; Hynes, HE; Loesch, DM; Parker, GA; Robert, NJ | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Baick, CH; Chiou, JY; Fruehauf, JP; Mehta, RS; Nalcioglu, O; Su, MY; Wang, J; Yu, H | 1 |
| Fidler, IJ; Karashima, T; Killion, JJ; Kim, SJ; Shepherd, DL; Uehara, H | 1 |
| Glaspy, J; Green, MD; Hackett, J; Holmes, FA; Kubista, E; Neumann, T | 1 |
| Miller, KD | 1 |
| Aperis, G; Barbounis, V; Demiri, M; Drufakou, S; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Cho, MJ; Kim, JS; Kim, Ki; Kim, SY | 1 |
| Li, WL; Qin, YK; Yao, Q; Zhu, SW | 1 |
| Bauduceau, O; Bernard, O; Ceccaldi, B; Dourhte, LM; Hervé, R; Le Moulec, S | 1 |
| Fumoleau, P | 1 |
| Sledge, GW | 4 |
| Siderov, J | 1 |
| Ilersich, AL; Verma, S | 1 |
| Almanza, C; Amenedo, M; Gamazo, JL; Gómez-Martín, C; González-Ageitos, A; González-Quintas, A; Losada, G; Ramos, M; Romero, C; Togores, P | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Marchionatti, S; Pedani, F; Recalenda, V; Tagini, V | 1 |
| Nabholtz, JM | 2 |
| Crown, J; Pegram, M | 1 |
| Kim, DS; Kim, SW; Kim, WD; Kim, WS; Lee, JS; Lee, SD; Suh, C | 1 |
| Blumenstengel, K; Höffken, K; Issa, MC; Kasper, C; Kath, R; Mügge, LO; Sayer, HG; Schilling, K; Vogt, T | 1 |
| Entin, I; Keisari, Y; Korenstein, R; Plotnikov, A | 1 |
| Ahiskali, R; Celikel, T; Ceyhan, BB; Duman, D; Duman, DG | 1 |
| Bessho, A; Eguchi, K; Harada, M; Harita, S; Hiraki, S; Hiraki, Y; Kamei, H; Kiura, K; Okimoto, N; Segawa, Y; Tabata, M; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y | 1 |
| Bernard-Marty, C; Cardoso, F; Piccart, MJ | 1 |
| Au, JL; Chen, D; DeHoff, C; Fischer, B; Grever, M; Kanter, S; Murgo, AJ; Otterson, GA; Song, S; Villalona-Calero, MA; Wientjes, MG; Yeh, TK; Young, D | 1 |
| Rivera, E | 1 |
| O'Shaughnessy, J | 3 |
| Arnold, A; Ayoub, JP; Dias, R; Gelmon, K; Ghahramani, P; Leyland-Jones, B; Verma, S | 1 |
| Barbounis, V; Demiri, M; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Bardou, VJ; Bladou, F; Camerlo, J; Genre, D; Gravis, G; Macquart-Moulin, G; Maraninchi, D; Salem, N; Serment, G; Viens, P | 1 |
| Becker, A; Bloching, M; Dunst, J; Hänsgen, G; Kuhnt, T; Lotterer, E; Passmann, M; Pelz, T; Pigorsch, S | 1 |
| Curley, T; Hartley-Asp, B; Kattan, MW; Kelly, WK; Larson, S; Morris, M; Scher, HI; Schwartz, L; Slovin, S; Solit, DB | 1 |
| Fazekas, K; Ladányi, A; Lövey, J; Németh, G; Tímár, J | 1 |
| Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Ki Hong, W; O'Reilly, MS; Onn, A; Wu, W | 1 |
| Hirakawa, T; Kobayashi, H; Nakano, H; Ogura, T; Okugawa, K; Sonoda, T | 1 |
| Fujii, Y; Hara, Y; Iwase, H; Sugiura, H; Toyama, T; Yamashita, H | 1 |
| Aglietta, M; Ballestrero, A; Capaldi, A; Danova, M; Friedman, D; Gonella, R; Montemurro, F; Patrone, F; Puglisi, M | 1 |
| Basurto, C; Bisacci, C; Cherubini, R; Colozza, M; Crinò, L; De Angelis, V; Franceschi, E; Gori, S; Mosconi, AM; Rulli, A; Sidoni, A; Tonato, M | 1 |
| Balbiani, L; Brosio, C; Caccia, G; Delfino, C; Flores Morales, D; Mickiewicz, E; Riva Gonzáles, L; Rodger, J; Zori Comba, A | 1 |
| Murad, AM | 1 |
| Adamo, V; Alafaci, E; Ferraro, G; Laudani, A; Pergolizzi, S; Scimone, A; Sergi, C; Settineri, N; Spano, F; Spitaleri, G | 1 |
| Eskens, FA; Hoekstra, R; Polee, MB; Sparreboom, A; Stoter, G; van de Schaaf, J; van der Gaast, A; Verweij, J | 1 |
| Fjaestad, K; Ostenstad, B; Risberg, T; Sommer, HH; Wist, EA | 1 |
| Biganzoli, L; Bottomley, A; Calvert, HA; Coens, C; Coleman, RE; Cufer, T; Efficace, F; Fargeot, P; Gamucci, T; Piccart, M; Twelves, C; Van Steen, K | 1 |
| Inciūra, A; Juozaityte, E | 1 |
| Broome, C; Burris, H; Greco, FA; Hainsworth, J; Houston, G; Jones, S; Thompson, D; White, M; Yardley, D | 1 |
| Barduagni, M; Ceribelli, A; Cognetti, F; Cortesi, E; De Marco, S; De Marinis, F; Fabi, A; Facciolo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Pellicciotta, M; Saltarelli, R | 1 |
| Anagnostopoulos, A; Aravantinos, G; Bafaloukos, D; Daniilidis, J; Dimopoulos, MA; Fountzilas, G; Janinis, J; Kalofonos, HP; Kalogera-Fountzila, A; Makatsoris, T; Nikolaidis, P; Rigatos, SK; Samantas, E; Stathopoulos, GP; Tolis, C | 1 |
| Amsalhem, P; Boaziz, C; Bouillet, T; Breau, JL; Brunel, P; Brunet-Pommeyrol, A; Hennebelle, F; Kanoui, A; Morere, JF; Morin, F; Piperno-Neumann, S; Spano, JP | 1 |
| Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Gallo, L; Giannessi, P; Orlandini, C; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M | 1 |
| Chasen, MR; Eek, R; McMichael, G; Mohammed, C; Rapoport, BL; Slabber, C; Vorobiof, DA | 1 |
| Jänicke, F; Köhler, G; Löning, T; Lück, HJ; Möbus, V; Müller, V; Pantel, K; Sattler, D; Thomssen, C; von Minckwitz, G; Wilczak, W; Witzel, I | 1 |
| Altundag, K; Baltali, E; Guler, N; Ozisik, Y; Tekuzman, G | 1 |
| Argiris, A; Eng, C; Haraf, DJ; Kozloff, MF; Milano, MT; Mittal, BB; Pelzer, H; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Costantini, M; Giannessi, P; Guarneri, V; Mammoliti, S; Moyano, A; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M | 1 |
| Andre, F; Bachelot, T; Barrelier, A; Delaloge, S; Dunant, A; Kabbaj, O; Marsiglia, H; Namer, M; Rouzier, R; Slimane, K; Spano, JP; Spielmann, M | 1 |
| Nortier, JW | 1 |
| Hudis, C; Keefe, D; Lieberman, G; Paton, V; Seidman, A; Tripathy, D | 1 |
| Fujioka, A; Fukushima, M; Kitazato, K; Nagayama, S; Nakagawa, F; Nukatsuka, M; Oshimo, H; Sugimoto, Y; Uchida, J | 1 |
| Cohen, EE; Haraf, DJ; Hellman, S; Mauer, AM; Mehta, N; Vokes, EE; Weichselbaum, RR | 1 |
| Horwitz, KB; Jacobsen, BM; Richer, JK; Schittone, SA | 1 |
| Barone, C; Bertetto, O; Birocco, N; Colantonio, I; Dongiovanni, D; Numico, G; Schena, M | 1 |
| Besova, NS; Gorbunova, VA | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Ottaviani, D; Polimeni, MA | 1 |
| Fornier, MN; Ghani, F; Hudis, C; Norton, L; Schwartz, MK; Seidman, AD; Thiel, R | 1 |
| Fidler, IJ; Kim, SJ; Lev, DC; Nam, DH; Onn, A; Price, JE; Stone, V; Yazici, S | 1 |
| Blanco, J; El Hilali, N; Rubio, N | 1 |
| Díaz-Montero, CM; McIntyre, BW | 1 |
| Ansari, TN; Khattak, BK; Mahmood, A; Rasul, S; Syed, AS | 1 |
| Ansari, R; Belani, CP; Lee, JS; Lilenbaum, R; Natale, RB; Robert, F; Rowland, K; Socinski, MA; Waterhouse, D | 1 |
| Chin, K; Hatake, K; Inamura, K; Ito, Y; Kobayashi, T; Mishima, Y; Mizunuma, N; Nagasaki, E; Nishimori, H; Shinozaki, E; Takahashi, S; Terui, Y; Yokoyama, M | 1 |
| Harman, EM; Keene, KS; Knauf, DG; McCarley, D; Zlotecki, RA | 1 |
| Gligorov, J; Nabholtz, JM | 1 |
| Kulp, B; Markman, M; Michener, CM; Peterson, G; Webster, KD | 1 |
| Berman, ML; Burger, RA; Disaia, PJ; Fruehauf, JP; Kyshtoobayeva, AS; Manetta, A; Mehta, RS; Monk, BJ; Tewari, KS; Yu, IR | 1 |
| Amsellem-Ouazana, D; Beuzeboc, P; Oudard, S; Peyromaure, M; Scotté, F; Vieillefond, A | 1 |
| Bae, SH; Chun, SH; Do, YR; Hyun, MS; Kim, KO; Kim, MK; Kwon, KY; Lee, KH; Ryoo, HM; Shin, SJ; Song, HS | 1 |
| Bhar, P; Desai, N; Doval, D; Hortobagyi, GN; Ibrahim, NK; Nair, MK; Page, R; Patel, KM; Rao, SC; Samuels, B | 1 |
| Yardley, DA | 1 |
| Alamanis, C; Bougas, D; Dimitrakopoulos, A; Giannopoulos, A; Kopterides, P; Kopteridis, P; Kosmas, C; Mitropoulos, D; Skopelitis, H; Stravodimos, K; Tsavaris, N | 1 |
| Acimović, L; Jeremić, B; Milicić, B; Milisavljević, S | 1 |
| Bokma, HJ; Bontenbal, M; Braun, HJ; Creemers, GJ; de Boer, AC; Goey, SH; Janssen, JT; Kerkhofs, LG; Leys, RB; Ruit, JB; Schmitz, PI; Schothorst, KL; Seynaeve, C; van der Velden, PC; Verweij, J | 1 |
| Arslan, M; Demiray, M; Ercan, I; Evrensel, T; Gokgoz, S; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Saraydaroglu, O; Tasdelen, I; Tolunay, S; Topal, U | 1 |
| Hofmann, J; Holash, J; Hu, L; Jaffe, RB; Sood, AK; Yancopoulos, GD | 1 |
| Albrecht, H; Burke, PA; DeNardo, GL; DeNardo, SJ; Gregg, JP; Natarajan, A; O'Donnell, RT; Richman, CM; Yuan, A | 1 |
| Fazli, L; Gleave, ME; Miyake, H; Rocchi, P; Vessella, B; Yamanaka, K; Zangemeister-Wittke, U | 1 |
| Moreno-Aspitia, A; Perez, EA | 1 |
| Cameron, DA; Carmichael, J; Howell, A; Jones, AL; Langley, RE; Parmar, M; Qian, W; Uscinska, B | 1 |
| Allouache, D; Bozec, L; Gawande, SR; Genot, JY; Mefti, F; Piperno-Neumann, S; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Abrams, M; Abu-Khalaf, MM; Ananthanarayanan, G; Burtness, BA; Chung, GG; DiGiovanna, MP; Ebisu, K; Farber, LR; Haffty, BG; Hsu, AD; Reiss, M; Salikooti, S; Windsor, S; Zelterman, D | 1 |
| Fujitani, K; Furukawa, H; Gotoh, M; Hirao, M; Narahara, H; Satomi, E; Taguchi, T; Takiuchi, H; Tsujinaka, T | 1 |
| Creagan, ET; Croghan, GA; Holtan, SG; Ingle, JN; Kaur, JS; Kottschade, LA; Markovic, SN; Pitot, HC; Rao, RD | 1 |
| Mohamad, MA; Sayed-Ahmad, MM | 1 |
| Bewig, B; Keussen, C; Lins, M; Schrader, C; von Freier, A | 1 |
| Colomer, R | 1 |
| Mathew, P; Troncoso, P; Vakar-Lopez, F | 1 |
| Ge, ZQ; Liu, CX; Yang, WY; Yin, DS; Yuan, YJ | 1 |
| Ishida, E; Konishi, N; Matsuyoshi, S; Nakamura, M; Shimada, K | 1 |
| Agostara, B; Barni, S; Bria, E; Colella, E; Cuppone, F; D'Ottavio, AM; Frontini, L; Izzo, F; Nistico, C; Sperduti, I; Terzoli, E; Valenza, R | 1 |
| Amadori, D; Frassineti, GL; Gianni, L; Maltoni, R; Massa, I; Milandri, C; Nanni, O; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Al-Makhalafi, Z; Al-Mohanna, FA; Baitei, EY; Collison, K; Farid, NR; Shi, Y; Zou, M | 1 |
| Norton, L | 1 |
| Downward, J; Swanton, C; Tomlinson, I | 1 |
| de Korte, MA; de Vries, EG; Gietema, JA; Jager, PL; Jonkman, S; Kosterink, JG; Lub-De Hooge, MN; Perik, PJ; Sleijfer, DT; van der Graaf, WT; van Veldhuisen, DJ | 1 |
| Thigpen, T | 1 |
| Athanassiadis, A; Fountzilas, G; Pavlidis, N; Pentheroudakis, G; Razis, E | 1 |
| Gradishar, WJ | 1 |
| Caprio, G; Di Seri, M; Frati, L; Romiti, A; Spinelli, GP; Terzoli, E; Tomao, F; Tomao, S | 1 |
| Keating, GM; Robinson, DM | 1 |
| Davidson, N; Harper, P; Harries, M; Ibrahim, N | 1 |
| Matsumoto, I; Ohta, Y; Shimizu, Y; Watanabe, G | 1 |
| Capomolla, E; Carpano, S; Cauchi, C; Conti, F; Foggi, P; Giacinti, L; Giannarelli, D; Leonetti, C; Lopez, M; Paoletti, G; Vici, P | 1 |
| Appel, S; Berry, D; Broadwater, G; Crocker, A; Dressler, L; Fleming, G; Harris, L; Hudis, C; Kirshner, J; Messino, M; Michaelson, R; Muss, H; Norton, L; Rincon, M; Sutton, L; Weaver, D; Winer, E | 1 |
| Albain, K; Asmar, L; Belt, R; Cobleigh, M; Fuchs, L; Ilegbodu, D; Leyland-Jones, B; Loesch, D; McCullough, C; Raju, R; Robert, N; Sayre, R; Slamon, D; Valentine, E | 1 |
| Amadori, D; Cecconetto, L | 1 |
| Bustam, A; Khoo, KS; Lehnert, M; Manzoor Zaidi, SH; Nair, R; Ngelangel, CA; Reece, WH; Song, S; Srimuninnimit, V | 1 |
| Akerley, W; Kennedy, T; Mega, T; Ready, N; Safran, H; Zaner, K | 1 |
| Babó, I; Harisi, R; Jeney, A; Kenessey, I; Oláh, J; Pogány, G; Timár, F | 1 |
| Fidler, IJ | 1 |
| Caravelli, J; D'Andrea, G; Hudis, C; Modi, S; Norton, L; Rosen, PP; Seidman, AD; Yao, TJ | 1 |
| Beijnen, JH; Helgason, HH; Huitema, AD; Kruijtzer, CM; Marcus, SG; Schellens, JH; Schornagel, JH; Schot, ME; ten Bokkel Huinink, WW | 1 |
| Delva, R; Douville, I; Longerey, B; Pienkowski, T; Tubiana, N; Vanhoefer, U | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Duivenvoorden, WC; Richard, C; Th'ng, JP; Yau, J | 1 |
| El-Naggar, AK; Gu, M; Jasser, SA; Kim, S; Myers, JN; Nong, X; Park, YW; Santillan, AA; Yazici, YD; Younes, MN | 1 |
| Berry, D; Bleiweiss, I; Broadwater, G; Cowan, D; Dressler, L; Ellis, M; Harris, LN; Hayes, DF; Lara, J; Lin, NU; Miron, A; Schnitt, SJ; Winer, EP | 1 |
| Burstein, HJ; Rugo, HS; Sledge, GW | 1 |
| Chang, HK; Chen, JS; Liaw, CC; Lin, YC; Wang, HM; Yang, TS | 1 |
| Bacik, J; Bains, M; Bajorin, D; Bosl, GJ; Budnick, A; Deluca, J; Ishill, N; Kondagunta, GV; Mazumdar, M; Motzer, RJ; Reich, L; Sheinfeld, J | 1 |
| Bensussan, A; Bizzini, B; Gallo, RC; Genne, P; Larcier, P; Le Buanec, H; Paturance, S; Rad, FH; Ryffel, B; Uzan, G; Zagury, D | 1 |
| Bae, SH; Baek, JH; Cho, GJ; Chung, HY; Chung, JS; Do, YR; Hyun, MS; Jang, JS; Kim, JG; Kwon, KY; Lee, KH; Lee, WS; Park, KU; Ryoo, HM; Sohn, CH; Sohn, SK; Song, HS; Yu, W | 1 |
| Burstein, HJ; Come, SE; Gelman, R; Haldoupis, M; Lin, NU; Parker, LM; Ryabin, N; Shulman, LN; Winer, EP | 1 |
| Dimitroulis, J; Karaindros, D; Katis, C; Koutandos, J; Stathopoulos, GP; Stathopoulos, J; Toubis, M | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Han, W; Heo, DS; Im, SA; Kim, DW; Kim, TY; Lee, KH; Lee, SH; Noh, DY; Oh, DY; Park, IA | 1 |
| Eatock, MM; Eskens, FA; Evans, TR; Ferry, DR; Hawkins, RE; Jones, RJ; Wilke, H | 1 |
| Clegg, AJ; Jones, J; Loveman, E; Takeda, AL; Tan, SC | 1 |
| Asensi, M; Benlloch, M; Brown, BD; Carretero, J; Estrela, JM; Mena, S; Obrador, E; Ortega, A; Petschen, I | 1 |
| Chung, HC; Im, SA; Kim, CS; Kim, SB; Lee, KS; Lee, MY; Park, YH; Rha, SY; Ro, J | 1 |
| Green, MD; Ng, R | 1 |
| Dent, S; Messersmith, H; Trudeau, M | 1 |
| Ewer, MS; O'Shaughnessy, JA | 1 |
| Cohen, MH; Gootenberg, J; Keegan, P; Pazdur, R | 1 |
| Chao, TY; Hong, RL; Hsieh, RK; Hwang, WS; Kao, WY; Lin, CH; Wang, CH | 1 |
| Ino, K; Kajiyama, H; Kikkawa, F; Nawa, A; Shibata, K; Terauchi, M; Yamashita, M | 1 |
| Agostini, C; Bachelot, T; Cassier, PA; Chabaud, S; Cure, H; Guastalla, JP; Jacquin, JP; Martin, C; Orfeuvre, H; Peaud, PY; Pérol, D; Salles, B; Tigaud, JD; Trillet-Lenoir, V | 1 |
| Baron, AD; Burstein, HJ; Gelman, R; Hart, RD; Keshaviah, A; Lambert-Falls, R; Marcom, PK; Winer, EP | 1 |
| Bianco, A; Campbell, S; Caputo, F; D'Agostino, D; Gilli, M; Marsico, SA; Mazzarella, G; Piantedosi, FV; Pontillo, A | 1 |
| Beer, TM; Garzotto, M; Lin, D; Montgomery, RB; Nelson, PS; Ryan, CW | 1 |
| Arima, K; Onishi, T; Soga, N; Sugimura, Y | 1 |
| Bria, E; Carpino, A; Cognetti, F; Cuppone, F; Fornier, M; Nisticò, C; Pace, A; Sperduti, I; Terzoli, E | 1 |
| Cheng, AL; Hsu, C; Hsu, CH; Hsu, WL; Lin, CC; Tsai, YC; Yang, CH; Yeh, KH | 1 |
| Li, Q; Liu, J; Wang, JY; Xu, BH; Zhang, P; Zhao, LM | 1 |
| Ishizu, K; Makuuchi, H; Sadahiro, S; Sunose, N; Tsuruo, T; Yamazaki, K; Yamori, T | 1 |
| Radaideh, SM; Sledge, GW | 1 |
| Amadori, D; Cecconetto, L; Fabbri, F; Maltoni, R; Massa, I; Milandri, C; Nanni, O; Passardi, A; Tesei, A; Zoli, W | 1 |
| Chung, HC; Im, CK; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Yoo, NC | 1 |
| Choi, BS; Robins, HI | 1 |
| Cella, D; Cobleigh, M; Davidson, NE; Dickler, M; Gralow, J; Miller, K; Perez, EA; Shenkier, T; Wang, M | 1 |
| Kodali, S; Ratnasabapathy, C; Sivamurthy, S | 1 |
| Cai, B; He, Y; Liu, L; Wan, X; Yu, X | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Ryu, MH; Sohn, HJ; Yook, JH | 1 |
| Egawa, S; Hatano, T; Ito, H; Kishimoto, K; Tomita, M; Wada, T; Yanada, S | 1 |
| Blum, JL; Clawson, A; Edelman, G; Geister, BV; Kirby, RL; O'Shaughnessy, JA; Pippen, JE; Robert, NJ; Savin, MA | 1 |
| Alcindor, T | 1 |
| Bai, CQ; Guo, HL; Song, YF; Wang, DT | 1 |
| Marty, M; Pivot, X | 1 |
| Bosl, GJ; Feldman, DR; Ishill, N; Jathavedam, A; Motzer, RJ; Patil, S; Turkula, S; Weinstock, DM | 1 |
| Amar, S; Perez, EA; Roy, V | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Kosmidis, P; Koutras, A; Maniadakis, N; Matsiakou, F; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Skarlos, D | 1 |
| Hortobagyi, GN | 2 |
| Bentley, S; Bernard, S; Brecher, M; Graham, M; Johnston, C; Serody, J; Shea, T; Steagall, A; Vaisman, A; Wiley, J | 1 |
| Crown, JP; Currie, V; Gilewski, TA; Hakes, TB; Heelan, R; Lebwohl, DE; Reichman, BS; Seidman, AD; Surbone, A; Yao, TJ | 2 |
| Cowan, KH; Fisherman, JS; Goldspiel, B; McCabe, M; Noone, M; O'Shaughnessy, JA; Ognibene, FP; Venzon, DJ | 1 |
| Crown, JP; Gilewski, TA; Hakes, TB; Hudis, CA; Lebwohl, DE; Norton, L; Reichman, BS; Seidman, AD; Surbone, A; Yao, TJ | 1 |
| Chiang, Y; Cowan, KH; Dunbar, CE; Goldspiel, B; Kohler, D; McDonagh, KT; Nienhuis, AW; O'Shaughnessy, JA; Sorrentino, BP; Wilson, W | 1 |
| Baselga, J; Crown, JP; Currie, V; Forsythe, P; Gilewski, TA; Hakes, TB; Hudis, CA; Reichman, BS; Seidman, AD; Yao, TJ | 1 |
| Buzdar, AU; Holmes, FA; Hortobagyi, GN | 1 |
| Cavalli, F; Goldhirsch, A; Pagani, O; Parma, G; Sessa, C | 1 |
| Green, MR; Lilenbaum, RC; MacManus, DA | 1 |
| Abrams, JS; Adams, J; Baltz, J; Canetta, R; Christian, M; Desmond-Hellmann, S; Friedman, MA; Montello, M; Onetto, N; Vena, DA | 1 |
| Hudis, CA; Norton, L; Seidman, AD | 1 |
| Donehower, RC; Kennedy, MJ; Rowinsky, EK | 1 |
| Anand, A | 1 |
| Eisenhauer, EA; Trudeau, M | 1 |
| Capri, G; Caraceni, A; Fulfaro, F; Gianni, L; Laffranchi, A; Martini, C; Munzone, E; Spreafico, C; Tarenzi, E; Villani, F | 1 |
| Gelmon, KA; Tolcher, AW | 1 |
| Chazard, M; Corette, L; Dieras, V; Garet, F; Marty, M; Mignot, L; Morvan, F; Onetto, N; Serin, D; Tubiana, N | 1 |
| Plaxe, SC | 1 |
| Crown, JP; Gilewski, TA; Hakes, TB; Heelan, R; Lebwohl, DE; Norton, L; Reichman, BS; Seidman, AD; Surbone, A; Yao, TJ | 1 |
| Crown, JP; Currie, V; Gilewski, TA; Hakes, TB; Heelan, R; Hudis, CA; Lebwohl, DE; Reichman, BS; Seidman, AD; Surbone, A | 1 |
| Ravdin, PM; Valero, V | 1 |
| Bowling, MK; Chen, TL; Donehower, RC; McGuire, WP; Rowinsky, EK; Slichenmyer, WJ | 1 |
| Holmes, FA | 3 |
| Benner, S; Calayag, M; Fossella, FV; Glisson, B; Huber, M; Lee, JS; Lippman, S; Murphy, WK; Perez-Soler, R; Shin, DM | 1 |
| Baldini, F; Biadi, O; Conte, PF; Gherarducci, G; Giannessi, PG; Mariani, M; Mengozzi, G; Strata, G; Surbone, A | 1 |
| Schalhorn, B | 1 |
| Abrams, JS; Arbuck, SG; Cheson, BD; Phillips, PH | 1 |
| Arbuck, SG; Dorr, A; Friedman, MA | 1 |
| Lakshmi, MS; Parker, C; Piura, B; Sherbet, GV | 1 |
| Booser, DJ; Buzdar, AU; Fraschini, G; Frye, D; Gibbs, HR; Holmes, FA; Hortobagyi, GN; Theriault, RL; Valero, V; Walters, RS | 1 |
| Abbruzzese, JL; Ajani, JA; Bready, B; Lassere, Y; Levin, B; Patt, Y; Pazdur, R; Soh, LT; Soo, E; Sugarman, S | 1 |
| Cajone, F; Debiasi, S; Lakshmi, MS; Parker, C; Sherbet, GV | 1 |
| Baughman, C; Cobeligh, M; Goldstein, LJ; McCaskill-Stevens, W; Neuberg, D; Robert, N; Rowinsky, E; Sledge, GW; Sparano, JA | 1 |
| Cowan, KH; Fisherman, JS; O'Shaughnessy, JA | 1 |
| Capri, G; Gianni, L; Munzone, E; Straneo, M | 1 |
| Buzdar, AU; Holmes, FA; Hortobagyi, GN; Theriault, RL | 1 |
| Bellet, RE; Buzdar, AU; Esparza, L; Fonseca, GA; Fraschini, G; Holmes, FA; Hortobagyi, GN; Theriault, RL; Valero, V; Walters, RS | 1 |
| Bedikian, AY; Burris, HA; Buzaid, AC; Eckardt, JR; Eton, O; Jenkins, J; Legha, SS; Smetzer, L; Von Hoff, DD; Weiss, GR | 1 |
| Bower, JH; Muenter, MD | 1 |
| Davidson, NG | 1 |
| Becher, R; Diergarten, K; Eberhardt, W; Harstrick, A; Klaassen, U; Pari, CP; Seeber, S; Strumberg, D; Wilke, H | 1 |
| Balmaceda, C; Baselga, J; Bruno, R; Crown, JP; Currie, V; Freilich, R; Gilewski, TA; Gollub, M; Hakes, TB; Hudis, CA; Lebwohl, DE; Norton, L; Raptis, G; Robles, M; Seidman, AD | 1 |
| Barnes, CS; Cowan, KH; Denicoff, AM; Goldspiel, BR; Gossard, MR; Kohler, DR; McCabe, M; Noone, MH; O'Shaughnessy, JA; Tolcher, AW; Zujewski, J | 1 |
| Berkman, A; Mardelli, TJ; Soe, MS | 1 |
| Piccart, MJ | 1 |
| Elfenbein, GJ; Fields, KK; Moscinski, LC; Perkins, JB | 1 |
| DeAngelis, LM; Freilich, RJ; Seidman, AD | 1 |
| Delorme, F; Eisenhauer, EA; Higgins, BP; Letendre, F; Lofters, WS; Muldal, AM; Norris, BD; Trudeau, ME; Vandenberg, TA | 1 |
| Boesgaard, M; Dombernowsky, P; Ejlertsen, B; Gehl, J; Jensen, BW; Jensen, TP | 1 |
| Bonneterre, J; Bontenbal, M; Catimel, G; Conte, P; Fumoleau, P; Gelmon, K; Klaassen, U; Nabholtz, JM; Namer, M; Spielmann, M; Winograd, B | 1 |
| Rougier, P | 1 |
| Azli, N; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, I; Lentz, MA; Misset, JL; Murawsky, M; Pouillart, P; Riva, A; Roche, H | 1 |
| Stearns, ME | 1 |
| Piccart, M | 1 |
| Trudeau, ME | 2 |
| Archer, PG; Jones, RB; Merouani, A; Schrier, RW; Shpall, EJ | 1 |
| Boesgaard, M; Dombernowsky, P; Gehl, J; Jensen, BV; Paaske, T | 2 |
| Klaassen, U; Seeber, S; Wilke, H | 1 |
| Hartmann, LC; Perez, EA | 1 |
| Boesgaard, M; Dombernowsky, P; Gehl, J; Paaske, T; Vittrup Jensen, B | 1 |
| Baldini, E; Conte, PF; Gennari, A; Michelotti, A; Salvadori, B; Tibaldi, C; Tognoni, A | 1 |
| Kennedy, MJ | 1 |
| Campbell, N; Chan, YT; Chick, JB; Davidson, NG; Perren, TJ; Thompson, JM | 1 |
| Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Gentile, A; Giannessi, PG; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Akerley, W | 1 |
| Holmes, FA; Hortobagyi, GN | 1 |
| Bonneterre, J; Catimel, G; Dieras, V; Dumortier, A; Garet, F; Graffand, N; Guastalla, JP; Kayitalire, L; Pellae-Cosset, B; Pouillart, P; Spielmann, M; Tubiana-Hulin, M | 1 |
| Diergarten, K; du Bois, A; Hecker, D; Jänicke, F; Konecny, G; Kühnle, H; Lindner, C; Lisboa, BW; Lück, HJ; Meerpohl, HG; Thomssen, C; Untch, M | 1 |
| Panagos, GE | 1 |
| Hande, KR; Johnson, DH; Paul, D | 1 |
| Beyer, J; Bokemeyer, C; Harstrick, A; Kohrmann, U; Metzner, B; Ruther, U; Schmoll, HJ; Verbeek, W; Weissbach, L | 1 |
| Ackland, S; Bishop, JF; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, IN; Stephenson, J; Tattersall, MH; Toner, GC; Walpole, E | 1 |
| Stearns, ME; Wang, M | 2 |
| Bell, DR; Bishop, JF; Friedlander, ML; Levi, JA; Michael, M; Olver, IN; Smith, JG; Toner, GC; Zalcberg, JR | 1 |
| Diéras, V | 3 |
| Delorme, F; Janowska, A; Mackey, J; Nabholtz, JM; Noel, D; Paterson, A; Riva, A; Smylie, M | 1 |
| Azli, N; Delecroix, V; Féty, R; Fumoleau, P; Perrocheau, G | 1 |
| Buzdar, AU; Holmes, FA; Hortobagyi, GN; Rahman, Z; Theriault, RL | 1 |
| Garrett, M; Hande, KR; Johnson, DH; Nicholson, B; Paul, D; Shyr, Y | 1 |
| Von Hoff, DD | 1 |
| Valero, V | 1 |
| Antoine, E; Khayat, D | 1 |
| Bonneterre, J; Launois, RJ; Reboul-Marty, JM | 1 |
| Chan, S | 1 |
| Aapro, MS; Alaki, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Melnychuk, D; Murawsky, M; Nabholtz, JM; Rapoport, B; Riva, A; Rosso, R; Thuerlimann, B; Trillet-Lenoir, V; Vandenberg, TA | 1 |
| al-Tweigeri, T; Au, D; Delorme, F; Mackey, JR; Nabholtz, JM; Noel, D; Paterson, AH; Riva, A; Sansregret, E; Smylie, M | 1 |
| Aapro, MS | 2 |
| Ackland, S; Bishop, JF; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, I; Stephenson, J; Tattersall, MH; Toner, G; Walpole, E | 1 |
| Andersen, E; Boesgaard, M; Dombernowsky, P; Jensen, BV | 1 |
| Barnabas, A; Benito, D; Colomer, R; Lluch, A; Martin, M; Massuti, B; Ojeda, B | 1 |
| Diergarten, K; du Bois, A; Köhler, G; Lisboa, B; Lück, HJ; Thomssen, C; Untch, M | 2 |
| Fuechsel, G; Kettner, E; Köhler, U; Olbricht, SS; Richter, B; Ridwelski, K | 1 |
| Carmichael, J; Hutchinson, T; Jones, A | 1 |
| Dicato, M; Duhem, C; Kleiber, K; Ries, F | 1 |
| Cavalli, F; Cerny, T; de Jong, J; Goldhirsch, A; Martinelli, G; Pagani, O; Sessa, C; Zimatore, M | 1 |
| Borquez, D; Harstrick, A; Klaassen, U; Müller, C; Seeber, S; Wilke, H | 1 |
| Greco, FA; Hainsworth, JD | 1 |
| Buzdar, AU; Holmes, FA; Hortobagyi, GN; Rahman, Z; Theriault, RL; Willey, J | 1 |
| Currie, V; Gollub, M; Hudis, CA; McCaffrey, J; Moynahan, ME; Norton, L; Seidman, AD; Tepler, I; Theodoulou, M; Tong, W | 1 |
| Champlin, R; Frye, D; Hortobagyi, G; Mehra, R; Rahman, Z; Rondon, G; Valero, V | 1 |
| Adkins, D; Ford, C; Reilly, W; Spitzer, G | 1 |
| Akerley, W; Cummings, F; Marchant, D; Safran, H; Sikov, WM; Strenger, R | 1 |
| Cascinu, S; Catalano, G; Cellerino, R; Ficarelli, R; Graziano, F; Safi, MA | 1 |
| Athanassiades, A; Bacoyiannis, C; Briassoulis, E; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Lawhorn, K; Lippman, SM; Shin, DM | 1 |
| Arquette, M; Bains, M; Cooper, J; Forastiere, AA; Ginsberg, R; Ilson, D; Kelsen, D | 1 |
| Clemons, M; Howell, A; Jayson, G; Leahy, M; Ranson, M; Valle, J | 1 |
| Baselga, J; Currie, V; Fennelly, D; Gilewski, T; Hellmann, S; Holmes, F; Hortobagyi, G; Hudis, C; Maickel, N; Moynahan, M; Norton, L; Raptis, G; Riccio, L; Seidman, A; Sklarin, N; Surbone, A; Uhlenhopp, M; Usakewicz, J; Yao, TJ | 1 |
| Rubens, RD | 1 |
| Dubbelman, R; Hiemstra, A; Lustig, V; Rodenhuis, S; ten Bokkel Huinink, WW | 1 |
| Cottu, PH; Espié, M; Extra, JM; Marty, M | 1 |
| Benassai, G; Caponigro, F; Carola, M; Citarella, A; Facchini, G; Iaffaioli, RV; Marzano, N; Persico, G; Santangelo, M; Tortoriello, A | 1 |
| Harstrick, A; Klaassen, U; Seeber, S; Wilke, H | 1 |
| Casado, A; Diaz-Rubio, E; Garcia Carbonero, I; Martin, M; Perez Segura, P | 1 |
| Ang, KK; Callender, DL; Clayman, GL; Gillenwater, AM; Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Lawhorn, K; Lee, JJ; Lippman, SM; Papadimitrakopoulou, V; Shin, DM | 1 |
| Spencer, CM; Wiseman, LR | 1 |
| Braguer, D; Briand, C; Kadi, A; Lehmann, M; Luis, J; Marvaldi, J; Pichard, V; Rognoni, JB | 1 |
| Androulakis, N; Georgoulias, V; Hatzidaki, D; Heras, P; Kakolyris, S; Kourousis, C; Samonis, G; Vamvakas, L; Vlachonicolis, J; Vlata, M | 1 |
| Cardarelli, N; Cascinu, S; Catalano, G; Giordani, P; Graziano, F; Marcellini, M; Menichetti, ET | 1 |
| Ball, E; deMagalhaes-Silverman, M; Hammert, L; Lembersky, B; Lister, J; Rybka, W | 1 |
| Barrett, JC; Baserga, R; Dunn, SE; Ehrlich, M; Hawkins, R; Reiss, K; Sharp, NJ; Solomon, G | 1 |
| Brodowicz, T; Grbovic, M; Marberger, M; Pflüger, H; Schnack, B; Steger, G; Wiltschke, C; Zielinski, CC | 1 |
| Graeven, U; König, M; Petrasch, S; Reinacher, A; Schmiegel, W; Welt, A | 1 |
| Bontenbal, M; de Wit, R; Klijn, JG; Seynaeve, C | 1 |
| Coniglio, D; Elkordy, M; Fishman, R; Gilbert, C; Hussein, A; Matters, L; Peters, WP; Petros, W; Ross, M; Rubin, P; Vredenburgh, J | 1 |
| Bonner, HS; Haller, DG; Huang, K; Recio, A; Shaw, LM; Vaughn, DJ | 1 |
| Ayers, D; Bryce, C; Campbell, C; Dulude, H; Gelmon, KA; Nakashima, L; O'Reilly, S; Ragaz, J; Rielly, S; Shenkier, T; Tolcher, A | 1 |
| Crown, J; Nabholtz, JM | 1 |
| Sparano, JA | 2 |
| Paridaens, R | 1 |
| Aapro, M | 1 |
| Crown, J | 3 |
| Mackey, J; Nabholtz, JM; Smylie, M; Tonkin, K | 1 |
| Pagani, O | 1 |
| Bastert, G; Goldschmidt, H; Haas, R; Hohaus, S; Huober, J; Martin, S; Meyer, A; Schneeweiss, A; Wallwiener, D; Wittmann, G | 1 |
| Espie, M | 1 |
| Baselga, J; D'Andrea, G; Fennelly, D; Gilewski, T; Hudis, C; Moynahan, ME; Norton, L; Raptis, G; Seidman, AD; Sklarin, N; Surbone, A; Templeton, MA; Theodoulou, M; Yao, TJ | 1 |
| Anagnostopoulos, A; Diakomanolis, E; Dimopoulos, MA; Fountzilas, G; Giannakoulis, N; Gika, D; Moulopoulos, LA; Papadimitriou, CA; Sarris, K; Voulgaris, Z | 1 |
| Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J | 1 |
| Miller, KD; Sledge, GW | 2 |
| Aisner, J; Belani, CP; Capozzoli, MJ; Egorin, MJ; Engstrom, C; Erkmen, K; Hiponia, D; Kearns, CM; Ramanathan, RK; Zacharski, D; Zuhowski, EG | 1 |
| Agelaki, S; Alexopoulos, A; Apostolaki, F; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kalbakis, K; Kosmas, C; Kourousis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Samonis, G; Sarra, E; Vlachonicolis, J | 1 |
| Amin, RM; Price, FV; Sumkin, J | 1 |
| Buckner, CD; Franco, C; Hazelton, B; Moore, M; Schwartzberg, LS; Smith, R; Van Amburg, A; Weaver, CH; White, L; Zhen, B | 1 |
| Brettell, M; Briggs, P; Chapple, P; Francis, P; Gardyn, J; Gates, P; Januszewicz, EH; Juneja, S; Millward, MJ; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Toner, GC; Wolf, M | 1 |
| Hudis, CA | 1 |
| Perez, EA | 1 |
| Weiner, LM | 1 |
| Vaughn, DJ | 1 |
| Birch, R; Buckner, CD; Giudice, R; Kalman, L; Schnell, F; Schwartzberg, LS; Sobong, E; Weaver, CH | 1 |
| Bressolle, F; Culine, S; Pinguet, F; Roch, I; Romieu, G | 1 |
| Janowska-Wieczorek, A; Mackey, J; Nabholtz, JM; Smylie, M; Tonkin, K | 1 |
| Berdel, WE; Cassens, U; Fietz, T; Hilgenfeld, E; Hoffmann, M; Hoppe, B; Kienast, J; Knauf, WU; Koenigsmann, M; Mohr, M; Sibrowski, W; Thiel, E | 1 |
| Asmar, L; Booser, DJ; Buzdar, AU; Fraschini, G; Frye, D; Gibbs, H; Holmes, FA; Hortobagyi, GN; Theriault, RL; Valero, V; Walters, RS; Willey, J | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Francis, P; Gates, P; Januszewicz, EH; Juneja, S; Millward, MJ; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Strickland, A; Toner, GC; Wolf, M; Zalcberg, J | 1 |
| Di Leo, A; Piccart, MJ | 1 |
| Kaufman, PA | 1 |
| Au, HJ; Au, R; Mackey, J; Morrish, D; Nabholtz, JM; Salter, E; Smylie, M; Tonkin, K | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kouroussis, C; Malamos, N; Mavroudis, D; Panagos, G; Papadouris, S; Potamianou, A; Samonis, G; Sara, E; Xydakis, E | 1 |
| Acito, L; Angiona, S; Bilancia, D; Costanzo, FD; Fioriti, L; Gasperoni, S; Giustini, L; Manzione, L; Sdrobolini, A; Valenti, L | 1 |
| Burris, HA | 1 |
| Ravdin, PM | 1 |
| Blohmer, JU; Costa, SD; Dresel, V; Eidtmann, H; Gademann, G; Hilfrich, J; Jackisch, C; Kaufmann, M; Merkle, E; Raab, G; von Minckwitz, G | 1 |
| Blanke, C; Cohen, A; Dickson, NR; Hande, K; Johnson, D; Nicholson, BP | 1 |
| Benner, S; Borquez, D; Harstrick, A; Klaassen, U; Lang, S; Oberhoff, C; Seeber, S | 1 |
| Dethling, J; Kühnle, H; Lück, HJ; Scholz, U | 1 |
| Amato, S; Barbieri, M; Fasce, H; Grasso, S; Lacava, J; Langhi, M; Leone, B; Machiavelli, M; Ortiz, E; Pérez, J; Rodríguez, R; Romero Acuña, J; Romero Acuña, L; Romero, A; Vallejo, C | 1 |
| Alvarez, A; Balbiani, L; Bertoncín, AM; Breier, S; Cazap, E; Cóppola, F; Di Notto, MR; Estévez, R; Grasso, S; Jovtis, S; Lewi, D; Mickiewicz, E; Pascual, M; Pazos, C; Róndinón, M; Suárez, A; Témperley, G; Trigo, M; Triguboff, E; Uranga, G; Ventriglia, M | 1 |
| Bearman, S; Cagnoni, P; Jones, R; Nieto, Y; Peters, W; Ross, M; Shpall, E; Vredenburgh, J | 1 |
| Bast, R; Buzdar, AU; Hortobagyi, GN; Ibrahim, NK; Murray, JL; Rahman, Z; Theriault, RL; Valero, V; Willey, J | 1 |
| Bergman, M; Ekholm, E; Huhtala, S; Salminen, E | 1 |
| Fossella, FV; Fox, NJ; Glisson, BS; Hong, WK; Kurie, JM; Lee, JS; Murphy, WK; Nyberg, DA; Perez-Soler, R; Pisters, KM; Ross, MB; Shin, DM | 1 |
| Alakl, M; Bodrogi, I; Buzzi, F; Chan, S; Crown, J; Duarte, R; Friedrichs, K; Gil Gil, M; González Mancha, R; Korec, S; Murawsky, M; Murray, E; Noel, D; Pintér, T; Richardson, G; Riva, A; Ronzoni, M; Simmonds, P; Van Belle, S; von Minckwitz, G; Vorobiof, D; Walpole, E; Yelle, L | 1 |
| Hayashi, K; Kuroi, K; Nagai, S; Toi, M; Tominaga, T | 1 |
| Blume, KG; Chao, NJ; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Stockerl-Goldstein, KE | 1 |
| Budman, D; Kreis, W | 1 |
| Crown, JP | 1 |
| Antman, KH; Ayello, J; Hesdorffer, CS; Kaufman, E; Papadopoulos, KP; Reiss, RF; Troxel, A; Vahdat, LT | 1 |
| Atassi, G; Guilbaud, N; Jan, M; Kraus-Berthier, L; Naze, M; Pierré, A | 1 |
| Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Feingold, JM; Kazierad, D; Khan, AM; Khan, IA; Rodriguez-Pinero, F; Tutschka, PJ | 1 |
| Alfonso, R; Casado, A; de Paz, L; Diaz-Rubio, E; Esteban, C; García-Conde, J; Garciía Carbonero, I; Insa, A; Lluch, A; Martín, M | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C | 1 |
| Alonso, S; Barnadas, A; Carañana, V; Colomer, R; De Paz, L; Fernández, Y; Guillem, V; Llombart, A; Lluch, A; Ojeda, B | 1 |
| Bunnell, CA; Burstein, HJ; Clarke, KD; Garber, JE; Manola, J; Matulonis, UA; Parker, LM; Scheib, R; Shulman, LN; Winer, EP; Younger, J | 1 |
| Gagnon, GA; Sallah, S | 1 |
| Awasthy, BS; Gairola, M; Julka, PK; Rath, GK; Sharma, DN | 1 |
| Amano, G; Furuta, A; Harada, Y; Ikegaki, H; Kijima, G; Ohnuki, K; Ohuchi, N; Satomi, S; Yoshida, R | 1 |
| Beijnen, JH; Kruijtzer, CM; Schellens, JH; Swart, M | 1 |
| Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Du, W; Hamm, C; Karanes, C; Klein, JL; Peters, WP; Rey, PM | 1 |
| Brodowicz, T; Herscovici, V; Koestler, WJ; Steger, GG; Tomek, S; Vaclavik, I; Wiltschke, C; Zielinski, CC | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Blijham, GH; Erdkamp, FL; Hillen, HF; Lalisang, RI; Nortier, JW; Schouten, HC; Voest, EE; Wals, J; Wils, JA | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
| Adenis, A; Armand, JP; Baille, P; Blanc, C; Bonneterre, J; Clouet, P; de Forni, M; Dembak, M; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Rougier, P | 1 |
| Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, M; Malmström, P; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Pluzanska, A; Sjödin, M; Sjöström, J | 1 |
| Aloe, A; Calabrese, P; Catino, A; De Lena, M; Latorre, A; Lorusso, V; Mazzei, A | 1 |
| Besenval, M; Boisdron-Celle, M; Delva, R; Gamelin, E; Lortholary, A; Maillard, P; Perard, D; Vernillet, L | 1 |
| Dalbot, DC; Gordon, RJ; Griffin, T; Moiseenko, VM; O'Reilly, SM; Osterwalder, B; Van Belle, S | 1 |
| Capasso, I; Carteni, G; Comella, G; Comella, P; D'Aiuto, G; D'Aniello, R; De Lucia, L; Di Bonito, M; Frasci, G; Frezza, P; Lapenta, L; Maiorino, L; Rivellini, F; Thomas, R | 1 |
| Demicheli, R; Garbagnati, F; Mariani, G; Potepan, P; Verderio, P; Zambetti, M | 1 |
| Kuhnt, T; Tanner, J | 1 |
| Chang, HK; Chen, JS; Liaw, CC; Lin, YC; Wang, CH | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M | 1 |
| Kurbacher, CM; Mallmann, P; Schwonzen, M | 1 |
| Kosmas, C; Koufos, C; Malamos, NA; Tsavaris, NB; Vadiaka, M | 1 |
| Azinovic, I; Brugarolas, A; Calvo, E; Cortes, J; de Irala, J; Fernandez-Hildago, O; Garzon, C; Martinez-Aguillo, M; Martinez-Monge, R; Ramon Y Cajal, T; Rodriguez, J | 1 |
| Angeles, C; Barnadas, A; Casado, A; Colomer, R; Lluch, A; Maroto, P; Massuti, B; Ojeda, B | 1 |
| Booser, D; Buzdar, AU; Dhingra, K; Fraschini, G; Frye, D; Holmes, FA; Hortobagyi, GN; Rivera, E; Theriault, RL; Valero, V; Walters, R | 1 |
| Alberola, V; Artal, A; Azagra, P; Camps, C; Carrato, A; Felip, E; González-Larriba, JL; Isla, D; Martin, C; Massutí, B; Rosell, R; Sánchez, JJ | 1 |
| Köhne, CH; Wilke, HJ; Wils, JA | 1 |
| Culine, S; Droz, JP | 1 |
| Al-Tweigeri, T; Azli, N; Mackey, JR; Nabholtz, JM; Noël, DR; North, S; Paterson, A; Riva, A; Smylie, M; Tonkin, K | 1 |
| Adachi, I; Ando, M; Katsumata, N; Nagata, K; Narabayashi, M; Watanabe, T | 1 |
| Balmes, P; Blanchon, F; Castelnau, O; Delaval, P; Gouva, S; Kleisbauer, JP; Léna, H; Muir, JF; Paillotin, D; Penot-Ragon, C; Perdu, D; Poirier, R; Pommier De Santi, P; Robinet, G; Thomas, P | 1 |
| Buzdar, AU; Dhingra, K; Hortobagyi, GN; Ibrahim, NK; Valero, V; Willey, J | 1 |
| Bajamonde, A; Baselga, J; Eiermann, W; Fleming, T; Fuchs, H; Leyland-Jones, B; Norton, L; Paton, V; Pegram, M; Shak, S; Slamon, DJ; Wolter, J | 1 |
| Berzins, J; Gorbunova, V; Jassem, J; Jelic, S; Mrsic-Krmpotic, Z; Munier, S; Nagykalnai, T; Pieńkowski, T; Płuzańska, A; Renard, J; Weil, C; Wigler, N | 1 |
| Georgoulias, VA | 1 |
| Aragão, BC; Garcia, R; Guimarães, RC; Murad, AM; Rodrigues, VH; Scalabrini'Neto, AO | 1 |
| Ansari, R; Gize, G; Miller, KD; Monaco, F; Nattam, S; Pennington, K; Sisk, J; Sledge, GW | 1 |
| Cetto, GL; Conte, P; Crino, L; Donati, S; Galligioni, E; Gennari, A; Mansutti, M; Mazzoni, F; Molino, A; Salvadori, B | 1 |
| Carrasco, E; Dueñas, R; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Adolph, A; Biem, S; Khan, K; Le, T | 1 |
| Boyer, MJ; Clarke, SJ; Davis, I; Goldstein, D; Millward, MJ; Mitchell, P; Olver, IN; Richardson, G | 1 |
| Bafaloukos, D; Briassoulis, E; Dimopoulos, AM; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Keramopoulos, A; Kosmidis, P; Papadimitriou, C; Pavlidis, N; Razis, E; Samantas, E | 1 |
| Bertuzzi, A; Capri, G; Cresta, S; Giani, A; Gianni, L; Grasselli, G; Locatelli, A; Materazzo, C; Perotti, A; Spreafico, C; Tarenzi, E; Valagussa, P; Viganò, L | 1 |
| Milla, L; Milla-Santos, A; Rallo, L; Solano, V | 1 |
| Campbell, M; Cantrell, J; Cartmell, A; Ghalie, R; Harvey, J; Modiano, M; Newcomb, T; Rubin, A; Schuster, M; Urba, W | 1 |
| Berruti, A; Bertetto, O; Bottini, A; Bumma, C; Castiglione, F; Danese, S; DeFabiani, E; Dogliotti, L; Donadio, M; Gorzegno, G; Lorusso, V; Manzin, E; Moro, G; Sarobba, MG | 1 |
| Aragão, BC; Garcia, R; Guimarães, RC; Murad, AM; Rodrigues, VH; Scalabrini-Neto, AO | 1 |
| Bojko, P; Borquez, D; Kasimir-Bauer, S; Mayer, S; Neumann, R; Seeber, S | 1 |
| Fountzilas, G; Razis, ED | 1 |
| Ambrosini, G; Antoine, EC; Azli, N; Benhammouda, A; Borg-Olivier, O; Chollet, P; Khayat, D; Mazen, MF; Monfardini, S; Ramazeilles, C; Riva, A; Sorio, R | 1 |
| Delozier, T; Fumoleau, P; Guastalla, JP; Kerbrat, P; Roché, H; Viens, P | 1 |
| Baker, M; Bradof, JE; Burris, HA; Erland, JB; Greco, FA; Grimaldi, M; Hainsworth, JD; Kalman, LA; Sullivan, T; Yardley, DA | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Frasci, G; Thomas, R | 1 |
| Rixe, O | 1 |
| Dieras, V; Perez, E; Valero, V | 1 |
| Dinney, CP; Inoue, K; Izawa, J; Karashima, T; Kedar, D; Kim, SJ; McConkey, DJ; Millikan, R; Perrotte, P; Shuin, T; Slaton, JW; Sweeney, P; Yoshikawa, C | 1 |
| Bergaglio, M; Cognetti, F; Del Mastro, L; Donati, S; Frevola, L; Lionetto, R; Lunardi, G; Michelotti, A; Papaldo, P; Rosso, R; Sguotti, C; Venturini, M | 1 |
| Avigan, D; Elias, AD; Frei, E; Ibrahim, J; Joyce, R; Levine, J; McCauley, M; McDermott, D; Richardson, P; Warren, D; Wheeler, C | 1 |
| Golunski, E; Knight, V; Koshkina, NV; Melton, S; Roberts, LE; Waldrep, JC | 1 |
| Evans, TL; Lynch, TJ | 1 |
| Baldini, E; Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C; Pazzagli, I; Salvadori, B | 1 |
| Baselga, J | 1 |
| Leyland-Jones, B | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Beuzeboc, P; Diéras, V; Laurence, V; Pierga, JY; Pouillart, P | 1 |
| Leyland-Jones, B; Smith, I | 1 |
| Carman, L; Colborn, D; Gutterman, L; Jones, J; Kuebler, JP; Larrimer, N; Laufman, LR; Moore, T; Patel, T; Pritchard, J; Roach, R; Segal, M; Spiridonidis, CH; Zangmeister, J | 1 |
| Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC | 1 |
| Astudillo, J; Felip, E; Maestre, J; Manzano, JL; Monzo, M; Rosell, R; Sanchez, JJ; Sanchez, JM; Taron, M | 1 |
| Blum, JL; Buzdar, A; Dieras, V; Horton, J; Lo Russo, PM; Osterwalder, B; Rutman, O | 1 |
| Bischoff, J; Forstpointner, R; Geuenich, S; Gutschow, K; Heinemann, V; Hiddemann, W; Kentenich, CH; Malekmohammadi, M; Sommer, H; Stemmler, HJ | 1 |
| Besova, NS; Bliumenberg, AG; Chekalova, MA; Gorbunova, VA; Khokhlova, SV; Kuznetsov, VV; Orel, NF; Poddubnyĭ, BK; Sinitsyna, ME; Smirnova, NB | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; Di Bonito, M; Frasci, G; Rubulotta, R; Thomas, R; Vallone, P | 1 |
| Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M | 1 |
| Clark, JW; Earle, CC; Fuchs, CS; Grossbard, ML; Grossman, SR; Kim, H; Kulke, MH; Mayer, RJ; Morgan, JA; Ryan, DP; Shivdasani, R | 1 |
| Bando, H; Hayashi, K; Kuroi, K; Saji, S; Tanaka, C; Toi, M | 1 |
| Arkad'eva, TV; Artamonova, EV; Davidenko, IS; Manziuk, LV; Poddubnaia, IV | 1 |
| Blanchard, JM | 1 |
| Carles, J; Climent, MA; Garcia del Muro, X; Germá, JR; Gumá, J; Marcuello, E; Maroto, P; Parra, MS; Paz-Ares, L; Tisaire, JL | 1 |
| Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Aihara, T; Kim, Y; Takatsuka, Y | 1 |
| von der Maase, H | 1 |
| Stadler, WM | 1 |
| Hussain, M; Smith, DC; Vaishampayan, U | 1 |
| Morere, JF | 1 |
| Choi, CW; Goo, BH; Kim, BS; Kim, JS; Kim, YH; Seo, JH; Shin, SW; Whang, YM | 1 |
| Amamoo, MA; Collichio, FA; Fogleman, J; Graham, M; Griggs, J | 1 |
| Conte, PF; Gennari, A; Landucci, E; Orlandini, C | 1 |
| Arroyo, CD; Hudis, C; Norton, L; Panageas, KS; Seidman, AD; Tan, L; Van Poznak, C | 1 |
| Ackland, S; Alba Conejo, E; Burger, HU; Eisenberg, P; Laws, S; Melnychuk, D; Moiseyenko, V; O'Reilly, SM; Osterwalder, B; Pienkowski, T; Talbot, DC; Van Belle, S | 1 |
| Dinney, CP; Fan, Z; Hicklin, DJ; Izawa, JI; Karashima, T; Kedar, D; Kim, SJ; Pettaway, C; Shuin, T; Slaton, JW; Sweeney, P | 1 |
| Booser, DJ; Cristofanilli, M; Frye, DK; Hortobagyi, GN; Rivera, E; Rosales, MM; Valero, V | 1 |
| Avigan, D; Elias, AD; Frei, E; Ibrahim, J; Joyce, R; McCauley, M; Reich, E; Richardson, P; Wheeler, C | 1 |
| Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Efstathiou, E; Gika, D; Gourgoulis, GM; Kalofonos, C; Papadimitriou, CA; Sarris, K; Skarlos, D | 1 |
| Zielinski, CC | 1 |
| Dueñas, R; Fernández, M; Jaén, A; Lozano, A; Martínez, E; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Ryan, DP; Willett, CG | 1 |
| Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S | 1 |
| Korn, EL; Simon, R | 1 |
| Maugard-Louboutin, C | 1 |
| Nightingale, SL | 1 |
| Einzig, AI; Gorowski, E; Sasloff, J; Wiernik, PH | 1 |
| Benjamin, RS; Legha, SS; Papadopoulos, N; Raber, M; Ring, S | 1 |
| Krakoff, IR; Legha, SS; Tenney, DM | 1 |
| Fu, YY; Huang, P; Li, BH; Shi, JN; Xin, CW; Yang, XL; Ying, Y; Zhang, ML; Zheng, ZQ | 1 |
159 review(s) available for paclitaxel and Metastase
| Article | Year |
|---|---|
Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Ethnicity; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2022 |
Sister Mary Joseph nodule as cutaneous manifestations of metastatic ovarian cancer: A case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Agents; CA-125 Antigen; Carboplatin; Female; Gynecologic Surgical Procedures; Humans; Liposomes; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Sister Mary Joseph's Nodule; Skin Neoplasms; Tomography, X-Ray Computed; Umbilicus | 2022 |
Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Rate | 2019 |
Advances in paclitaxel combinations for treating cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Uterine Cervical Neoplasms | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Management; Drug Monitoring; Everolimus; Female; Humans; Immunoconjugates; Incidence; Lapatinib; Lung Diseases, Interstitial; Neoplasm Metastasis; Paclitaxel; Pneumonia; Receptor, ErbB-2; Trastuzumab | 2020 |
Treatment landscape of metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomi
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pemetrexed; Publication Bias; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer.
Topics: Albumins; Breast Neoplasms; Female; Humans; Neoplasm Metastasis; Paclitaxel; Risk Factors; Treatment Outcome | 2021 |
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2017 |
Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Disease Progression; Disease-Free Survival; Female; Humans; Indiana; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2017 |
[Advanced bladder cancer : From chemo- to immunotherapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Transitional Cell; Clinical Trials, Phase III as Topic; Humans; Immunotherapy; Neoplasm Metastasis; Paclitaxel; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2018 |
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Survival Rate | 2019 |
The winning formulation: the development of paclitaxel in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemistry, Pharmaceutical; Clinical Trials as Topic; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2013 |
Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
Topics: Albumins; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Nanoparticles; Nanotechnology; Neoplasm Metastasis; Paclitaxel; Research; Taxoids; Treatment Outcome | 2014 |
An update on the pharmacotherapy for endometrial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Practice Guidelines as Topic; Radiography; Randomized Controlled Trials as Topic | 2013 |
Consistent efficacy and safety of gemcitabine-paclitaxel in patients with metastatic breast cancer: a retrospective comparison of East Asian and global studies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Asia, Western; Breast Neoplasms; China; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic | 2014 |
[Chemotherapy in male external genital organs (testicular and penile cancer)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cryopreservation; Etoposide; Fluorouracil; Humans; Ifosfamide; Male; Methotrexate; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Paclitaxel; Penile Neoplasms; Spermatozoa; Testicular Neoplasms; Vinblastine | 2013 |
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2014 |
Advances in cervical cancer pharmacotherapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Uterine Cervical Neoplasms | 2014 |
nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Factors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Early Detection of Cancer; Female; Humans; Infusions, Intravenous; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Treatment of metastatic pancreatic adenocarcinoma: a review.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2014 |
Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Drug Therapy, Combination; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2014 |
Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2015 |
nab-Paclitaxel dose and schedule in breast cancer.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2015 |
The role of taxanes in triple-negative breast cancer: literature review.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Nab-paclitaxel in patients with metastatic melanoma.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Humans; Melanoma; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Skin Neoplasms | 2015 |
Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts.
Topics: Albumins; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Expert Testimony; Female; Humans; Neoplasm Metastasis; Paclitaxel; Practice Guidelines as Topic; Precision Medicine | 2016 |
The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2016 |
A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2016 |
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Genes, erbB-2; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2008 |
Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Ifosfamide; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prognosis; Testicular Neoplasms; Time Factors; Treatment Failure; Urogenital Surgical Procedures; Vinblastine | 2008 |
Paclitaxel and docetaxel in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Carriers; Drug Delivery Systems; Female; Humans; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Survival Rate; Treatment Outcome | 2010 |
Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Logistic Models; Male; Melanoma; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Remission Induction; Sex Factors; Skin Neoplasms; Treatment Outcome; Vinblastine | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2011 |
Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2011 |
Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.
Topics: Albumins; Animals; Breast Neoplasms; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2011 |
Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
Topics: Albumins; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Melanoma; Molecular Targeted Therapy; Neoplasm Metastasis; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Skin Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A | 2013 |
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Platinum Compounds; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2002 |
Gemcitabine and targeted therapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Hematologic Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
End points for new agents in induction chemotherapy for locally advanced head and neck cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Systemic therapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Diphosphonates; Enzyme Inhibitors; ErbB Receptors; Estrogen Receptor Modulators; Female; Humans; Neoplasm Metastasis; Paclitaxel; Patient Care Planning | 2002 |
[Radiation recall dermatitis after docetaxel and external beam radiotherapy. Report of two cases and review of the literature].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel; Radiodermatitis; Radiotherapy; Taxoids | 2002 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Combination versus sequential single-agent therapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Research Design; Taxoids; Trastuzumab | 2002 |
Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Hematologic Diseases; Humans; Hysterectomy; Life Tables; Lymphatic Irradiation; Lymphatic Metastasis; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Radiation Injuries; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Retrospective Studies; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Gemcitabine combined with docetaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Trastuzumab | 2003 |
Docetaxel-anthracycline combinations in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2003 |
Use and abuse of taxanes in the management of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bias; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Substance-Related Disorders; Taxoids | 2003 |
Liposomal anthracyclines in metastatic breast cancer: clinical update.
Topics: Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Doxorubicin; Heart Diseases; Humans; Liposomes; Neoplasm Metastasis; Paclitaxel | 2003 |
Liposomal anthracyclines for breast cancer: overview.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Doxorubicin; Heart Failure; Humans; Liposomes; Neoplasm Metastasis; Paclitaxel | 2003 |
Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
[The guidelines for diagnostics and treatment of cervical cancer].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Ifosfamide; Irinotecan; Lymph Node Excision; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Palliative Care; Practice Guidelines as Topic; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors; Uterine Cervical Neoplasms | 2004 |
The role of taxanes in the treatment of breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2005 |
Gemcitabine plus paclitaxel in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2005 |
What is the best schedule for administration of gemcitabine-taxane?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Remission Induction; Taxoids; Trastuzumab | 2005 |
Use of dose-dense chemotherapy in the management of breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Movement; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols; Recombinant Proteins | 2006 |
Chromosomal instability, colorectal cancer and taxane resistance.
Topics: Antineoplastic Agents; Aurora Kinase A; Aurora Kinases; Chromosomal Instability; Clinical Trials as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Microtubules; Mitosis; Neoplasm Metastasis; Paclitaxel; Protein Kinases; Protein Serine-Threonine Kinases; Spindle Apparatus; Taxoids; Vincristine | 2006 |
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Paclitaxel | 2006 |
Albumin-bound paclitaxel: a next-generation taxane.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Drug Administration Schedule; Drug Delivery Systems; Endothelial Cells; Female; Glycerol; Humans; Infusions, Intra-Arterial; Nanotechnology; Neoplasm Metastasis; Osteonectin; Paclitaxel; Randomized Controlled Trials as Topic; Solvents; Survival Rate; Therapeutic Equivalency | 2006 |
Gemcitabine and taxanes in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2006 |
[Study of drugs against neoplastic metastasis].
Topics: Animals; Antineoplastic Agents; Cell Movement; Chromones; Deoxyuridine; Doxorubicin; Enzyme Inhibitors; Fatty Alcohols; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Morpholines; Neoplasm Metastasis; Paclitaxel; Pyridines; Ribavirin; Signal Transduction; Sirolimus | 2006 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Multicenter Studies as Topic; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors | 2007 |
Managing cardiotoxicity in anthracycline-treated breast cancers.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Clinical Trials, Phase III as Topic; Doxorubicin; Female; Heart; Humans; Liposomes; Neoplasm Metastasis; Paclitaxel; Razoxane; Trastuzumab | 2007 |
Gemcitabine in the management of metastatic breast cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Heart Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2007 |
Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2008 |
Metastatic squamous cell carcinoma of the urachus.
Topics: Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Fatal Outcome; Humans; Male; Neoplasm Metastasis; Paclitaxel; Tomography, X-Ray Computed; Urachus; Urinary Bladder Neoplasms | 2007 |
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Taxoids; Vascular Endothelial Growth Factor A | 2008 |
Treatment of metastatic breast cancer: looking towards the future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Medical Oncology; Neoplasm Metastasis; Paclitaxel; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Management of breast cancer: status and future trends.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Female; Hormones; Humans; Mastectomy; Neoplasm Metastasis; Paclitaxel | 1995 |
Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Analysis | 1995 |
Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Combination chemotherapy with Taxol (paclitaxel) in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Radiotherapy, Adjuvant; Treatment Outcome | 1994 |
[Favorable remission rates of metastatic breast cancer with taxol therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 1993 |
[Paclitaxel (taxol)--a cytostatic drug with a new kind of mechanism of action].
Topics: Cell Division; Female; Humans; Microtubules; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Paclitaxel; Spindle Apparatus | 1993 |
Paclitaxel (Taxol) in breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Drug Resistance; Female; Humans; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents | 1994 |
Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Humans; National Institutes of Health (U.S.); Neoplasm Metastasis; Paclitaxel; United States | 1994 |
Case report: paclitaxel-induced myocardial ischemia.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Myocardial Ischemia; Neoplasm Metastasis; Paclitaxel | 1996 |
Taxoid compounds in breast cancer: current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1995 |
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids; Thiotepa | 1995 |
Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Neoplasm Metastasis; Paclitaxel; Remission Induction | 1995 |
Docetaxel delivers new management opportunities for gastrointestinal carcinomas.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Docetaxel; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids | 1995 |
Treatment of advanced breast cancer: current status.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1996 |
Paclitaxel and carboplatin for advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Breast Neoplasms; Carboplatin; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Tolerance; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Quality of Life; Thrombopoietin | 1996 |
Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Topics: Aminopterin; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Synergism; Drugs, Investigational; Female; Fluorouracil; Genetic Therapy; Humans; Leucovorin; Neoplasm Metastasis; Oncogenes; Paclitaxel; Radiotherapy, Adjuvant | 1996 |
Paclitaxel combination therapy in the treatment of metastatic breast cancer.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Fluorouracil; Humans; Ifosfamide; Neoplasm Metastasis; Paclitaxel | 1996 |
Metastatic breast cancer.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome | 1996 |
Paclitaxel and doxorubicin in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Humans; Neoplasm Metastasis; Paclitaxel | 1996 |
Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Vinblastine; Vinorelbine | 1996 |
Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel | 1997 |
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Quality of Life | 1997 |
The taxoids: same roots, different drugs.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids | 1997 |
Docetaxel in combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
[A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1997 |
Review of docetaxel/doxorubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1997 |
Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Metastasis; Nervous System Diseases; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 1997 |
Review of recent trials of chemotherapy for advanced breast cancer: the taxanes.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
The role of docetaxel in improving treatment outcomes in advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Prospects with docetaxel in the treatment of patients with breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Uterine Cervical Neoplasms | 1998 |
[Chemotherapy in metastasized breast carcinoma].
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoplasm Metastasis; Neoplasms, Second Primary; Paclitaxel; Palliative Care; Quality of Life; Survival Rate; Taxoids | 1998 |
Evolution in the treatment of advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
Taxanes in the treatment of breast cancer: a prodigy comes of age.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Proteins; Paclitaxel; Palliative Care; Survival Analysis; Taxoids; Tubulin; Vinca Alkaloids | 1999 |
The current state of adjuvant therapy for breast cancer: focus on paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Administration Schedule; Humans; Neoplasm Metastasis; Paclitaxel | 1999 |
Metastatic breast cancer: the role of chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy | 1999 |
Paclitaxel plus nonanthracycline combinations in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Humans; Neoplasm Metastasis; Paclitaxel | 1999 |
Paclitaxel in the treatment of esophageal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Esophageal Neoplasms; Humans; Neoplasm Metastasis; Paclitaxel | 1999 |
Review and outlook for the role of paclitaxel in urothelial carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Neoplasm Metastasis; Paclitaxel; Urinary Bladder Neoplasms | 1999 |
A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic | 1999 |
Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Mitomycin; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine | 1999 |
Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Pyrazoles; Pyrazolones; Randomized Controlled Trials as Topic | 1999 |
Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Single-agent docetaxel (Taxotere) in randomized phase III trials.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Failure | 1999 |
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Recent progress in the clinical development of docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Estramustine; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Expanding options in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Phytogenic; Humans; Male; Neoplasm Metastasis; Paclitaxel; Paraganglioma | 2000 |
Developments in the treatment of gastric cancer in Europe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Palliative Care; Prednisolone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
Paclitaxel: epirubicin in metastatic breast cancer--a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2001 |
Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; In Situ Hybridization, Fluorescence; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Safety; Single-Blind Method; Survival Analysis; Trastuzumab; Treatment Outcome | 2001 |
Dose scheduling--Herceptin.
Topics: Abdominal Muscles; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Drug Antagonism; Drug Evaluation, Preclinical; Drug Synergism; Feasibility Studies; Female; Fluorouracil; Half-Life; Haplorhini; Humans; Infusions, Intravenous; Injections, Subcutaneous; Methotrexate; Neoplasm Metastasis; Paclitaxel; Safety; Trastuzumab; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Interaction between Herceptin and taxanes.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Heart Diseases; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Nervous System Diseases; Neutropenia; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, ErbB-3; Salvage Therapy; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2001 |
Role of Herceptin in primary breast cancer: views from North America and Europe.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Interactions; Europe; Female; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; North America; Paclitaxel; Palliative Care; Pilot Projects; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Safety; Survival Analysis; Tamoxifen; Taxoids; Trastuzumab; Treatment Outcome | 2001 |
The role of chemotherapy in early non-small-cell lung cancer management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Survival Analysis | 2001 |
[Molecular mechanisms of oncogenic transformation: what's new?].
Topics: Animals; Antineoplastic Agents, Phytogenic; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Disease Progression; Drug Resistance; Fusion Proteins, bcr-abl; Humans; Mice; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Neural Cell Adhesion Molecules; Paclitaxel; Protein Serine-Threonine Kinases; Radiation Tolerance; Rats; Thrombospondins; Transforming Growth Factor beta; Tuberous Sclerosis | 2002 |
Current and future perspectives in advanced bladder cancer: is there a new standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Metastasis; Paclitaxel; Patient Selection; Practice Guidelines as Topic; Research Design; Risk Factors; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Gemcitabine doublets in advanced urothelial cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Renal Insufficiency; Survival Analysis; Trastuzumab; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Novel gemcitabine-containing triplets in the management of urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Platinum compounds in the treatment of advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Mastectomy; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Preoperative Care; Severity of Illness Index; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Role of epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2000 |
Gemcitabine/anthracycline combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant gemcitabine therapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycins; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Streptozocin | 2002 |
[Cancer of the breast].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tamoxifen | 1992 |
472 trial(s) available for paclitaxel and Metastase
| Article | Year |
|---|---|
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Immune Checkpoint Inhibitors; Lymphocyte Depletion; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptors, Antigen, T-Cell; T-Lymphocyte Subsets; Triple Negative Breast Neoplasms; Young Adult | 2022 |
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome | 2020 |
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adolescent; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Double-Blind Method; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Triple Negative Breast Neoplasms; Young Adult | 2020 |
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Double-Blind Method; Drug Approval; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Survival Rate; Triple Negative Breast Neoplasms; United States; United States Food and Drug Administration; Young Adult | 2020 |
Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2020 |
Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study.
Topics: Adenocarcinoma; Aged; Albumins; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Progression-Free Survival; Radiation-Sensitizing Agents; Thrombocytopenia; Treatment Outcome | 2020 |
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2020 |
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Janus Kinase Inhibitors; Middle Aged; Neoplasm Metastasis; Nitriles; Paclitaxel; Pyrazoles; Pyrimidines; Receptor, ErbB-2 | 2021 |
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Rate | 2021 |
Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Prednisolone; Pyrimidines | 2021 |
Does bevacizumab carry a hope for metastatic triple-negative breast cancer in the era of immunotherapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Progression-Free Survival; Prospective Studies; Remission Induction; Triple Negative Breast Neoplasms | 2022 |
Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Retreatment; Trastuzumab; Treatment Outcome; Young Adult | 2017 |
Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Everolimus; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies | 2017 |
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Epothilones; Female; Humans; Models, Biological; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases | 2017 |
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Paclitaxel; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib; Treatment Outcome | 2017 |
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Sirolimus; Squamous Cell Carcinoma of Head and Neck | 2017 |
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
Topics: Adult; Aged; Breast Neoplasms; Canada; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Mammalian orthoreovirus 3; Middle Aged; Neoplasm Metastasis; Oncolytic Virotherapy; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2018 |
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Breast Neoplasms, Male; Carboplatin; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Single-Blind Method; Temozolomide; Young Adult | 2018 |
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Furans; Gemcitabine; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Republic of Korea; Time Factors; Treatment Outcome; Young Adult | 2017 |
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Placebos; Progression-Free Survival; Proto-Oncogene Mas; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Hyaluronoglucosaminidase; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; San Francisco; Survival Rate; Treatment Outcome | 2018 |
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Squamous Cell Carcinoma of Head and Neck | 2018 |
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2018 |
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Topics: Aged; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Genes, erbB-1; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Paclitaxel; Receptor Protein-Tyrosine Kinases; Survival Analysis; Vascular Endothelial Growth Factor A | 2018 |
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Middle Aged; Neoplasm Metastasis; Neutrophils; Paclitaxel; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2018 |
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.
Topics: Animals; Breast Neoplasms; Capecitabine; CD11c Antigen; Cell Line, Tumor; Cell Membrane; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Ketones; Leukocytes, Mononuclear; Macrophages; Mice; Mice, SCID; Myeloid Cells; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Pilot Projects; Transcription, Genetic; Transforming Growth Factor beta | 2018 |
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Female; Humans; Longitudinal Studies; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Netherlands; Paclitaxel; Progression-Free Survival; Receptor, ErbB-2 | 2018 |
Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2019 |
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2018 |
A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Oncology
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms | 2018 |
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Time Factors; Triple Negative Breast Neoplasms; United States | 2019 |
A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Geriatric Assessment; Humans; Male; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2019 |
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2019 |
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2019 |
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dasatinib; Drug Administration Schedule; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins pp60(c-src); Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2019 |
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Humans; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Estrogen; Survival Rate | 2019 |
Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Non-Randomized Controlled Trials as Topic; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2019 |
Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2019 |
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperidines; Pyrroles; Treatment Outcome; Triazines | 2013 |
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Castor Oil; Cost Savings; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Markov Chains; Models, Economic; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Spain; Time Factors; Treatment Outcome | 2013 |
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Medical Futility; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome | 2013 |
Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinolines; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2013 |
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Epothilones; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2013 |
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Survival Rate | 2013 |
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Squamous Cell; Organoplatinum Compounds; Paclitaxel; Survival; Survival Rate; Treatment Outcome | 2013 |
A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Triple Negative Breast Neoplasms | 2013 |
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Placebos; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2013 |
Bi-weekly paclitaxel and capecitabine as a second- or third-line treatment for advanced breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Salvage Therapy; Survival Rate | 2013 |
Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Castor Oil; Chemistry, Pharmaceutical; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Solvents; Therapeutic Equivalency; Young Adult | 2013 |
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Membrane Transport Proteins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymorphism, Genetic; Prognosis; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2014 |
Improved survival with bevacizumab in advanced cervical cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Analysis; Topotecan; Uterine Cervical Neoplasms | 2014 |
Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma.
Topics: Adenoviridae; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Endostatins; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Proteins; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Epothilones; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Proportional Hazards Models; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Chorionic Gonadotropin; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; International Agencies; Lenograstim; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Precision Medicine; Prognosis; Recombinant Proteins; Survival Rate; Testicular Neoplasms; Young Adult | 2014 |
Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Breast Neoplasms; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Metastasis; Paclitaxel | 2015 |
Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Double-Blind Method; Electrocardiography; Female; Humans; Long QT Syndrome; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2015 |
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Image-Guided; Survival Rate | 2015 |
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Count; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Triple Negative Breast Neoplasms | 2015 |
A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2015 |
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Diarrhea; Female; Hemoglobins; Humans; Japan; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Survival Rate | 2015 |
A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Tegafur; Young Adult | 2015 |
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2015 |
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Small Cell Lung Carcinoma | 2016 |
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Drug Administration Schedule; Epothilones; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2015 |
Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer.
Topics: Antineoplastic Agents, Phytogenic; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms | 2015 |
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mice, Knockout; Neoplasm Metastasis; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Protocols; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Translational Research, Biomedical | 2015 |
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
Topics: Adult; Aged; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2 | 2015 |
Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Retreatment; Treatment Outcome | 2015 |
Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Survival Rate; Taxoids; Triple Negative Breast Neoplasms; Young Adult | 2015 |
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Proportional Hazards Models; Treatment Outcome; Tumor Burden | 2016 |
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Research Design; Survival Analysis; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Treatment Outcome | 2016 |
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2016 |
Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Injections; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cardiotoxicity; Female; Humans; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Troponin I; Ventricular Function, Left | 2016 |
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Female; Genetic Vectors; Humans; Male; Mammalian orthoreovirus 3; Middle Aged; Neoplasm Metastasis; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2016 |
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrimidines; Sulfonamides; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2016 |
A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2016 |
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2016 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life; Receptor, ErbB-2; Survival Rate | 2016 |
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-c
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Sulfonamides | 2016 |
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III tr
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cyclophosphamide; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Quality of Life; Receptor, ErbB-2; Retreatment; Treatment Outcome | 2016 |
Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Survival Analysis; Treatment Outcome | 2016 |
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Panitumumab; Squamous Cell Carcinoma of Head and Neck | 2016 |
Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial.
Topics: Albumins; Colorectal Neoplasms; Female; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Paclitaxel | 2017 |
Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Animals; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Mice; Middle Aged; Models, Biological; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies | 2016 |
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Female; Follow-Up Studies; Heart; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organs at Risk; Paclitaxel; Prospective Studies; Radiation Dosage; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Survival Rate | 2017 |
Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Retrospective Studies | 2017 |
Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Topotecan | 2008 |
Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Skin Diseases | 2008 |
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; France; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Scalp; Skin Neoplasms; Soft Tissue Neoplasms; Time Factors; Treatment Outcome | 2008 |
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2009 |
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Placebos; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2008 |
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 2009 |
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2009 |
Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms | 2009 |
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Female; Genes, erbB-2; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Trastuzumab; Up-Regulation | 2009 |
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Feasibility Studies; Female; Heart; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stroke Volume; Survival Rate; Trastuzumab; Treatment Outcome; Ventricular Function, Left | 2009 |
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Penile Neoplasms; Stomatitis; Survival Rate; Treatment Outcome | 2009 |
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Carboplatin; Carcinoma; CD56 Antigen; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neural Cell Adhesion Molecules; Organophosphorus Compounds; Paclitaxel; Stilbenes; Survivors; Thyroid Neoplasms; Treatment Outcome; Young Adult | 2009 |
Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2009 |
Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Japan; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2009 |
Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel; Uterine Cervical Neoplasms | 2009 |
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Probability; Risk Assessment; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2009 |
Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2009 |
Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Frail Elderly; Humans; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2009 |
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Paclitaxel; Proliferating Cell Nuclear Antigen; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2010 |
A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Protocols; Female; Follow-Up Studies; Humans; Japan; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Quality of Life; Recurrence; Research Design; Uterine Cervical Neoplasms | 2010 |
Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Constipation; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Humans; Hydrazines; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2009 |
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Male; Melanoma; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms | 2010 |
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Rate; Uterine Cervical Neoplasms | 2010 |
Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Micelles; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2010 |
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Estradiol; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Paclitaxel; Polyglutamic Acid; Prostatic Neoplasms; Taxoids | 2010 |
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Pyrroles; Safety; Sunitinib; Survival Rate | 2010 |
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2010 |
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Health Status; Humans; Lapatinib; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quinazolines; Receptor, ErbB-2 | 2010 |
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cytokines; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Pyrazoles; Skin Neoplasms; Sulfonamides | 2010 |
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Humans; Interferons; Isotretinoin; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quality of Life; Survival Rate; Teratogens; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Survival; Tegafur; Treatment Outcome | 2011 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Tegafur | 2010 |
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Female; Humans; Liver Diseases; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Pilot Projects | 2010 |
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrazines; Skin Neoplasms | 2010 |
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Breast Neoplasms; Disease Progression; Female; Hispanic or Latino; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome; Tretinoin | 2011 |
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Phenotype; Receptor, ErbB-2 | 2011 |
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity.
Topics: Aged; Antibodies, Neoplasm; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Drug Administration Schedule; Female; Humans; Immunity; Immunotherapy; Lymphocyte Activation; Lymphocyte Activation Gene 3 Protein; Middle Aged; Monocytes; Neoplasm Metastasis; Paclitaxel; Remission Induction; Treatment Outcome | 2010 |
Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2010 |
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Middle Aged; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2010 |
Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Confidence Intervals; Disease Progression; Drug Combinations; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2010 |
Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2011 |
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Uveal Neoplasms | 2010 |
Randomized phase II study comparing dose escalated weekly paclitaxel vs. standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Humans; Infusions, Parenteral; Japan; Neoplasm Metastasis; Paclitaxel; Patient Selection; Research Design; Stomach Neoplasms | 2011 |
Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Urologic Neoplasms | 2011 |
Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease Progression; Endpoint Determination; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome | 2011 |
Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Health Status; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Young Adult | 2012 |
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Dasatinib; Edema; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pleural Effusion, Malignant; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Oligonucleotides; Paclitaxel; Receptor, ErbB-2 | 2011 |
Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tegafur; Treatment Outcome; Uracil | 2011 |
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Young Adult | 2011 |
A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Drug Administration Schedule; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Trastuzumab | 2011 |
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Proportional Hazards Models; Treatment Outcome | 2011 |
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; United States; Vascular Endothelial Growth Factor A | 2011 |
Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Pelvic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Breast Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Humans; Japan; Male; Metabolic Clearance Rate; Middle Aged; Nanoparticles; Nausea; Neoplasm Metastasis; Neoplasms; Paclitaxel; Treatment Outcome | 2012 |
Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life | 2011 |
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2011 |
A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2012 |
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Retreatment; Treatment Outcome | 2011 |
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence; Treatment Outcome | 2012 |
Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Stomach Neoplasms | 2011 |
Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Inflammatory Breast Neoplasms; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Thiotepa; Treatment Outcome | 2012 |
Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Thailand; Treatment Outcome | 2012 |
Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Trastuzumab; Treatment Outcome | 2012 |
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Receptor, ErbB-2 | 2012 |
A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Hyperglycemia; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Sirolimus; Thrombocytopenia; Treatment Outcome | 2012 |
Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2012 |
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fibroblast Growth Factor 2; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Suramin; Taxoids; Treatment Outcome | 2012 |
Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Nomograms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2012 |
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Paclitaxel; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib | 2013 |
A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome | 2012 |
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Paclitaxel; Skin Neoplasms; Temozolomide; Thionucleotides; Treatment Outcome | 2013 |
Phase I study of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2012 |
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib; Treatment Outcome; Uvea; Uveal Neoplasms | 2012 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2 | 2013 |
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Sample Size; Survival Analysis | 2013 |
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Follow-Up Studies; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tissue Array Analysis; Vascular Endothelial Growth Factor A | 2013 |
Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Radiotherapy; Time Factors | 2013 |
Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Logistic Models; Middle Aged; Neoplasm Metastasis; New York City; Paclitaxel; Prospective Studies; Quality of Life | 2002 |
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2002 |
Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Palliative Care; Recurrence; Survival Rate; Taxoids; Time Factors | 2002 |
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Estramustine; Female; Humans; Microtubules; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival; Taxoids; Treatment Outcome; Venous Thrombosis | 2002 |
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Incidence; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2002 |
Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Analysis; Taxoids | 2002 |
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Time Factors; Treatment Outcome | 2002 |
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infections; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Estramustine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Remission Induction; Survival Analysis; Taxoids | 2003 |
Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Survival Analysis | 2003 |
Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Gene Expression; Genes, erbB-2; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids; Trastuzumab | 2003 |
Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Palliative Care; Prospective Studies; Spain; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2003 |
Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
[Clinical research of taxotere in treatment of metastatic breast cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2003 |
[Metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Germany; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection | 2003 |
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Budgets; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Metastasis; Ontario; Paclitaxel; Population Surveillance; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine; Women's Health | 2003 |
Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pulmonary Fibrosis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2003 |
Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Thiotepa; Treatment Outcome | 2003 |
Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2003 |
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Suramin; Time Factors | 2003 |
Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Canada; Cohort Studies; Disease-Free Survival; Drug Administration Schedule; Female; Genes, erbB-2; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Trastuzumab; Treatment Outcome | 2003 |
Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Cohort Studies; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Neoplasm Metastasis; Oropharyngeal Neoplasms; Paclitaxel; Radiotherapy Dosage; Stomatitis; Survival Analysis; Time Factors | 2003 |
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2003 |
Biweekly paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 2003 |
Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capability.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Heart; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2004 |
Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Selection; Survival Rate; Treatment Outcome; World Health Organization | 2003 |
Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection; Salvage Therapy; Survival Analysis; Trastuzumab; Treatment Outcome; World Health Organization | 2003 |
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Trastuzumab; Treatment Outcome | 2003 |
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Treatment Outcome | 2004 |
A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2004 |
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Quality of Life; Survival Analysis | 2004 |
Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2004 |
The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Time Factors; Treatment Outcome | 2004 |
Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome | 2004 |
Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2004 |
Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Heart Failure; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Risk Factors; Ventricular Dysfunction, Left | 2004 |
First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Female; Humans; Liposomes; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel; Soft Tissue Neoplasms; South Africa; Survival Analysis; Treatment Outcome | 2004 |
Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2004 |
Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Radiometry; Time Factors; Treatment Outcome | 2004 |
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Quality of Life | 2004 |
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Heart; Heart Diseases; Heart Failure; Humans; Immunohistochemistry; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome; Ventricular Dysfunction, Left | 2004 |
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pleural Effusion; Prognosis; Treatment Outcome | 2004 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Vomiting | 2005 |
Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Toxicity profile and objective response of paclitaxel in metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pakistan; Survival Rate; Treatment Outcome | 2005 |
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life | 2005 |
Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Female; Follow-Up Studies; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy, High-Energy; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Transitional Cell; Drug Therapy, Combination; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome; Urologic Neoplasms | 2005 |
The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Safety; Stomach Neoplasms; Treatment Outcome | 2005 |
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Breast Neoplasms; Disease Progression; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2005 |
Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quality of Life; Risk Assessment; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2005 |
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis | 2005 |
Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2005 |
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Statistics, Nonparametric; Survival Analysis; United Kingdom | 2005 |
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2005 |
Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Time Factors | 2005 |
Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Pyridines; Risk; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2005 |
Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2006 |
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2006 |
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Female; Humans; Interleukin-6; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Time Factors; Treatment Outcome | 2006 |
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2006 |
Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Failure | 2006 |
Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Salvage Therapy; Survival Rate | 2006 |
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cetuximab; Drug Synergism; ErbB Receptors; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2006 |
Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cyclosporine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Neutropenia; Paclitaxel; Salvage Therapy; Vinblastine; Vinorelbine | 2007 |
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Black or African American; Breast Neoplasms; Female; Genes, erbB-2; Genes, p53; Humans; Neoplasm Metastasis; Paclitaxel; Predictive Value of Tests; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; White People | 2006 |
A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2007 |
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Stem Cell Transplantation; Treatment Outcome | 2007 |
Albumin-bound paclitaxel improves response rate vs docetaxel in metastatic breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2007 |
Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Female; Fever; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recurrence; Stomach Neoplasms; Survival Rate | 2007 |
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Hypersensitivity; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polyglutamic Acid; Taxoids | 2007 |
Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Survival Analysis; Time Factors; Vomiting | 2007 |
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tomography, X-Ray Computed | 2008 |
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Drug Administration Schedule; Drug Carriers; Drug Compounding; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Korea; Micelles; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols; Polymers; Time Factors; Treatment Outcome | 2008 |
A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Fever; Foot Dermatoses; Hand Dermatoses; Humans; Liposomes; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Paresthesia; Polyethylene Glycols; Salvage Therapy; Treatment Outcome | 2008 |
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Taxoids | 2008 |
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Constipation; Disease Progression; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2008 |
Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Diethylstilbestrol; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome; Tubulin Modulators; Venous Thrombosis | 2007 |
Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Drug Resistance, Neoplasm; Female; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Quality of Life; Salvage Therapy; Treatment Outcome; Urologic Neoplasms | 2007 |
Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins | 2007 |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2007 |
Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Humans; Leucovorin; Maximum Tolerated Dose; Middle Aged; Models, Theoretical; Neoplasm Metastasis; Paclitaxel; Tegafur; Uracil | 2007 |
A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hematologic Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Analysis | 2008 |
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Quality of Life; Receptor, ErbB-2; Survival Analysis | 2007 |
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Topics: Abdominal Neoplasms; Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2009 |
A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1995 |
Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report.
Topics: Adult; Aged; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins | 1993 |
Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Neoplasm Metastasis; Paclitaxel | 1993 |
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Remission Induction; Salvage Therapy | 1994 |
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome | 1995 |
A phase I trial of paclitaxel and etoposide for metastatic or recurrent malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 1995 |
Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chi-Square Distribution; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; National Institutes of Health (U.S.); Neoplasm Metastasis; Neutropenia; Paclitaxel; Referral and Consultation; Remission Induction; United States | 1995 |
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Care Facilities; Chemotherapy, Adjuvant; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lymphatic Metastasis; Neoplasm Metastasis; New York City; Paclitaxel; Quality of Life; Remission Induction; Survival Rate | 1995 |
Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Resistance; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction | 1995 |
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distribution; Doxorubicin; Drug Administration Schedule; Female; Heart; Heart Failure; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction | 1995 |
Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction | 1995 |
Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cross-Over Studies; Disease Progression; Female; Humans; Infusions, Intravenous; Middle Aged; Mitomycins; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Remission Induction | 1995 |
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Treatment Outcome | 1993 |
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Bone Marrow Diseases; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Treatment Outcome | 1993 |
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
Topics: Adult; Aged; Cimetidine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Famotidine; Female; Histamine H2 Antagonists; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Premedication; Prospective Studies | 1995 |
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Hypersensitivity; Drug Resistance; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids | 1995 |
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1993 |
Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms; Docetaxel; Drug Administration Schedule; Drug Eruptions; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1994 |
Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Prospective Studies | 1994 |
Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.
Topics: Adult; Alopecia; Antibiotics, Antineoplastic; Breast Neoplasms; Chemotherapy, Adjuvant; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1994 |
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Taxoids | 1995 |
Single-agent paclitaxel at first relapse following adjuvant chemotherapy for breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1995 |
Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Salvage Therapy; Survival Analysis | 1995 |
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cimetidine; Dexamethasone; Diphenhydramine; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Edema; Female; Humans; Injections, Intravenous; Leukopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel; Premedication; Taxoids | 1996 |
Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Equipment Failure; Erythrocyte Transfusion; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Home Infusion Therapy; Humans; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1996 |
Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel.
Topics: Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Female; Humans; Neoplasm Metastasis; Paclitaxel | 1995 |
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 1996 |
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 1996 |
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 1996 |
First-line treatment of metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Europe; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; North America; Paclitaxel; Taxoids | 1996 |
Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Breast Neoplasms; Carmustine; Cisplatin; Creatinine; Cyclophosphamide; Dose-Response Relationship, Drug; Electrolytes; Female; Hematopoiesis; Humans; Kidney Function Tests; Neoplasm Metastasis; Neutropenia; Paclitaxel; Renal Insufficiency; Risk Factors; Transplantation, Autologous | 1996 |
Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Rate | 1996 |
Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Heart; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 1996 |
Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 1996 |
A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Rate | 1996 |
Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer.
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Eruptions; Drug Tolerance; Humans; Lung Diseases; Lung Neoplasms; Muscular Diseases; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 1996 |
Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low; Cyclophosphamide; Epirubicin; Female; France; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1997 |
Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1997 |
Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1997 |
Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fatigue; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Mucous Membrane; Neoplasm Metastasis; Nervous System Diseases; Paclitaxel | 1997 |
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Quality of Life | 1997 |
Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 1997 |
Docetaxel in combination with doxorubicin: a phase I dose-finding study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pilot Projects; Survival Rate; Taxoids | 1997 |
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pilot Projects; Taxoids | 1997 |
Docetaxel combined with vinorelbine: phase I results and new study designs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Liver Neoplasms; Neoplasm Metastasis; Neutropenia; Paclitaxel; Research Design; Taxoids; Vinblastine; Vinorelbine | 1997 |
Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Heart; Humans; Neoplasm Metastasis; Paclitaxel | 1997 |
Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 1997 |
Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bacterial Infections; Breast Neoplasms; Cause of Death; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fever; Heart Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia | 1997 |
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Constipation; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Mitomycins; Neoplasm Metastasis; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia; Vinblastine | 1997 |
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fever; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1997 |
A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Prednisone; Survival Analysis | 1997 |
Doxorubicin plus paclitaxel in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stroke Volume; Ventricular Function, Left | 1997 |
Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Feasibility Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom Coordinating Committee for Cancer Research Breast Cancer Sub-Committee.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Humans; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quality of Life | 1997 |
Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Dose-finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Paclitaxel | 1997 |
Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction | 1997 |
Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Mitoxantrone; Neoplasm Metastasis; Paclitaxel | 1997 |
Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Heart; Heart Function Tests; Humans; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Stroke Volume | 1997 |
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Heart; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Respiratory Function Tests | 1997 |
A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction | 1997 |
A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stomach Neoplasms; Treatment Outcome | 1997 |
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Immunosuppression Therapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 1997 |
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 1997 |
A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 1997 |
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 1997 |
[Taxotere: the first drug better than acrdiamycin, the most frequently used drug in the treatment of metastasized breast cancer. Phase III study shows a better response than standard treatment].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1997 |
Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Vinblastine; Vinorelbine | 1998 |
Fluorouracil-based combinations in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Forecasting; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1998 |
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids | 1998 |
Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Salvage Therapy; Survival Analysis; Taxoids; Vinblastine | 1998 |
Phase II study of paclitaxel in pretreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Survival Analysis; Thrombocytopenia; Time Factors | 1998 |
Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Leukopenia; Neoplasm Metastasis; Paclitaxel; Thrombocytopenia; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 1998 |
Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 1998 |
The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction | 1998 |
A phase II trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1998 |
A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1998 |
Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Vinblastine | 1998 |
Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel | 1998 |
Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Failure | 1998 |
Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids | 1998 |
Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Thiotepa | 1998 |
[Breast cancer: new therapeutic strategies].
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Multiple; Female; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Taxoids; Treatment Outcome | 1998 |
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 1999 |
Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Survival Analysis; Uterine Cervical Neoplasms | 1999 |
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lymphocyte Count; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Ventricular Function, Left | 1999 |
Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel | 1999 |
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 1999 |
Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Taxoids | 1999 |
Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Neoplasm Metastasis; Paclitaxel; Prospective Studies | 1999 |
Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support.
Topics: Adult; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Survival Analysis | 1999 |
Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunomagnetic Separation; Leukapheresis; Mitoxantrone; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Thiotepa | 1999 |
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Heart Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel; Severity of Illness Index; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 1999 |
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Severity of Illness Index; Survival Rate; Thiotepa; Treatment Outcome | 1999 |
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Ventricular Function, Left | 1999 |
Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Time Factors | 1999 |
Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Paclitaxel, UFT, and calcium folinate in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tegafur; Treatment Outcome; Uracil | 1999 |
Paclitaxel and UFT plus oral calcium folinate in pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Female; Follow-Up Studies; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Premedication; Tegafur; Treatment Outcome; Uracil | 1999 |
UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leucovorin; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Tegafur; Treatment Outcome; Uracil | 1999 |
Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Survival Rate; Vinblastine; Vinorelbine | 1999 |
Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Argentina; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Treatment Outcome | 1999 |
Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Drug Resistance; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1999 |
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
[Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids | 1999 |
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Recurrence; Thiotepa; Transplantation, Autologous; Treatment Outcome | 1999 |
CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Thiotepa; Transplantation, Autologous | 1999 |
Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Treatment Outcome | 2000 |
Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Safety; Time Factors; Vinblastine; Vinorelbine | 2000 |
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Tomography, Emission-Computed | 2000 |
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction | 2000 |
Docetaxel administered on a weekly basis for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Fibrinogen; Fibrinolysis; Hemorrhage; Humans; Male; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Urokinase-Type Plasminogen Activator | 2000 |
[Clinical efficacy of low-dose weekly docetaxel combined with oral 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced or metastatic breast cancer: a pilot trial].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Floxuridine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids | 2000 |
Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Synergism; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Radiotherapy; Risk; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2000 |
Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer.
Topics: Adult; Anthracyclines; Antineoplastic Agents, Phytogenic; Austria; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Ventricular Function, Left | 2000 |
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Docetaxel; Female; France; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Quality of Life; Taxoids | 2000 |
High efficacy of paclitaxel and doxorubicin as first-line therapy in advanced breast cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2000 |
Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2000 |
[A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Australia; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Europe; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Failure; United States | 2000 |
Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Italy; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2000 |
Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
[Paclitaxel versus doxorubicin in first-line therapy of metastatic breast carcinoma].
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2000 |
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Disease Progression; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Stomatitis; Survival Analysis; Taxoids; Thiotepa; Thrombocytopenia; Transplantation Conditioning | 2000 |
Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Liposomes; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Polyethylene Glycols | 2000 |
Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Greece; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Survival Rate | 2001 |
Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome; Vomiting | 2000 |
Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stroke Volume | 2000 |
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Breast Neoplasms, Male; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2000 |
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2001 |
Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Remission Induction; Survival Analysis; Taxoids | 2001 |
Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2001 |
Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Vinblastine; Vinorelbine | 2001 |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2001 |
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome | 2001 |
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Trastuzumab | 2001 |
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2001 |
Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heart; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Thrombocytopenia | 2001 |
Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Greece; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis | 2001 |
Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Epirubicin; Female; Humans; Myocardium; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Survival Analysis; Taxoids | 2001 |
Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Prognosis; Treatment Outcome | 2001 |
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Italy; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2001 |
Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy | 2001 |
Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Analysis; Taxoids | 2001 |
Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2001 |
Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2001 |
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Taxoids | 2001 |
A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Survival Rate; Treatment Failure; Treatment Outcome | 2001 |
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tissue Distribution; Treatment Outcome | 2001 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
Weekly docetaxel (Taxotere) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
[Efficacy and toxicity of a taxotere/cisplatin combination in first line chemotherapy in patients with disseminated ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2002 |
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization | 2002 |
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2002 |
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2002 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase II study of weekly docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2002 |
Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusion Pumps; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Analysis | 2002 |
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2002 |
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Uracil | 2002 |
The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Estrogens; Female; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Life Tables; Melphalan; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Progesterone; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Thiotepa; Time Factors; Treatment Outcome | 2002 |
Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Ifosfamide; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Outpatients; Paclitaxel; Prospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
[Cancer of the breast].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tamoxifen | 1992 |
Phase II trial of taxol in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Carcinoma, Renal Cell; Drug Evaluation; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1991 |
445 other study(ies) available for paclitaxel and Metastase
| Article | Year |
|---|---|
Conjugate (MTC-220) of muramyl dipeptide analogue and paclitaxel prevents both tumor growth and metastasis in mice.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Bone Marrow Cells; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Division; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cytokines; Dipeptides; Female; Humans; Inflammation Mediators; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel | 2011 |
Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Drug Synergism; Mice; Neoplasm Metastasis; Nod2 Signaling Adaptor Protein; Paclitaxel; Signal Transduction | 2017 |
Mitochondria-Targeted Lupane Triterpenoid Derivatives and Their Selective Apoptosis-Inducing Anticancer Mechanisms.
Topics: Animals; Antineoplastic Agents; Apoptosis; Betulinic Acid; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Heterografts; Humans; Membrane Potential, Mitochondrial; Mitochondria; Neoplasm Metastasis; Neoplasm Transplantation; Organophosphorus Compounds; Pentacyclic Triterpenes; Reactive Oxygen Species; Structure-Activity Relationship; Triterpenes; Zebrafish | 2017 |
Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis.
Topics: Animals; Animals, Genetically Modified; Breast Neoplasms; Catalysis; Cell Line, Tumor; Enzyme Inhibitors; Female; Focal Adhesion Protein-Tyrosine Kinases; Glycoproteins; Humans; Integrins; Isoenzymes; Molecular Docking Simulation; Neoplasm Metastasis; NF-kappa B; Paxillin; Phosphorylation; Sialyltransferases; Signal Transduction; Talin; Zebrafish | 2021 |
IGF1R-α6 integrin-S100A4 network governs the organ-specific metastasis of chemoresistant epithelial ovarian cancer cells.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Integrin alpha6; Mice; Neoplasm Metastasis; Paclitaxel; Platinum; Receptor, IGF Type 1; S100 Calcium-Binding Protein A4; Signal Transduction | 2022 |
Downregulation of LINC01296 suppresses non-small-cell lung cancer via targeting miR-143-3p/ATG2B.
Topics: Animals; Apoptosis; Autophagy-Related Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoplasm; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice, Nude; MicroRNAs; Neoplasm Metastasis; Paclitaxel; RNA, Long Noncoding; Vesicular Transport Proteins | 2021 |
Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Cost-Benefit Analysis; Female; Humans; Immune Checkpoint Inhibitors; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Quality-Adjusted Life Years; Survival Rate; United States; Uterine Cervical Neoplasms | 2022 |
ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of nonapoptotic phosphatidylserine.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mice; Myeloid-Derived Suppressor Cells; Neoplasm Metastasis; Neoplasms, Second Primary; Paclitaxel; Phosphatidylserines; Skin Neoplasms; Tumor Microenvironment | 2022 |
Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mucoproteins; Neoplasm Metastasis; Nitriles; Oncogene Proteins; Ovarian Neoplasms; Paclitaxel; Proteolysis; Pyrimidines; Reverse Transcriptase Inhibitors; Xenograft Model Antitumor Assays | 2022 |
Modulatory Effects of Biosynthesized Gold Nanoparticles Conjugated with Curcumin and Paclitaxel on Tumorigenesis and Metastatic Pathways-In Vitro and In Vivo Studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line; Cell Line, Tumor; Curcumin; Drug Resistance, Multiple; Female; Gold; HEK293 Cells; Humans; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Humans; Liver Neoplasms; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2023 |
Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK.
Topics: Actins; Animals; Cell Adhesion; Cell Growth Processes; Cell Movement; Cytoskeleton; Disease Models, Animal; Drug Synergism; Ethnopharmacology; Female; Humans; Matrix Metalloproteinases; MDA-MB-231 Cells; Medicine, Chinese Traditional; Mice; Myotonin-Protein Kinase; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; rho-Associated Kinases; Signal Transduction; Triple Negative Breast Neoplasms | 2023 |
Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Female; Glycoproteins; Humans; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Metastasis Unleashed: Hyposialylation Empowers Chemo-Evasive Circulating Tumor Cell Clusters in Breast Cancer.
Topics: Cell Line, Tumor; Humans; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Female; Heterocyclic Compounds, 3-Ring; Humans; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Triple Negative Breast Neoplasms; Wnt Signaling Pathway | 2019 |
Inhibiting tumour metastasis by DQA modified paclitaxel plus ligustrazine micelles in treatment of non-small-cell lung cancer.
Topics: A549 Cells; Animals; Apoptosis; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Dequalinium; Down-Regulation; Drug Carriers; Drug Liberation; Extracellular Matrix; Humans; Lung Neoplasms; Mice; Micelles; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Xenograft Model Antitumor Assays | 2019 |
Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Female; Humans; Middle Aged; Models, Biological; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy-Refractory Testicular Tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Male; Neoplasm Metastasis; Paclitaxel; Sorafenib; Testicular Neoplasms; Young Adult | 2019 |
Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes.
Topics: Animals; Antineoplastic Agents; Autophagy; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Disease Progression; Female; Fibrosis; Humans; Hydroxychloroquine; Irinotecan; Liposomes; Mice; Mice, Nude; Nanomedicine; Neoplasm Metastasis; Neoplasm Transplantation; NIH 3T3 Cells; Paclitaxel; Pancreatic Neoplasms; Peptides; Wound Healing | 2019 |
Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Case-Control Studies; Cell Movement; Cell Proliferation; Connective Tissue Growth Factor; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Injectable gel self-assembled by paclitaxel itself for in situ inhibition of tumor growth.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Delayed-Action Preparations; Female; Gels; Hydrogen Bonding; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Paclitaxel | 2019 |
Docosahexaenoic acid suppresses migration of triple-negative breast cancer cell through targeting metastasis-related genes and microRNA under normoxic and hypoxic conditions.
Topics: Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Docosahexaenoic Acids; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; MicroRNAs; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Wound Healing | 2020 |
Long noncoding RNA LCAT1 functions as a ceRNA to regulate RAC1 function by sponging miR-4715-5p in lung cancer.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mice; MicroRNAs; Models, Biological; Neoplasm Metastasis; Oncogenes; Paclitaxel; Prognosis; rac1 GTP-Binding Protein; RNA Interference; RNA, Long Noncoding | 2019 |
Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Markov Chains; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate | 2020 |
Tumor Responsive and Tunable Polymeric Platform for Optimized Delivery of Paclitaxel to Treat Glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dextrans; Drug Carriers; Drug Liberation; Female; Glioblastoma; Humans; Hydrogen-Ion Concentration; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Polyesters; Secondary Prevention; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Hippo Signaling Pathway; Humans; MAP Kinase Kinase Kinases; Membrane Proteins; Metformin; Mice, Inbred BALB C; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Serine-Threonine Kinases; Protein Transport; Signal Transduction; Tamoxifen; Transcription Factors; Tumor Suppressor Proteins; YAP-Signaling Proteins | 2020 |
Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Female; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Triple Negative Breast Neoplasms | 2020 |
Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; United States | 2020 |
Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Middle Aged; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2020 |
Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Monoamine Oxidase Inhibitors; Neoplasm Metastasis; Paclitaxel | 2020 |
Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Particle Size; Pharmaceutical Preparations; Wound Healing; Xanthones; Xenograft Model Antitumor Assays | 2020 |
Obg-like ATPase 1 inhibited oral carcinoma cell metastasis through TGFβ/SMAD2 axis in vitro.
Topics: Adenosine Triphosphatases; Cadherins; Carcinoma; Cell Line, Tumor; Down-Regulation; GTP-Binding Proteins; Humans; Mouth Neoplasms; Neoplasm Metastasis; Paclitaxel; Signal Transduction; Smad2 Protein; Snail Family Transcription Factors; Transforming Growth Factor beta; Up-Regulation | 2020 |
Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules.
Topics: Animals; Breast Neoplasms; Deoxycytidine; Drug Combinations; Drug Delivery Systems; Female; Gemcitabine; Kidney; Liver; Lung; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Spleen; Tissue Distribution | 2020 |
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Rate | 2021 |
Angiosarcomas of Primary Gynecologic Origin - A Case Series and Review of the Literature.
Topics: Adult; Aged; Combined Modality Therapy; Drug Therapy; Female; Genital Neoplasms, Female; Hemangiosarcoma; Humans; Laparotomy; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2020 |
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Bevacizumab; CA-125 Antigen; Carbamates; Carboplatin; Cystadenocarcinoma, Serous; Disease Progression; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; MAP Kinase Kinase 1; Medroxyprogesterone; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Oximes; Paclitaxel; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Recurrence; Sulfonamides; Tamoxifen; Treatment Outcome; Young Adult | 2020 |
Breast Cancer-Derived Microparticles Reduce Cancer Cell Adhesion, an Effect Augmented by Chemotherapy.
Topics: Actin Cytoskeleton; Adult; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell-Derived Microparticles; Extracellular Vesicles; Female; Humans; Hyaluronan Receptors; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2020 |
FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Double-Blind Method; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms; United States; United States Food and Drug Administration | 2020 |
Major and durable response to second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity cancer patient.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Frailty; Head and Neck Neoplasms; Humans; Malnutrition; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2021 |
Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells.
Topics: Apoptosis; Cell Proliferation; Cell Survival; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hyaluronic Acid; MCF-7 Cells; Micelles; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Ritonavir; Triple Negative Breast Neoplasms | 2021 |
Multiple-line Chemotherapy for a Patient with Unresectable Mucinous Cystic Neoplasm of the Pancreas.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Neoplasm Metastasis; Paclitaxel; Pancreas; Pancreatic Neoplasms; Progression-Free Survival | 2021 |
Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Gastrointestinal Neoplasms; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Prospective Studies; Ramucirumab; Survival Analysis; T-Lymphocytes, Regulatory; Treatment Outcome; Tumor Burden; Tumor Microenvironment | 2021 |
Abdominal Wall Metastasis of Pancreatic Cancer: The Tip of the Iceberg-Case Report.
Topics: Abdominal Wall; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Treatment Outcome | 2021 |
Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Progression-Free Survival | 2021 |
Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.
Topics: Angiopoietin-2; Animals; Biglycan; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Fibrosis; Humans; Mice; Mice, Knockout; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Prognosis; Signal Transduction; Stromal Cells; Treatment Outcome; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2021 |
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Propensity Score | 2021 |
Systemic metastasis-targeted nanotherapeutic reinforces tumor surgical resection and chemotherapy.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease Models, Animal; Drug Carriers; Epithelial-Mesenchymal Transition; Female; Heparin, Low-Molecular-Weight; Human Umbilical Vein Endothelial Cells; Humans; Male; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Nanoparticles; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Proof of Concept Study; Rats; Stilbenes; Theranostic Nanomedicine | 2021 |
The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Enzyme Inhibitors; Female; Humans; Mice; Neoplasm Metastasis; Paclitaxel; Prognosis; ral GTP-Binding Proteins; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Chemoimmunotherapy after progression on single-agent pembrolizumab for metastatic urothelial carcinoma: a case series.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Urinary Bladder Neoplasms | 2021 |
Successful Treatment of a Locally Recurrent and Metastatic Malignant Phyllodes Tumor with Accelerated Radiotherapy and Nab-Paclitaxel, Cisplatin, and Liposomal Doxorubicin Chemotherapy.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Phyllodes Tumor; Polyethylene Glycols; Positron Emission Tomography Computed Tomography; Remission Induction | 2021 |
Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Organoplatinum Compounds; Organs at Risk; Paclitaxel; Radiation Pneumonitis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; User-Computer Interface | 2021 |
Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies | 2021 |
[A Case of Pseudopancreatic Cyst Development during Bevacizumab plus Paclitaxel Therapy for Pancreatic Metastasis of Breast Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cysts; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2021 |
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; France; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Calpain; Carcinoembryonic Antigen; Cell Plasticity; Cell Proliferation; Drug Resistance, Neoplasm; E1A-Associated p300 Protein; Female; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lentivirus; MCF-7 Cells; Neoplasm Metastasis; Neoplasm Proteins; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Transforming Growth Factor beta2 | 2017 |
Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Drug Combinations; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Nivolumab; Oxonic Acid; Paclitaxel; Tegafur; Tomography, X-Ray Computed | 2017 |
Oral cancer cells sustainedly infected with Porphyromonas gingivalis exhibit resistance to Taxol and have higher metastatic potential.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteroidaceae Infections; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression; Humans; Male; Mice; Mouth Neoplasms; Neoplasm Metastasis; Paclitaxel; Porphyromonas gingivalis; Receptor, Notch1; Xenograft Model Antitumor Assays | 2017 |
Myoepithelial carcinoma with RB1 mutation: remarkable chemosensitivity to carcinoma of unknown origin therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Male; Mutation; Myoepithelioma; Neoplasm Metastasis; Paclitaxel; Radiotherapy, Adjuvant; Retinoblastoma Binding Proteins; Treatment Outcome; Ubiquitin-Protein Ligases | 2017 |
Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Calibration; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Models, Theoretical; Neoplasm Metastasis; Paclitaxel; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Decision Making; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; United States | 2017 |
Free paclitaxel-loaded E-selectin binding peptide modified micelle self-assembled from hyaluronic acid-paclitaxel conjugate inhibit breast cancer metastasis in a murine model.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; E-Selectin; Humans; Hyaluronic Acid; Mice; Micelles; Neoplasm Metastasis; Paclitaxel; Peptides; Polyethylene Glycols | 2017 |
On Uterine Angiosarcomas: 2 Additional Cases.
Topics: Antineoplastic Agents; Carboplatin; Disease-Free Survival; Docetaxel; Fatal Outcome; Female; Hemangiosarcoma; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Paclitaxel; Uterine Neoplasms; Uterus | 2017 |
Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2017 |
Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Humans; Liposomes; Mice; Neoplasm Metastasis; Oligopeptides; Oxidation-Reduction; Paclitaxel; RNA, Small Interfering | 2017 |
HPI/AMF inhibition halts the development of the aggressive phenotype of breast cancer stem cells.
Topics: Breast Neoplasms; Cell Hypoxia; Cell Movement; Cell Proliferation; Doxorubicin; Epithelial-Mesenchymal Transition; Female; Gluconates; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Neoplasm Metastasis; Neoplastic Stem Cells; Paclitaxel; RNA, Small Interfering; Sugar Phosphates; Sulfonamides | 2017 |
Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Retreatment; Risk Factors; Survival Analysis; Treatment Outcome | 2017 |
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; T-Lymphocytes, Cytotoxic; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2017 |
Stress-inducible gene
Topics: Activating Transcription Factor 3; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mice; Neoplasm Metastasis; Paclitaxel; Stress, Physiological | 2017 |
[Third- and Fourth-Line Chemotherapies including Paclitaxel and Bevacizumab for Metastatic Breast Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2017 |
Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
Topics: Aged; Albumins; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Cost of Illness; Deoxycytidine; Drug Costs; Female; Filgrastim; Fluorouracil; Gemcitabine; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Time Factors | 2017 |
Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Lignans; MCF-7 Cells; Neoplasm Metastasis; Paclitaxel | 2017 |
Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Diagnosis, Differential; Female; Humans; Lung Neoplasms; Nasal Septal Perforation; Neoplasm Metastasis; Paclitaxel | 2017 |
Metastatic Microcystic Adnexal Carcinoma with DNA Sequencing Results and Response to Systemic Antineoplastic Chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p18; Humans; Male; Mutation; Neoplasm Metastasis; Paclitaxel; Positron Emission Tomography Computed Tomography; Radiotherapy, Adjuvant; Sequence Analysis, DNA; Skin Neoplasms; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Treatment Failure | 2017 |
A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2017 |
Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Complete response of metastatic gastric cancer to chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Remission Induction; Stomach Neoplasms; Tegafur | 2017 |
Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Delivery Systems; Humans; Mice; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Peptides; Receptor, EphA2 | 2018 |
Evaluation of Anti-Metastatic Potential of the Combination of Fisetin with Paclitaxel on A549 Non-Small Cell Lung Cancer Cells.
Topics: A549 Cells; Actins; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flavonoids; Flavonols; Gene Expression Profiling; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Vimentin | 2018 |
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2018 |
Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Survival Analysis | 2018 |
Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Caseins; Cell Line, Tumor; Drug Liberation; Female; Hyaluronic Acid; Hydroxamic Acids; Mammary Neoplasms, Experimental; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Nanoconjugates; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Prodrugs; Protein Binding | 2018 |
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2018 |
Secondary Ameloblastic Carcinoma of Mandible with Pulmonary Metastasis.
Topics: Adult; Ameloblastoma; Antineoplastic Agents; Biopsy; Carboplatin; Contrast Media; Female; Humans; Lung Neoplasms; Mandible; Mandibular Neoplasms; Mandibular Osteotomy; Neoplasm Metastasis; Odontogenic Tumors; Paclitaxel; Palliative Care; Treatment Outcome | 2018 |
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Treatment Outcome | 2018 |
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Female; Humans; Markov Chains; Models, Biological; Neoplasm Metastasis; Paclitaxel | 2018 |
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neurotoxicity Syndromes; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Progression-Free Survival; Republic of Korea; Survival Rate; Treatment Outcome | 2017 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Quality-Adjusted Life Years; United Kingdom | 2018 |
Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Protein Binding; Protein Serine-Threonine Kinases; Transfection; Up-Regulation | 2018 |
Functional paclitaxel plus honokiol micelles destroying tumour metastasis in treatment of non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Line, Tumor; Cell Survival; Dequalinium; Drug Interactions; Drug Liberation; Humans; Lignans; Lung Neoplasms; Mice; Micelles; Neoplasm Metastasis; Paclitaxel; Temperature; Xenograft Model Antitumor Assays | 2018 |
Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Drug Therapy; Female; HEK293 Cells; Humans; Induction Chemotherapy; Intracellular Signaling Peptides and Proteins; Macrophages; MAP Kinase Signaling System; Mice; Neoplasm Metastasis; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Prognosis; Protein Serine-Threonine Kinases; Quality of Life; Stromal Cells; Tumor Microenvironment | 2018 |
Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2018 |
Retrospective study on efficacy of a paclitaxel combined with a leucovorin and fluorouracil regimen for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2019 |
Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Retrospective Studies; Uterine Cervical Neoplasms | 2018 |
Melatonin inhibits breast cancer cell invasion through modulating DJ-1/KLF17/ID-1 signaling pathway.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cadherins; Cell Movement; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Inhibitor of Differentiation Protein 1; MCF-7 Cells; Melatonin; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Deglycase DJ-1; Signal Transduction; Transcription Factors | 2019 |
Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their lipid raft integrity.
Topics: AC133 Antigen; Animals; Caveolin 1; Cell Line, Tumor; Cholesterol; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Membrane Microdomains; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neoplastic Stem Cells; Paclitaxel; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2018 |
COL‑3 enhances the anti‑proliferative and pro‑apoptotic effects of paclitaxel in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; MCF-7 Cells; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Tetracyclines | 2019 |
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2019 |
Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Linear Models; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2018 |
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Failure | 2019 |
The efficacy of platinum-based chemotherapy for immune checkpoint inhibitor-resistant advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Programmed Cell Death 1 Receptor; Retrospective Studies | 2019 |
Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; B7-H1 Antigen; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Indoles; Kaplan-Meier Estimate; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Mice; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Tubulin; Tubulin Modulators; Xenograft Model Antitumor Assays | 2019 |
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cost-Benefit Analysis; Female; France; Humans; Male; Markov Chains; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Population Surveillance; Receptor, ErbB-2; Treatment Outcome | 2019 |
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2018 |
Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?
Topics: Albumins; Biomarkers; Breast Neoplasms; Caveolin 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Paclitaxel | 2019 |
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Progression-Free Survival; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Survival Rate | 2019 |
Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; MCF-7 Cells; Mice; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
A sinister black finding in the stomach.
Topics: Acrylonitrile; Aged; Aniline Compounds; Barrett Esophagus; Benzimidazoles; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Melanoma; Mutation; Neoplasm Metastasis; Paclitaxel; Prognosis; Stomach; Tomography, X-Ray Computed; Tubulin Modulators; Uveal Neoplasms | 2019 |
First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Treatment Outcome | 2019 |
Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diet, Ketogenic; Feasibility Studies; Female; Fever; Humans; Hyperbaric Oxygenation; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies | 2019 |
Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomedical Research; Cost-Benefit Analysis; Female; Humans; Medical Oncology; Middle Aged; Neoplasm Metastasis; Paclitaxel; Progression-Free Survival; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2019 |
Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Paclitaxel; Progression-Free Survival; Retrospective Studies; Survival Rate; Turkey | 2019 |
Nomograms predicting survival and patterns of failure in patients with cervical cancer treated with concurrent chemoradiotherapy: A special focus on lymph nodes metastases.
Topics: Adult; Aged; Aged, 80 and over; Brachytherapy; Calibration; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Nomograms; Paclitaxel; Pelvis; Proportional Hazards Models; Uterine Cervical Neoplasms; Young Adult | 2019 |
A 35 Year Old Bangladeshi Lady with Hereditary Mucinous Ovarian Cancer, Complicated with Omental Metastasis.
Topics: Adult; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Cisplatin; Cystadenocarcinoma, Mucinous; Female; Humans; Hysterectomy; Neoplasm Metastasis; Omentum; Ovarian Neoplasms; Paclitaxel; Pelvis; Salpingo-oophorectomy; Tomography, X-Ray Computed | 2019 |
Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine ± cisplatin combination.
Topics: Adenocarcinoma; Albumins; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Duodenal Neoplasms; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nivolumab; Oxonic Acid; Paclitaxel; Palliative Care; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Tegafur; Treatment Failure | 2020 |
Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Endocytosis; Humans; Membrane Microdomains; Mice, Nude; Nanoparticles; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Polylactic Acid-Polyglycolic Acid Copolymer; Xenograft Model Antitumor Assays | 2019 |
First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Gene Expression Regulation, Neoplastic; Humans; Markov Chains; Neoplasm Metastasis; Paclitaxel | 2019 |
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retreatment; Retrospective Studies | 2020 |
Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; DNA Repair; Female; Homologous Recombination; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel | 2019 |
Chondroitin Sulfate-Linked Prodrug Nanoparticles Target the Golgi Apparatus for Cancer Metastasis Treatment.
Topics: Cell Line, Tumor; Chondroitin Sulfates; Drug Delivery Systems; Golgi Apparatus; Humans; Nanoparticles; Neoplasm Metastasis; Neoplasms; Paclitaxel; Prodrugs | 2019 |
Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; CD8-Positive T-Lymphocytes; Cohort Studies; Cyclophosphamide; Dendritic Cells; Female; Follow-Up Studies; Humans; Leukocytes, Mononuclear; Lymphocytes, Tumor-Infiltrating; Middle Aged; Mitoxantrone; Monocytes; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Thiotepa; Vinblastine | 2019 |
Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Salvage Therapy; Skin Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prospective Studies | 2013 |
Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Phenotype; Prohibitins | 2013 |
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2013 |
Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Doxorubicin; Female; Follow-Up Studies; Humans; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Polyethylene Glycols; Prognosis; Retrospective Studies; Time Factors | 2013 |
First line therapy for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fatigue; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Docetaxel; Erlotinib Hydrochloride; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2013 |
BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.
Topics: Antimitotic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Biomarkers; Biphenyl Compounds; Breast Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Heterocyclic Compounds, 2-Ring; Humans; MCF-7 Cells; Neoplasm Metastasis; Nitrophenols; Nocodazole; Paclitaxel; Piperazines; Prognosis; Pteridines; Sulfonamides | 2013 |
[Administration of low-dose albumin-bound paclitaxel for the treatment of advanced and recurrent breast cancer patients].
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Tomography, X-Ray Computed | 2013 |
Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Practice Patterns, Physicians'; Treatment Outcome | 2013 |
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Movement; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indoles; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Topotecan | 2013 |
AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Epothilones; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Phosphorylation; Phthalazines; Polyploidy; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms; Tubulin Modulators; Xenograft Model Antitumor Assays | 2013 |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Survival Analysis; Taxoids | 2013 |
Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: A new possible therapeutic strategy for melanoma.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Caspases; Cell Culture Techniques; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Humans; Melanoma; Neoplasm Metastasis; Paclitaxel | 2013 |
A serial micropipette microfluidic device with applications to cancer cell repeated deformation studies.
Topics: Automation; Biomechanical Phenomena; Cell Line, Tumor; Cell Shape; Elasticity; Equipment Design; Extracellular Matrix; Humans; Materials Testing; Microfluidics; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Single-Cell Analysis; Stress, Mechanical; Viscosity | 2013 |
Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Identification and analysis of CD133(+) melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response.
Topics: AC133 Antigen; Antigens, CD; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gene Transfer Techniques; Glycoproteins; Humans; Immunohistochemistry; Melanoma; Neoplasm Metastasis; Neoplastic Stem Cells; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Peptides | 2014 |
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Ifosfamide; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Drug Costs; Female; France; Hospital Costs; Hospitals, Private; Hospitals, University; Humans; Kaplan-Meier Estimate; Middle Aged; National Health Programs; Neoplasm Metastasis; Paclitaxel; Public Sector; Retrospective Studies; Taxoids; Time Factors; Transportation; Trastuzumab; Treatment Outcome | 2014 |
Prognostic value of tumor volume for patients with nasopharyngeal carcinoma treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy, Intensity-Modulated; Retrospective Studies; Young Adult | 2014 |
U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2014 |
Combination chemotherapy of carboplatin and paclitaxel for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Skin Neoplasms; Treatment Failure | 2013 |
[Preoperative chemotherapy for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Tegafur | 2013 |
[Usefulness of bevacizumab combination chemotherapy for advanced breast cancer].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2013 |
The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
Topics: Animals; Apoptosis; Cell Line, Tumor; Depsipeptides; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Inflammatory Breast Neoplasms; Mice; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2013 |
[Efficacy of supportive care for albumin-bound paclitaxel(nab-paclitaxel)in 20 patients with metastatic breast cancer].
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence | 2014 |
Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma.
Topics: Adult; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Mammary Neoplasms, Animal; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Bridged-Ring Compounds; Cell Line, Tumor; Endometrial Neoplasms; Female; Gene Knockdown Techniques; Humans; Neoplasm Metastasis; Paclitaxel; Stathmin; Taxoids; Treatment Outcome | 2014 |
First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Survival Rate | 2014 |
Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Rare case of syndrome of inappropriate antidiuretic hormone as the initial presentation of ovarian cancer recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Inappropriate ADH Syndrome; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Tomography, X-Ray Computed | 2015 |
(111)In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Indium Radioisotopes; Neoplasm Metastasis; Paclitaxel; Radionuclide Imaging; Receptor, ErbB-2; Trastuzumab | 2014 |
Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Suramin; Xenograft Model Antitumor Assays | 2014 |
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Metastasis; Odds Ratio; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Consolidation Chemotherapy; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2015 |
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study.
Topics: Albumins; Antineoplastic Agents; Bevacizumab; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2015 |
The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma.
Topics: Adenosine; Animals; Antineoplastic Agents; Cell Physiological Phenomena; Disease Progression; Drug Screening Assays, Antitumor; Humans; Inosine; Melanoma; Mice; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Receptor, Adenosine A3; Tumor Cells, Cultured | 2014 |
A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Paclitaxel; Retrospective Studies | 2015 |
Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma.
Topics: Biomarkers; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Metastasis; Oropharyngeal Neoplasms; Paclitaxel; Predictive Value of Tests; Radiotherapy, Intensity-Modulated; Sensitivity and Specificity | 2016 |
[A case of metastatic salivary duct carcinoma successfully treated with trastuzumab-based targeted therapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal; Humans; Male; Neoplasm Metastasis; Paclitaxel; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2014 |
Loss of the obscurin-RhoGEF downregulates RhoA signaling and increases microtentacle formation and attachment of breast epithelial cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Surface Extensions; Cytoskeleton; Dose-Response Relationship, Drug; Down-Regulation; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Metastasis; Neoplastic Stem Cells; Paclitaxel; Protein Serine-Threonine Kinases; Rho Guanine Nucleotide Exchange Factors; rhoA GTP-Binding Protein; RNA Interference; Signal Transduction; Time Factors; Transfection; Tubulin; Tubulin Modulators | 2014 |
Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Humans; Inflammation; Neoplasm Metastasis; Paclitaxel; Toll-Like Receptor 4 | 2014 |
[Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence | 2014 |
Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer.
Topics: Adult; Aged; Albumins; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Osteonectin; Paclitaxel; Prognosis; Prospective Studies; Survival Rate | 2014 |
The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Polyurethanes; Retrospective Studies; Treatment Outcome | 2014 |
Grade 4 epistaxis in a woman with metastatic breast cancer treated with bevacizumab: a case report.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Epistaxis; Female; Humans; Neoplasm Grading; Neoplasm Metastasis; Paclitaxel; Severity of Illness Index | 2014 |
Trastuzumab in advanced breast cancer--a decade of experience in Germany.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Germany; Hormones; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Survival Rate; Trastuzumab; Vinblastine; Vinorelbine; Young Adult | 2014 |
Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.
Topics: Adjuvants, Pharmaceutic; Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Endothelial Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Maximum Tolerated Dose; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Xenograft Model Antitumor Assays | 2014 |
Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic paclitaxel.
Topics: Administration, Metronomic; Animals; Anti-Arrhythmia Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Verapamil; Xenograft Model Antitumor Assays | 2015 |
An imagable and photothermal "Abraxane-like" nanodrug for combination cancer therapy to treat subcutaneous and metastatic breast tumors.
Topics: Albumin-Bound Paclitaxel; Albumins; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Therapy, Combination; Female; Humans; Indocyanine Green; Models, Molecular; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Phototherapy; Protein Conformation; Subcutaneous Tissue | 2015 |
The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Cation Transport Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Gene Knockout Techniques; Humans; MCF-7 Cells; Mice, Nude; Molecular Targeted Therapy; Neoplasm Metastasis; Paclitaxel; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Time Factors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.
Topics: Albumins; Apoptosis; Aurora Kinase B; Cell Line, Tumor; Cell Movement; Cell Nucleus Shape; Cell Proliferation; Cell Shape; Cell Survival; Drug Resistance, Neoplasm; Extracellular Space; Humans; Lactic Acid; Melanoma; Mitosis; Necrosis; Neoplasm Metastasis; Organophosphates; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines | 2015 |
Three-dimensional collagen type I matrix up-regulates nuclear isoforms of the microtubule associated protein tau implicated in resistance to paclitaxel therapy in ovarian carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Culture Techniques; Collagen Type I; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Immunohistochemistry; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Isoforms; RNA Interference; RNA, Small Interfering; tau Proteins | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (β-amino ester) nanoparticles co-delivering two siRNA and paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Female; Humans; Hydrogen-Ion Concentration; Mice; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Polyesters; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2015 |
[Clinical experience of nab-Paclitaxel treatment in 31 patients with breast cancer].
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel | 2014 |
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Topics: Adult; Antineoplastic Agents, Immunological; Breast Neoplasms; Female; Humans; Meningeal Carcinomatosis; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2016 |
Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
Topics: Adult; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis; United Kingdom | 2015 |
[A case of stage IV breast cancer with long-term partial response treated with tri-weekly paclitaxel plus bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel | 2015 |
Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Recurrence; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis.
Topics: Animals; Breast Neoplasms; Carcinogenesis; Cell Movement; Cyclin-Dependent Kinase 5; Dose-Response Relationship, Drug; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Humans; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Molecular Targeted Therapy; Neoplasm Metastasis; Paclitaxel; Pyrimidines; Random Allocation; Xenograft Model Antitumor Assays | 2015 |
Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2015 |
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Doxorubicin; Female; Follow-Up Studies; Humans; Mesoderm; Metaplasia; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; PTEN Phosphohydrolase; Sirolimus; Survival Rate; Young Adult | 2015 |
Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Blocking IL1β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Macrophages; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Receptors, Interleukin-1; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Burden | 2015 |
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Spain | 2015 |
Drug exposure in a metastatic human lung adenocarcinoma cell line gives rise to cells with differing adhesion, proliferation, and gene expression: Implications for cancer chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cisplatin; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel | 2015 |
[Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use].
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Efficacy and Safety of Weekly Paclitaxel Therapy for Advanced Gastric Cancer Patients with Disseminated Intravascular Coagulation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disseminated Intravascular Coagulation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Safety; Stomach Neoplasms | 2015 |
Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Drug Administration Schedule; Drug Synergism; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic | 2015 |
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model.
Topics: Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Ibandronic Acid; Immunocompetence; Male; Neoplasm Metastasis; Osteolysis; Paclitaxel; Rats; Rats, Sprague-Dawley | 2015 |
[Examination of the Response Rate of Paclitaxel and Bevacizumab Therapy for Metastatic Advanced Breast Cancer According to the Lymphopenia Grade].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease Progression; Humans; Lymphopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2015 |
[A Case of Rapidly Progressive Metastatic Castration-Resistant Prostate Cancer : Durable Control by Early Induction of Carboplatin and Paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms, Castration-Resistant; Remission Induction | 2015 |
Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate | 2016 |
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Interleukin-1 Receptor-Associated Kinases; Mice; Mice, SCID; Neoplasm Metastasis; Paclitaxel; Phosphorylation | 2015 |
Proteomic identification of prognostic tumour biomarkers, using chemotherapy-induced cancer-associated fibroblasts.
Topics: Antineoplastic Agents; Antioxidants; Autophagy; Azathioprine; Biomarkers, Tumor; Cell Differentiation; Cells, Cultured; Cellular Senescence; Disease-Free Survival; Fibroblasts; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Proteomics; Stress, Physiological; Tumor Microenvironment | 2015 |
Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2015 |
The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Insurance Claim Review; Insurance, Health; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Time-to-Treatment; United States | 2015 |
Suppression for lung metastasis by depletion of collagen I and lysyl oxidase via losartan assisted with paclitaxel-loaded pH-sensitive liposomes in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Collagen Type I; Drug Delivery Systems; Hydrogen-Ion Concentration; Liposomes; Losartan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Paclitaxel; Protein-Lysine 6-Oxidase | 2016 |
A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Prospective Studies; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome; Young Adult | 2016 |
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbonic Anhydrase IX; Carbonic Anhydrases; Cyclophosphamide; Doxorubicin; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib | 2016 |
An iTEP-salinomycin nanoparticle that specifically and effectively inhibits metastases of 4T1 orthotopic breast tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzaldehydes; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Elastin; Electrophoresis, Polyacrylamide Gel; Female; Humans; Immune Tolerance; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Peptides; Pyrans; Tissue Distribution | 2016 |
Highly variable cancer subpopulations that exhibit enhanced transcriptome variability and metastatic fitness.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clone Cells; Doxorubicin; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Variation; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Paclitaxel; Recurrence; Ribonucleoproteins, Small Nuclear; RNA, Messenger; Single-Cell Analysis; Spliceosomes; Transcriptome | 2016 |
Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Recurrence; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Humans; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; S100 Calcium-Binding Protein A4; Sumoylation; Xenograft Model Antitumor Assays | 2016 |
The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk; Uterine Cervical Neoplasms | 2016 |
New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2016 |
α-Lipoic acid sensitizes lung cancer cells to chemotherapeutic agents and anoikis via integrin β1/β3 downregulation.
Topics: Anoikis; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Down-Regulation; Drug Synergism; Drug Therapy; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Integrin beta1; Integrin beta3; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Reactive Oxygen Species; Thioctic Acid | 2016 |
Better Nanoparticle Targeting with P-Selectin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Mice; Molecular Targeted Therapy; Nanoparticles; Neoplasm Metastasis; Neoplasms, Experimental; P-Selectin; Paclitaxel; Treatment Outcome; Tumor Microenvironment | 2016 |
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Splenic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Humans; Italy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Surveys and Questionnaires | 2016 |
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Tumor Burden | 2016 |
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Compassionate Use Trials; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC).
Topics: 3' Untranslated Regions; Adult; Aged; Animals; Apoptosis; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Lung Neoplasms; Mice; MicroRNAs; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; RNA Interference; tau Proteins; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3.
Topics: Animals; Cathepsins; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Female; Glucuronidase; Humans; Lymphangiogenesis; Lymphatic Vessels; Macrophages; Mice, Inbred BALB C; Neoplasm Metastasis; Paclitaxel; Phenotype; Up-Regulation; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-3 | 2016 |
MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; MAP Kinase Signaling System; Mice; Microfilament Proteins; Microtubules; Neoplasm Metastasis; Paclitaxel; Protein Isoforms; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Humans; Maintenance Chemotherapy; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2017 |
Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Female; Gene Amplification; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Risk Factors; Trastuzumab; Treatment Outcome | 2017 |
Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tegafur; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2017 |
Translocation of BBAP from the cytoplasm to the nucleus reduces the metastatic ability of vemurafenib-resistant SKMEL28 cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Sulfonamides; Ubiquitin-Protein Ligases; Vemurafenib | 2017 |
Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma.
Topics: Animals; Antimetabolites; Antiviral Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Nucleocytoplasmic Transport Proteins; Paclitaxel; Ribavirin; Signal Transduction; Tongue Neoplasms; TOR Serine-Threonine Kinases | 2017 |
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2017 |
High-metastatic triple-negative breast-cancer variants selected in vivo become chemoresistant in vitro.
Topics: Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2017 |
[Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Recurrence; Treatment Outcome | 2016 |
[Analysis of 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel in Advanced Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Stomach Neoplasms | 2016 |
Biomimetic Human Serum Albumin Nanoparticle for Efficiently Targeting Therapy to Metastatic Breast Cancers.
Topics: Animals; Biomimetics; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Humans; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Serum Albumin, Human | 2017 |
Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy.
Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Endometrioid; Cell Proliferation; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Prolactin; Tumor Cells, Cultured | 2017 |
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Black or African American; Breast Neoplasms; Female; Humans; Logistic Models; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; Treatment Failure; White People | 2008 |
Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.
Topics: Albumins; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Humans; Luciferases; Mice; Models, Biological; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2008 |
Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Fatal Outcome; Female; Hemoptysis; Humans; Neoplasm Metastasis; Paclitaxel | 2008 |
Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzopyrans; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Isoquinolines; Male; Mice; Mice, Inbred C3H; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Tetrazoles | 2008 |
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Breast Neoplasms; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Frequency; Genotype; Haplotypes; Homozygote; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymorphism, Genetic; Regression Analysis; Survival Analysis; Treatment Outcome | 2009 |
Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Topics: Adult; Albumins; Antineoplastic Agents; Attitude of Health Personnel; Breast Neoplasms; Canada; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Incidence; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Surveys and Questionnaires | 2009 |
Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hospitalization; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Preoperative Care; Treatment Outcome | 2009 |
Albumin-bound paclitaxel: new drug. Breast cancer metastases: no progress.
Topics: Albumins; Breast Neoplasms; Drug Approval; Europe; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic | 2009 |
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Delivery Systems; Female; Humans; Melanoma; Neoplasm Metastasis; Paclitaxel; Protein Kinases; Signal Transduction; Sirolimus; Skin Neoplasms; TOR Serine-Threonine Kinases | 2009 |
Metastasis at the site of a venous needle puncture in a patient with advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Fatal Outcome; Female; Fluorouracil; Humans; Needles; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Punctures; Radiotherapy; Uterine Cervical Neoplasms | 2009 |
Third S. S. Ratnam memorial lecture 2007. Ovarian cancer: Is there hope for women?
Topics: Adult; CA-125 Antigen; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Laparoscopy; Mass Screening; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Ultrasonography | 2009 |
Perforating cutaneous metastasis from an ovarian adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Rupture, Spontaneous; Skin Neoplasms | 2010 |
Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.
Topics: Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Immunohistochemistry; Liposomes; Lymph Nodes; Lymphatic Metastasis; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Tumor Burden; Vitamin E | 2009 |
Identification of selective inhibitors of cancer stem cells by high-throughput screening.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Paclitaxel; Pyrans | 2009 |
Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Toremifene | 2009 |
Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 2009 |
An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Taxoids; United Kingdom | 2009 |
Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Female; Genotype; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymorphism, Genetic; Stomach Neoplasms; Treatment Outcome | 2010 |
Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
[The combined effect of paclitaxel and toremifene therapy for metastatic breast cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Synergism; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Toremifene | 2009 |
Intravenous paclitaxel against metastasis of human gastric tumors of diffuse type.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Green Fluorescent Proteins; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Peritoneum; Stomach Neoplasms; Transfection | 2010 |
Early distant relapse in early stage triple-negative breast cancer: usefulness of FDG-PET for diagnosis of distant metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
[Combination chemotherapy with gemcitabine and paclitaxel in a hemodialysis patient with metastatic urothelial carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Urinary Bladder Neoplasms | 2010 |
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 17; Female; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Quinazolines; Treatment Outcome | 2010 |
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Endothelium, Vascular; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Diphosphonates; Docetaxel; Double-Blind Method; Drug Synergism; Female; Genes, erbB-2; Humans; Incidence; Jaw Diseases; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Oral Hygiene; Osteonecrosis; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2010 |
The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Synergism; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Salvage Therapy; Topotecan; Uterine Cervical Neoplasms | 2010 |
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cross-Over Studies; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Liposomes; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Paresthesia; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2010 |
Long-term efficiency and toxicity of adjuvant dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy in high-risk breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Mammography; Neoplasm Metastasis; Paclitaxel; Prognosis; Prospective Studies; Recurrence; Risk; Treatment Outcome | 2010 |
A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Endocytosis; Endothelial Cells; Humans; Immunohistochemistry; Liver Neoplasms; Male; Mice; Nanocapsules; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Stilbenes | 2010 |
Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Neoplasm Metastasis; Paclitaxel; Proteinuria; Treatment Outcome | 2010 |
Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Survival Rate | 2011 |
AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Breast Neoplasms; Cells, Cultured; Endostatins; Endothelium, Vascular; Female; Genetic Therapy; Humans; Lung Neoplasms; Mice; Mutant Proteins; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Polyploidy; Recombinant Proteins | 2011 |
Platinum - sensitive relapsed epithelial ovarian cancer: not all the patients benefit from reinduction with carboplatin and paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Female; Humans; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
[Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
Topics: Adult; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab; Treatment Failure | 2010 |
[Clinical characteristics and prognosis of large cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pneumonectomy; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Tumor Burden; Young Adult | 2010 |
[The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Receptors, Estrogen; Toremifene | 2010 |
Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
4-Methyl-3-nitro-benzoic acid, a migration inhibitor, prevents breast cancer metastasis in SCID mice.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Separation; Female; Flow Cytometry; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Nitrobenzoates; Paclitaxel; Xenograft Model Antitumor Assays | 2011 |
Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Oligonucleotides; Paclitaxel; Vascular Endothelial Growth Factor A | 2011 |
Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Retrospective Studies; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome | 2010 |
Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.
Topics: Albumins; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Drug Synergism; Female; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Neoplasm Transplantation; Paclitaxel; Transplantation, Heterotopic; Xenograft Model Antitumor Assays | 2011 |
Cancer: Macrophages limit chemotherapy.
Topics: Animals; Breast Neoplasms; Cell Count; Drug Resistance, Neoplasm; Humans; Macrophages; Mice; Models, Biological; Neoplasm Metastasis; Neutrophils; Paclitaxel; Prognosis; T-Lymphocytes, Cytotoxic; Tumor Microenvironment | 2011 |
p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Doxorubicin; Humans; Mice; Mitogen-Activated Protein Kinase 12; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Phenanthrenes; Phosphatidylinositol 3-Kinase; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2011 |
Sequential or concomitant chemotherapy in limited stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Radiotherapy, Conformal; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies | 2012 |
Successful management of metastatic urothelial carcinoma with gemcitabine and Paclitaxel chemotherapy in a hemodialysis patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Time Factors; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Urothelium | 2011 |
Unravelling the antimetastatic potential of pentoxifylline, a methylxanthine derivative in human MDA-MB-231 breast cancer cells.
Topics: Acridine Orange; Apoptosis; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; Clone Cells; Dose-Response Relationship, Drug; Ethidium; Extracellular Matrix; Female; Gelatinases; Humans; Neoplasm Metastasis; Paclitaxel; Pentoxifylline; Xanthines | 2011 |
Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2012 |
Dairy milk fat augments paclitaxel therapy to suppress tumour metastasis in mice, and protects against the side-effects of chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cachexia; Colonic Neoplasms; Dietary Fats; Dietary Supplements; Female; gamma-Glutamyltransferase; Mice; Mice, Inbred BALB C; Milk; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Soybean Oil; Time Factors | 2011 |
Malignant Brenner tumor of the ovary: analysis of 13 cases.
Topics: Adenofibroma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brenner Tumor; Carboplatin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel | 2012 |
Triptolide, histone acetyltransferase inhibitor, suppresses growth and chemosensitizes leukemic cells through inhibition of gene expression regulated by TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Diterpenes; Enzyme Inhibitors; Epoxy Compounds; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Inflammation; Leukemia; Molecular Structure; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Paclitaxel; Phenanthrenes; Signal Transduction; Thalidomide; Tumor Necrosis Factor-alpha | 2011 |
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies | 2011 |
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
Topics: Aged; Animals; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cohort Studies; Disease-Free Survival; Epithelial Cells; Female; Follow-Up Studies; Humans; Leukocytes; Lung Neoplasms; Macrophage Colony-Stimulating Factor; Macrophages; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, Macrophage Colony-Stimulating Factor; Signal Transduction; Survival Rate; Tumor Microenvironment | 2011 |
Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?
Topics: Adult; Aged; Carcinoma; Cisplatin; Disease-Free Survival; Drug Therapy; Female; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome; Urothelium | 2013 |
Extraperitoneal metastases from recurrent ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Cisplatin; Combined Modality Therapy; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome | 2012 |
DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Proliferation; Female; Guaiacol; Ketones; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Tumor Burden | 2012 |
Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy.
Topics: Adult; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Female; Fluorouracil; Humans; Male; Microtubules; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2011 |
Comparison of limited-volume perioperative high-dose-rate brachytherapy and wide-field external irradiation in resected head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy Dosage | 2012 |
Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Costs and Cost Analysis; Cyclophosphamide; Databases, Factual; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2013 |
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Taxoids; Treatment Outcome; Young Adult | 2012 |
Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model.
Topics: Angiogenesis Inhibitors; Animals; Apolipoproteins A; Disease Models, Animal; Humans; Kringles; Male; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Peptide Fragments; Prostatic Neoplasms; Recombinant Proteins; Xenograft Model Antitumor Assays | 2012 |
The inhibition of tumor growth and metastasis by self-assembled nanofibers of taxol.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Female; Hydrogel, Polyethylene Glycol Dimethacrylate; Hydrolysis; Male; Mice; Mice, Inbred C57BL; Nanofibers; Neoplasm Metastasis; Neoplasms; Paclitaxel | 2012 |
Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Treatment Failure | 2012 |
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Metabolome; Metabolomics; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
[Administration of nab-paclitaxel for 9 metastatic breast cancer patients].
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
User-defined protein marker assay development for characterization of circulating tumor cells using the CellSearch® system.
Topics: Apoptosis; Biomarkers, Tumor; Cell Count; Cell Line, Tumor; Cell Movement; Flow Cytometry; Green Fluorescent Proteins; Humans; Hyaluronan Receptors; Keratin-18; Neoplasm Metastasis; Neoplasm Proteins; Neoplastic Stem Cells; Paclitaxel; Peptide Fragments; Reagent Kits, Diagnostic; Sensitivity and Specificity; Software; Time Factors | 2012 |
2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Female; Lipids; Mammary Neoplasms, Experimental; Mice; Nanoparticles; Neoplasm Metastasis; Paclitaxel | 2013 |
ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Receptor, ErbB-2; Receptors, IgG; Survival Rate; Taxoids; Trastuzumab | 2012 |
Abandoning "TAP" as treatment of metastatic endometrial cancer: a serious example of the consequences resulting from the failure to adequately define the question being addressed in a phase 3 trial.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials, Phase III as Topic; Doxorubicin; Endometrial Neoplasms; Female; Humans; Neoplasm Metastasis; Paclitaxel | 2012 |
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Salvage Therapy; Urinary Bladder Neoplasms; Urologic Neoplasms | 2012 |
Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence | 2013 |
Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells.
Topics: Actins; Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cell Movement; Cisplatin; Cytoskeleton; Etoposide; Guanine Nucleotide Exchange Factors; Humans; Myosin Light Chains; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Phosphorylation; Rho Guanine Nucleotide Exchange Factors; rho-Associated Kinases; rhoA GTP-Binding Protein; Stomach Neoplasms; Vincristine | 2012 |
Treatment update in small-cell lung cancer: from limited to extensive disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Topotecan | 2012 |
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Decision Making, Computer-Assisted; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Furans; Humans; Ketones; Markov Chains; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
Elucidating mechanical transition effects of invading cancer cells with a subnucleus-scaled microfluidic serial dimensional modulation device.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial Cells; Female; Humans; Microfluidic Analytical Techniques; Microfluidics; Microtubules; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Paclitaxel | 2013 |
Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Lymph Nodes; Mice; Microscopy, Confocal; Nanoparticles; Neoplasm Metastasis; Paclitaxel | 2013 |
[A case of unresectable HER2-positive advanced gastric cancer successfully treated by combination therapy with trastuzumab and paclitaxel].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2012 |
Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Separation; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Indazoles; Mice; Mice, Nude; Mitosis; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Protein Serine-Threonine Kinases; Pyrimidines; RNA, Small Interfering; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Tubulin Modulators | 2013 |
[Analysis of chemotherapeutic efficacies in metastatic triple-negative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Platinum Compounds; Prognosis; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine; Young Adult | 2012 |
Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aurora Kinase A; Azepines; Carcinoma, Ovarian Epithelial; Cell Adhesion; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Female; Humans; Mice; Mitosis; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; RNA Interference; RNA, Small Interfering; src-Family Kinases; Xenograft Model Antitumor Assays | 2014 |
Breast cancer in patients with sickle cell disease can be treated safely with weekly paclitaxel.
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel | 2013 |
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Fluorescent Antibody Technique, Indirect; Humans; Immunophenotyping; Inhibitory Concentration 50; Interferon alpha-2; Interferon-alpha; Melanoma; Microscopy, Electron; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Temozolomide; Time Factors; Tumor Cells, Cultured; Vindesine | 2002 |
A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy.
Topics: Aged; Female; Humans; Neoplasm Metastasis; Paclitaxel; Radiography; Thymoma; Thyroid Neoplasms; Tomography Scanners, X-Ray Computed | 2002 |
Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Division; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Fibroblast Growth Factor 2; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols; Prostatic Neoplasms; Random Allocation; Recombinant Proteins; Taxoids; Xenograft Model Antitumor Assays | 2002 |
Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Case-Control Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols | 2003 |
[Chemotherapy protocol with taxol increase survival by 31 percent].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2002 |
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
Topics: Adjuvants, Immunologic; Adult; Aged; Apoptosis; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Division; Clinical Trials as Topic; Doxorubicin; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Random Allocation; Time Factors; Treatment Outcome | 2003 |
Chemotherapy in gastric cancer: a never ending saga.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Stomach Neoplasms | 2003 |
Polymer-conjugated paclitaxel as a radiosensitizing agent--a big step forward for combined modality therapy?
Topics: Antineoplastic Agents; Combined Modality Therapy; Humans; Neoplasm Metastasis; Neoplasms; Paclitaxel; Polyglutamic Acid; Radiation-Sensitizing Agents; Taxoids | 2003 |
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Transitional Cell; Cyclohexanes; Docetaxel; Drug Synergism; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes; Taxoids; Time Factors; Transplantation, Heterologous; Urinary Bladder Neoplasms | 2003 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Docetaxel; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Paclitaxel; Radiography; Rats; Rats, Inbred F344; Taxoids; Time Factors; Treatment Outcome | 2002 |
Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Bone and Bones; Bone Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; ErbB Receptors; Fibroblast Growth Factor 2; Immunohistochemistry; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Docetaxel; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Multicenter Studies as Topic; Narcotics; Neoplasm Metastasis; Paclitaxel; Pain; Pain Measurement; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Taxoids | 2003 |
E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Female; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Metastasis; Paclitaxel; Patient Selection; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
[Cylindroma of the trachea, a rate tumor with unusual evolution].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma, Adenoid Cystic; Cisplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Radiography, Thoracic; Radiotherapy Dosage; Taxoids; Tracheal Neoplasms; Treatment Outcome | 2003 |
Calcitriol and alopecia--is it the hair apparent?
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Docetaxel; Humans; Male; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Taxoids | 2003 |
Tumor growth retardation, cure, and induction of antitumor immunity in B16 melanoma-bearing mice by low electric field-enhanced chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bleomycin; Cell Division; Cisplatin; Combined Modality Therapy; Electric Stimulation Therapy; Macrophages; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Spleen; T-Lymphocytes; Time Factors | 2003 |
Extraorbital sebaceous carcinoma with rapidly developing visceral metastases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Fatal Outcome; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Orbit; Paclitaxel; Sebaceous Gland Neoplasms; Taxoids; Viscera | 2003 |
Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids | 2003 |
Low-dose irradiation and short-exposure suboptimal-dose paclitaxel adversely modulate metastatic potential of squamous carcinoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Line, Tumor; Colony-Forming Units Assay; Cytoskeleton; Data Interpretation, Statistical; Disease Models, Animal; Humans; Immunohistochemistry; Interphase; Liver Neoplasms; Mice; Mice, SCID; Microscopy, Confocal; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2003 |
Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Fibroblast Growth Factor 2; Humans; Interleukin-8; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Models, Biological; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A | 2003 |
In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Division; Chromosome Banding; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2004 |
[New: gemzar plus taxan in metastatic breast carcinoma. Optimal combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Norway; Paclitaxel; Premedication; Prognosis; Prospective Studies; Risk Assessment; Sampling Studies; Survival Analysis; Treatment Outcome | 2004 |
Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Patient Selection; Quality of Life; Treatment Outcome; Uterine Neoplasms | 2004 |
Breast cancer with synchronous metastases: trends in survival during a 14-year period.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
[Adjuvant chemotherapy with taxoid-containing drugs in breast cancer: soon to be expected in the Netherlands].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2004 |
Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2004 |
Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Models, Animal; Drug Combinations; Female; Mice; Mice, SCID; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Pyridines; Tegafur; Transplantation, Heterologous | 2004 |
Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
Topics: Apoptosis; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Female; Gene Expression Profiling; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Ligands; Microscopy, Confocal; Neoplasm Metastasis; Neoplasms; Paclitaxel; Progesterone; Promoter Regions, Genetic; Protein Isoforms; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors; Transcription, Genetic | 2005 |
[Role of taxanes in treatment of breast cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Data Interpretation, Statistical; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Taxoids; Time Factors; Trastuzumab | 2004 |
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Tissue Distribution; Trastuzumab | 2005 |
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Female; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Platelet-Derived Growth Factor; Pyrimidines; Radiography; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Time Factors | 2005 |
Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Gene Expression Regulation, Enzymologic; Humans; Luciferases; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Transfection; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Acquisition of anoikis resistance in human osteosarcoma cells does not alter sensitivity to chemotherapeutic agents.
Topics: Anoikis; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Separation; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Extracellular Matrix; Flow Cytometry; Humans; Hypoxia; Neoplasm Metastasis; Osteosarcoma; Paclitaxel; Propidium; Vinblastine | 2005 |
[An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2005 |
Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Treatment Outcome | 2005 |
Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.
Topics: Cisplatin; Cyclophosphamide; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Neoplasm Metastasis; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Topotecan | 2005 |
Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascites; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Mice; Mice, Nude; Necrosis; Neoplasm Metastasis; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
Topics: Antibodies, Monoclonal; Antigens; Antigens, Neoplasm; Bone Marrow; Cathepsins; Combined Modality Therapy; Electrophoresis, Polyacrylamide Gel; Epitopes; Glycoproteins; Humans; Immunohistochemistry; Male; Maleimides; Maximum Tolerated Dose; Models, Chemical; Mucin-1; Mucins; Neoplasm Metastasis; Paclitaxel; Peptide Library; Peptides; Polyethylene Glycols; Prostatic Neoplasms; Protein Binding; Radioimmunotherapy; Radiometry; Yttrium Radioisotopes | 2005 |
A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
Topics: Androgens; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-Associated Death Protein; bcl-X Protein; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Inhibitory Concentration 50; Male; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Metastasis; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Oligonucleotides; Oligonucleotides, Antisense; Paclitaxel; Prostate; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caveolin 1; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2005 |
Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2006 |
Contribution of nitric oxide and epidermal growth factor receptor in anti-metastatic potential of paclitaxel in human liver cancer cell (HebG2).
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; ErbB Receptors; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Metastasis; Nitric Oxide; Paclitaxel; RNA, Messenger | 2005 |
Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Antineoplastic Agents, Phytogenic; Bradycardia; Carcinoma; Electrocardiography; Female; Follow-Up Studies; Heparin; Humans; Middle Aged; Myocardial Ischemia; Nausea; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2005 |
Protracted remission of metastatic epithelioid angiosarcoma with weekly infusion of doxorubicin, paclitaxel, and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diagnosis, Differential; Doxorubicin; Hemangiosarcoma; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Testicular Neoplasms; Treatment Outcome | 2006 |
Inhibition of tumor metastasis in vivo by combination of paclitaxel and hyaluronic acid.
Topics: Amino Acid Sequence; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blood Proteins; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Movement; Electrophoresis, Gel, Two-Dimensional; Female; Hyaluronic Acid; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Neoplasm Metastasis; Paclitaxel; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis; Swine; Treatment Outcome; Uterine Cervical Neoplasms | 2006 |
FADD phosphorylation is critical for cell cycle regulation in breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Fas-Associated Death Domain Protein; Female; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Middle Aged; Neoplasm Metastasis; Paclitaxel; Phosphorylation; Receptors, Estrogen; Signal Transduction; Tamoxifen; Tumor Cells, Cultured | 2006 |
Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model.
Topics: Animals; Apoptosis; Cell Proliferation; Disease Models, Animal; Female; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; RNA Interference; S100 Calcium-Binding Protein A4; S100 Proteins; Thyroid Neoplasms | 2006 |
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Disease Progression; Female; Heart Diseases; Heart Neoplasms; Humans; Indium Radioisotopes; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Metastasis; Paclitaxel; Pentetic Acid; Peptide Fragments; Predictive Value of Tests; Receptor, ErbB-2; Tomography, Emission-Computed, Single-Photon; Trastuzumab; Troponin I | 2006 |
Albumin-bound Paclitaxel: in metastatic breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Glycerol; Humans; Nanostructures; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 2006 |
Albumin-bound Paclitaxel in metastatic breast cancer: viewpoints.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Glycerol; Humans; Nanostructures; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 2006 |
Management of malignant pleural effusion by multimodality treatment including the use of paclitaxel administered by 24-hour intrathoracic infusion for patients with carcinomatous pleuritis.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pleural Effusion; Pleural Effusion, Malignant; Pleural Neoplasms; Pleurisy; Time Factors; Treatment Outcome | 2006 |
High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome | 2006 |
Antivascular therapy of cancer metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Growth Substances; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Pyrimidines; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor | 2006 |
Naturally occurring resistance of bone marrow mononuclear and metastatic cancer cells to anticancer agents.
Topics: Antineoplastic Agents; Ascitic Fluid; Bone Marrow Cells; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Formazans; Humans; Inhibitory Concentration 50; Male; Neoplasm Metastasis; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Pleural Effusion, Malignant; Tetrazolium Salts | 2006 |
Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Adenoid Cystic; Cisplatin; Disease Models, Animal; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Neoplasm Metastasis; Oncogene Protein v-akt; Paclitaxel; Parotid Gland; Phosphorylation; Purines; Salivary Gland Neoplasms; Taxoids; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.
Topics: Animals; Antibodies; Antibody Formation; Cancer Vaccines; Cell Line, Tumor; Colorectal Neoplasms; Female; HT29 Cells; Humans; Immune Sera; Immunization; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Rhabdomyosarcoma; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Ki-67 Antigen; Lymph Node Excision; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-bcl-2; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Tumor Suppressor Protein p53 | 2007 |
Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease.
Topics: Animals; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Glutamine; Glutathione; Melanoma, Experimental; Mice; Neoplasm Metastasis; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Thionucleotides; Treatment Outcome; Tumor Necrosis Factor-alpha; X-Rays | 2007 |
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Approval; Headache; Humans; Lung Neoplasms; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pain; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration; Vomiting | 2007 |
Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelium; Female; Humans; Mesoderm; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel | 2007 |
Paclitaxel plus carboplatin for women with advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Postmenopause; Premenopause; Soft Tissue Neoplasms; Survival Rate; Vomiting | 2007 |
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Adhesion; Cell Line, Tumor; Collagen Type II; Colonic Neoplasms; Female; Fibronectins; Floxuridine; Fluorouracil; Humans; Irinotecan; Laminin; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Models, Biological; Neoplasm Metastasis; Paclitaxel | 2007 |
Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Laryngeal Nerves; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Vinblastine; Vinorelbine; Vocal Cord Paralysis | 2008 |
Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer.
Topics: Anoikis; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Cell Line, Tumor; Female; Gene Silencing; Humans; Neoplasm Metastasis; Oncogene Protein v-akt; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Receptor, trkB; RNA, Small Interfering; Signal Transduction | 2008 |
[A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin].
Topics: Adult; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Humans; Ifosfamide; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Salvage Therapy; Splenic Neoplasms; Testicular Neoplasms | 2008 |
Activity of paclitaxel in metastatic squamous anal carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Anus Neoplasms; Carcinoma, Squamous Cell; ErbB Receptors; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2008 |
[Inhibitory effect of huangqi and dangshen extraction with pacilitaxel on metastasis and angiogenesis on mouse Lewis lung carcinoma model].
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Codonopsis; Drugs, Chinese Herbal; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel | 2008 |
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infections; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Premedication; Retrospective Studies; Transplantation, Autologous | 2008 |
Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Female; Forecasting; Humans; Neoplasm Metastasis; Paclitaxel | 1995 |
Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Salvage Therapy | 1993 |
Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Clinical Protocols; Drug Resistance; Etoposide; Genetic Vectors; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Informed Consent; Interleukin-3; Interleukin-6; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancytopenia; Recombinant Fusion Proteins; Recombinant Proteins; Retroviridae; Stem Cell Factor; Transplantation, Autologous; Vinblastine | 1994 |
Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Middle Aged; Neoplasm Metastasis; Neutrophils; Paclitaxel | 1995 |
Paclitaxel in doxorubicin-resistant metastatic breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
An overview of phase II studies of docetaxel in patients with metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Ovarian cancer.
Topics: Female; Humans; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate; United States | 1994 |
Evaluation of taxol cardiotoxicity in metastatic breast cancer.
Topics: Arrhythmias, Cardiac; Breast Neoplasms; Echocardiography; Female; Heart; Heart Conduction System; Heart Rate; Humans; Infusions, Intravenous; Neoplasm Metastasis; Paclitaxel | 1993 |
Clinical trials referral resource. Clinical trials with paclitaxel in metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Metastasis; Paclitaxel | 1994 |
Metastasis-associated mts1 gene expression correlates with increased p53 detection in the B16 murine melanoma.
Topics: Calcium-Binding Proteins; Cell Cycle; Gene Expression; Melanocyte-Stimulating Hormones; Melanoma; Neoplasm Metastasis; Paclitaxel; S100 Proteins; Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1994 |
Metastasis-associated mts1 gene expression is down-regulated by heat shock in variant cell lines of the B16 murine melanoma.
Topics: alpha-MSH; Animals; Cell Division; Cell Line; Clone Cells; Gene Expression Regulation, Neoplastic; Genetic Variation; Heat-Shock Proteins; Hot Temperature; Melanoma, Experimental; Methionine; Mice; Neoplasm Metastasis; Paclitaxel; Sulfur Radioisotopes; Tretinoin | 1994 |
Use of Taxol (paclitaxel) in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1994 |
Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Humans; Infusions, Intravenous; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Unknown Primary; Paclitaxel; Parkinson Disease | 1995 |
Taxol reduces circulating tumor cells to prevent bone metastases in SCID mice.
Topics: Animals; Bone Neoplasms; Cell Survival; Humans; Idoxuridine; Keratins; Male; Mice; Mice, SCID; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Transplantation, Heterologous; Tubulin; Tumor Cells, Cultured | 1995 |
Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Doxorubicin; Female; Heart; Heart Failure; Humans; Infusions, Intravenous; Middle Aged; Muscular Diseases; Nausea; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pain; Paresthesia; Remission Induction; Stroke Volume; Ventricular Function, Left; Vomiting | 1996 |
Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Female; Heart; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Prospective Studies; Randomized Controlled Trials as Topic; Razoxane | 1996 |
Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Resistance, Neoplasm; Germinoma; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Testicular Neoplasms | 1996 |
Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice.
Topics: Alendronate; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Lumbar Vertebrae; Male; Metalloendopeptidases; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Prostatic Neoplasms; Survival Rate; Tumor Cells, Cultured | 1996 |
Paclitaxel plus vinorelbine in metastatic breast Ca patients with contraindications to receive anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Vinblastine; Vinorelbine | 1998 |
Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1998 |
Effect of microtubule disruption on cell adhesion and spreading.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Adhesion; Cell Size; Docetaxel; Dose-Response Relationship, Drug; Humans; Integrins; Microtubules; Neoplasm Metastasis; Nocodazole; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1998 |
High-dose chemotherapy and autologous stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast cancer: hematopoietic tolerance and efficacy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Transplantation, Autologous | 1998 |
A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Adhesion; Cell Division; Codon; Collagen; Culture Media, Conditioned; Female; Humans; Insulin-Like Growth Factor I; Laminin; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Point Mutation; Polymerase Chain Reaction; Precipitin Tests; Receptor, IGF Type 1; Signal Transduction; Tumor Cells, Cultured | 1998 |
Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Neoplasms; Paclitaxel; Taxoids | 1998 |
Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Uterine Neoplasms | 1999 |
Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1999 |
High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Treatment Outcome | 1999 |
[Facts and perspectives in the therapy of cancers of the breast, ovary and bronchi].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bronchial Neoplasms; Female; Humans; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Postoperative Care | 1999 |
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Doxorubicin; Ellipticines; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Pleural Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Paclitaxel-epirubicin in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pilot Projects | 1999 |
[Tumor therapy. New concepts for advanced cases].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2000 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |
Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Dexamethasone; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids | 2000 |
Recurrent metastatic fallopian tube carcinoma in pregnancy.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Salvage Therapy | 2001 |
Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Breast Neoplasms; Cell Survival; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Flow Cytometry; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Immunohistochemistry; Immunomagnetic Separation; Keratins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Risk Factors; Stem Cells; Taxoids; Time Factors; Tumor Cells, Cultured | 2001 |
[Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lung Neoplasms; Mitomycin; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2001 |
Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Biopsy; Blood Vessels; Blotting, Northern; Cadherins; Carcinoma, Transitional Cell; Cell Movement; Collagen; Collagenases; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Interferon-alpha; Interleukin-8; Laminin; Lymphokines; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Prognosis; Proteoglycans; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2001 |
Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model.
Topics: Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Renal Cell; Cricetinae; Injections, Intravenous; Kidney Neoplasms; Liposomes; Lung; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Organ Size; Paclitaxel; Survival Rate; Time Factors; Tumor Cells, Cultured | 2001 |
Lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2001 |
Addition of trastuzumab to chemotherapy produces 50% increase in survival in patients selected by FISH.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Female; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Neoplasm Metastasis; Paclitaxel; Patient Selection; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2001 |
[Efficacy of biweekly paclitaxel therapy in advanced or recurrent breast cancer].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Feasibility Studies; Female; Histamine H2 Antagonists; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Ranitidine | 2002 |
Docetaxel: new preparation. No first-line use in metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; France; Hormone Replacement Therapy; Humans; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2001 |
[Combination of taxotere and doxorubicin in chemotherapy of disseminated breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2001 |
Clinical experience of capecitabine in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure | 2002 |
[Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Chi-Square Distribution; Female; Genes, erbB-1; Humans; Immunohistochemistry; Neoplasm Metastasis; Paclitaxel; Predictive Value of Tests; Proliferating Cell Nuclear Antigen; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53 | 2002 |
Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
Topics: Androgens; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Blood Vessels; Cell Cycle Proteins; Cell Division; Cetuximab; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Humans; Interleukin-8; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Prostatic Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins; Tyrosine; Up-Regulation; Xenograft Model Antitumor Assays | 2002 |
Selecting dose-intense drug combinations: metastatic breast cancer.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Leukocytes; Models, Biological; Neoplasm Metastasis; Organ Specificity; Paclitaxel | 1992 |
Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Cell Movement; Gelatinases; Humans; Male; Mice; Mice, SCID; Microbial Collagenase; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Pepsin A; Prostatic Neoplasms; Proteins | 1992 |
From the Food and Drug Administration.
Topics: 5-alpha Reductase Inhibitors; Alkaloids; Androstenes; Antineoplastic Agents, Phytogenic; Azasteroids; Female; Finasteride; Humans; Male; Mammaplasty; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Prostatic Hyperplasia; Prostheses and Implants; Silicones; United States; United States Food and Drug Administration | 1992 |
A phase II trial of taxol in metastatic melanoma.
Topics: Adult; Alkaloids; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1990 |
Phase I study of taxol using a 5-day intermittent schedule.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Bone Marrow; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hematopoiesis; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Time Factors | 1986 |
PSY-1, a Taxus chinensis var. mairei extract, inhibits cancer cell metastasis by interfering with MMPs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Neoplasm Metastasis; Plant Leaves; Polysaccharides; Taxus | 2014 |